Crystallization and structural characterization of protein complexes involved in the energy metabolism of Yarrowia lipolytica by Wrzesniewska, Blanka
 
 
 
 
 
Crystallization and structural characterization of protein  
complexes involved in the energy metabolism of  
 Yarrowia lipolytica 
 
 
 
Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften 
 
 
vorgelegt beim Fachbereich Biochemie, Chemie und Pharmazie 
der Goethe-Universität 
in Frankfurt am Main 
 
 
 
 
von 
Blanka Ksymena Wrzesniewska 
aus Opole (Polen) 
 
 
 
 
 
Frankfurt am Main 2009 
(D30) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vom Fachbereich Biochemie, Chemie und Pharmazie der Goethe-Universität als Dissertation 
angenommen. 
 
 
Dekan:     Prof. Dr. Dieter Steinhilber 
 
Gutachter:    Prof. Dr. Bernd Ludwig 
Prof. Dr. Ulrich Brandt 
 
 
 
 
Datum der Disputation: 27.04.2009 
 
 
  
 
 
Die vorliegende Arbeit wurde in der Zeit von September 2004 bis September 2008 im Gus-
tav-Embden Zentrum der Biologischen Chemie, Molekulare Bioenergetik, des Universitäts-
klinikums der Goethe-Universität in Frankfurt am Main unter Anleitung von Prof. Dr. Ulrich 
Brandt durchgeführt. 
 
Acknowledgements 
I would like to sincerely thank Prof. Ulrich Brandt who offered me a warm welcome in the 
Molecular Bioenergetics group, provided with financial support and necessary research facili-
ties in his lab. For his excellent scientific supervision, advice, continuous support and passion 
for science, I am greatly thankful. 
 
I am grateful to Prof. Bernd Ludwig for taking the responsibility of external supervision.  
 
I would like to thank Dr. Volker Zickermann for outstanding scientific guidance, valuable 
suggestions and many fruitful discussions, as well as for critical reading of the manuscript.  
 
 I thank Prof. Carola Hunte for support in crystallography and fruitful cooperation. 
 
I would also like to thank  
Prof. Hermann Schägger for scientific discussions and helpful suggestions. 
Dr. Stefan Kerscher for scientific support in the molecular biology field. 
Dr. Ilka Wittig for introduction to cell culture techniques as well as mass spectrometry. 
Maja Tocilescu for a helpful hand, lots of stimulating discussions and for being a dear friend. 
Karin Siegmund and Andrea Duchene for excellent technical assistance, encouragement and 
lots of heart. 
Dr. Klaus Zwicker for valuable suggestions and kindness.  
Esther Nübel for ‘all that jazz…’ 
Lucie Sokolova for performing the LILBID experiments. 
Dipl.-Ing. Gudrun Beyer for valuable hints in the molecular biology field. 
Nicola Crosetto for introduction to SPR techniques. 
Andrea Böttcher for support in IT-related issues. 
 
I am very thankful to all group members for creating a nice working environment.  
 
Last, but not least, I would like to thank Kris, without whom I wouldn’t have been, where I 
am now.  
Finally, I am grateful to my family Mom, Dad, Anetka, Mariusz, Michal, Marta, Sandra, Iwo-
na, Zbyszek who always believed in me.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Mojej rodzinie,Krzysiowi 
 
 
 
 
 
 
Crystallization and structural characterization of protein  
complexes involved in the energy metabolism of  
 Yarrowia lipolytica 
 
 
 
 
 
 
Part I 
Fab co-complexes of proton pumping  
NADH:ubiquinone oxidoreductase (complex I) 
 
 
 
Part II 
UDP-glucose pyrophosphorylaseINDEX OF CONTENTS 
 
 
I 
 
Part I-General introduction..............................................................................................................1 
1  Complex I – mysterious molecular machinery ........................................................................2 
1.1  Subunit composition of complex I ......................................................................................3 
1.2  Functional modules of complex I  ........................................................................................4 
1.3  Structure of complex I ........................................................................................................5 
1.4  Energy coupling hypothesis  ................................................................................................7 
2  Crystallization of membrane proteins......................................................................................8 
2.1  Selection of a suitable detergent .........................................................................................8 
2.2  Types of membrane protein crystals ...................................................................................9 
2.3  Antibody fragments for co-crystallization with membrane proteins  ...................................  11 
2.3.1  Fab and Fv fragments...............................................................................................  13 
2.4  Crystallization of membrane proteins with anti-body fragments ........................................  15 
2.5  Enlargement of the polar surface – alternative to the antibody fragments ..........................  17 
Part I-Results ..................................................................................................................................  18 
3  Generation of antibody Fab fragments ..................................................................................  19 
3.1  Production and purification of monoclonal antibodies.......................................................  19 
3.2  Generation of proteolytic antibody fragments ...................................................................  22 
3.2.1  Crystalline papain ....................................................................................................  23 
3.2.2  Immobilized ficin ....................................................................................................  25 
3.2.3  Immobilized papain .................................................................................................  26 
3.3  Purification of functional Fab fragments ...........................................................................  27 
3.3.1  Cation exchange ......................................................................................................  27 
3.3.2  Anion exchange .......................................................................................................  28 
3.3.3  Immobilized papain digestion mixture as Fab source ................................................  30 
3.3.4  Isolation of pure Fab fragments from the immobilized papain digestion mixture  .......  32 
3.3.4.1  Double gel filtration ........................................................................................  32 
3.3.4.2  Protein G spin columns followed by gel filtration ............................................  33 
4  Surface plasmon resonance measurements ............................................................................  36 
4.1  Affinities of the monoclonal antibodies and the Fab fragments to complex I .....................  36 
4.2  Influence of conformation on the binding of the monoclonal antibodies to complex I........  36 
5  Preparation of the CI/Fab co-complexes ...............................................................................  38 
5.1  CI/1F5 Fab co-complexes  .................................................................................................  38 INDEX OF CONTENTS 
 
 
II 
 
5.2  CI/Fab 44G10 co-complexes ............................................................................................  39 
5.3  CI/Fab 31A8 co-complexes ..............................................................................................  40 
5.4  Activity assays and phosphate determination OF CI/Fab co-complexes ............................  42 
6  Crystallization of CI/Fab co-complexes ................................................................................  44 
6.1  CI/Fab 31A8 co-complex crystallization  ...........................................................................  44 
6.2  CI/Fab 44G10 co-complexes crystallization  ......................................................................  47 
6.3  CI/Fab 1F5 co-complexes crystallization ..........................................................................  49 
6.3.1  Initial crystallization conditions ...............................................................................  49 
6.3.2  Optimization of crystallization conditions ................................................................  51 
6.3.2.1  Additive screen................................................................................................  51 
6.3.2.2  Oils in crystallization of CI/Fab co-complexes .................................................  52 
6.3.2.3  Seeding ...........................................................................................................  53 
6.3.2.4  Lipids and the crystals quality  ..........................................................................  53 
6.3.2.5  Temperature ....................................................................................................  54 
6.3.2.6  Crystal growth using pH gradient.....................................................................  54 
6.3.2.7  Dehydration of co-complex crystals .................................................................  56 
6.3.2.8  Soaking of the co-complex crystals in Ta6Br12
2+ ...............................................  56 
6.3.3  Diffraction of CI/Fab 1F5 crystals ............................................................................  57 
Part I-Discussion .............................................................................................................................  59 
7  Solving the X-Ray structure of mitochondrial complex I  .......................................................  60 
7.1  Preparation of homogenous Fab fragments .......................................................................  61 
7.2  Fab-mediated crystallization of complex I ........................................................................  63 
7.2.1  CI/Fab 1F5 crystals ..................................................................................................  64 
7.2.2  Crystallization with conformation specific antibody fragments .................................  65 
8  Précis ...................................................................................................................................  68 
Part II-Theoretical introduction.....................................................................................................  69 
9  Ugp1p –introduction.............................................................................................................  70 
9.1  UDP-glucose pyrophosphorylase – the reaction mechanism  ..............................................  70 
9.2  UDP-glucose at the croassroads of sugar metabolism .......................................................  71 
9.3  UGPases ..........................................................................................................................  74 
9.4  Regulation of the enzymatic activity of UDP-glucose pyrophosphorylase .........................  76 
9.5  UGPases – structural analysis ...........................................................................................  76 
Part II-Results  .................................................................................................................................  79 INDEX OF CONTENTS 
 
 
III 
 
10  Ugp1p - results .....................................................................................................................  80 
10.1  Purification of Ugp1p  ...................................................................................................  81 
10.2  Oligomers of Ugp1p from Y. lipolytica  .........................................................................  83 
10.3  Crystallization of Ugp1p ..............................................................................................  84 
10.3.1  Initial crystallization conditions ...............................................................................  84 
10.3.2  Optimization of the crystallization conditions  ...........................................................  86 
10.3.3  Ugp1p crystallization under oil ................................................................................  87 
10.4  Diffraction of Ugp1p crystals .......................................................................................  88 
Part II-Discussion ...........................................................................................................................  90 
11  Discussion  ............................................................................................................................  91 
11.1  Co-purification of Ugp1p .............................................................................................  91 
11.2  Domain architecture of Ugp1p from Y. lipolytica..........................................................  91 
11.3  Architecture of the Active site of Ugp1p ......................................................................  93 
11.3.1  Active site with bound UDP-glucose  ........................................................................  93 
11.3.2  Active site with bound UTP .....................................................................................  94 
11.4  Conformational changes upon substrate binding ...........................................................  95 
11.5  Oligomerisation of Ugp1p from Y. lipolytica ................................................................  96 
12  Précis ...................................................................................................................................  98 
13  Materials and Methods .......................................................................................................  100 
13.1  Materials  ....................................................................................................................  100 
13.1.1  Cell culture materials .............................................................................................  100 
13.1.2  Proteolytic Fab production .....................................................................................  100 
13.1.3  Protein chemistry ...................................................................................................  101 
13.1.4  Surface plasmon resonance ....................................................................................  101 
13.1.5  Crystallization materials.........................................................................................  102 
13.1.6  Monoclonal antibodies ...........................................................................................  103 
13.2  Hybridoma cell culture techniques .............................................................................  103 
13.2.1  General aspects ......................................................................................................  103 
13.2.2  Thawing of frozen stock cultures ...........................................................................  104 
13.2.3  Single cell cloning .................................................................................................  104 
13.2.4  Cell vitality determination  ......................................................................................  104 INDEX OF CONTENTS 
 
 
IV 
 
13.2.5  Monoclonal antibody production  ............................................................................  104 
13.2.6  Freezing of cells.....................................................................................................  105 
13.2.7  ELISA ...................................................................................................................  105 
13.2.8  Native ELISA ........................................................................................................  106 
13.2.9  Cell culture sterility ...............................................................................................  106 
13.3  Purification of monoclonal antibodies ........................................................................  106 
13.4  Affinity measurements of monoclonal anti-bodies and Fab fragments using surface 
plasmon resonance (Biacore) ...................................................................................................  107 
13.5  Production of  Proteolytic Fab fragments  ....................................................................  108 
13.5.1  Digestion of immunoglobulins ...............................................................................  108 
13.5.1.1  Immobilized ficin (Pierce) .............................................................................  108 
13.5.1.2  Crystalline papain (Roche Diagnostics) .........................................................  108 
13.5.1.3  Immobilized papain (Pierce) ..........................................................................  108 
13.5.2  Purification of proteolytic Fab fragments ...............................................................  109 
13.5.2.1  Anion exchange – Mono Q column (GE Health Care) ....................................  109 
13.5.2.2  Cation exchange – S Hyper D column (Bio Sepra) .........................................  109 
13.5.2.3  Immobilized protein G magnetic beads (Dynabeads®Protein G) ....................  109 
13.5.2.4  Immobilized protein G columns – NAb™ Protein G Spin Columns (Pierce) ..  110 
13.5.2.5  Size exclusion chromatography – HiLoad 16/60 Superdex (GE Health Care) .  110 
13.5.3  Storage of purified Fab fragments ..........................................................................  110 
13.6  General protein chemistry methods ............................................................................  110 
13.6.1  Growth of Yarrowia lipolytica ...............................................................................  110 
13.6.2  Preparation of mitochondrial membranes ...............................................................  111 
13.6.3  Purification of complex I .......................................................................................  111 
13.6.4  Protein quantification .............................................................................................  112 
13.6.5  Doubled SDS-polyacrylamide gel electrophoresis ..................................................  112 
13.6.6  Activity measurements  ...........................................................................................  112 
13.6.6.1  NADH:HAR oxidoreductase activity .............................................................  112 
13.6.6.2  dNADH:DBQ oxidoreductase activity ...........................................................  112 
13.6.7  Western blotting ....................................................................................................  113 
13.6.8  Immunodetection ...................................................................................................  113 
13.6.8.1  Chemiluminescent detection ..........................................................................  113 INDEX OF CONTENTS 
 
 
V 
 
13.6.8.2  Chromogenic detection ..................................................................................  113 
13.6.9  Determination of lipid phosphorus by malachite green assay ..................................  113 
13.7  Preparation of complex I Fab co-complexes ...............................................................  114 
13.8  Purification of Ugp1p from Yarrowia lipolytica .........................................................  114 
13.9  Crystallization techniques ..........................................................................................  115 
13.9.1  Preparation of the CI/Fab crystallization sample  .....................................................  115 
13.9.2  Vapor diffusion  ......................................................................................................  115 
13.9.2.1  Hanging drop.................................................................................................  115 
13.9.2.2  Sitting drop ...................................................................................................  115 
13.9.2.3  pH fine tuning of the crystallization conditions ..............................................  115 
13.9.2.4  pH/PEG fine tuning of the crystallization conditions ......................................  115 
13.9.2.5  pH gradient vapor diffusion ...........................................................................  116 
13.9.2.6  Vapor diffusion with oil barrier .....................................................................  116 
13.9.3  Dehydration of the co-complex crystals..................................................................  116 
13.9.4  Soaking of the co-complex crystals in Ta6Br12
2+ .....................................................  116 
13.9.5  Microbatch ............................................................................................................  117 
13.9.6  Seeding  ..................................................................................................................  117 
13.9.7  Screening for optimal conditions ............................................................................  117 
13.9.7.1  ‘Traditional’ screening...................................................................................  117 
13.9.7.2  Automated screening and monitoring  .............................................................  118 
13.9.8  Cryoprotection and freezing ...................................................................................  118 
13.9.8.1  Complex I/Fab co-complex crystals ...............................................................  118 
13.9.8.2  Ugp1p crystals  ...............................................................................................  118 
14  Ausführliche deutschsprachige Zusammenfassung  ..............................................................  119 
14.1  NADH:Ubichinon Oxidoreduktase (Komplex I) .........................................................  119 
14.2  Kristallisation von Membranproteinkomplexen mit hilfe von Antikörperfragmenten ..  120 
14.3  Herstellung und Reinigung von Fab Fragmenten ........................................................  121 
14.3.1  Reinigung monoklonaler Antikörper ......................................................................  121 
14.3.2  Einfluss  der  Komplex  I  Konformation  auf  die  Bindung  von  monoklonalen 
Antikörpern ........................................................................................................................  121 
14.3.3  Herstellung von Fab Fragmenten............................................................................  121 
14.4  Herstellung von Fab-Komplex I Co-komplexen..........................................................  122 
14.5  Kristallisation von Komplex I-Fab Co-komplexen ......................................................  122 INDEX OF CONTENTS 
 
 
VI 
 
14.6  UDP-Glucose Pyrophosphorylase ..............................................................................  123 
15  Abbreviations .....................................................................................................................  125 
16  Index of figures ..................................................................................................................  127 
17  Index of tables ....................................................................................................................  130 
18  Reference list .....................................................................................................................  131 
CURRICULUM VITAE ...............................................................................................................  146 INDEX OF CONTENTS 
 
 
I 
  
 
 
  1 
 
 
 
 
 
 
 
 
 
Part I-General introduction 
 
 
NADH:ubiquinone oxidoreductase (complex I) 
 
Antibody mediated crystallization of membrane proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 COMPLEX I – MYSTERIOUS MOLECULAR MACHINERY  
   
 
 
  2 
1  COMPLEX I – MYSTERIOUS MOLECULAR MACHINERY  
NADH:ubiquinone oxidoreductase (complex I, EC 1.6.5.3) is the largest, most complicated 
but least understood member of the respiratory chain [1]. Although, the bovine enzyme was 
first purified more than 50 years ago [2], the knowledge on its mechanism and structure still 
remains limited. Electron microscopic studies of complex I from different sources typically 
showed an L-shaped molecule, with a peripheral arm protruding into the mitochondrial matrix 
and a perpendicular membrane arm embedded in a lipid bilayer [3-7]. As the electron entry 
site of mitochondrial electron transfer chain, complex I plays a critical role in molecular bio-
energetics (Figure 1.1). The enzyme couples the transfer of two electrons from NADH to ubi-
quinone to the translocation of four protons across the inner mitochondrial membrane and the 
plasma membrane of many bacteria. This generates the major portion of the proton motive 
force required for the ATP synthesis by complex V. Complex I has been shown to be a com-
ponent of multi-complex assemblies called respirasomes [8] the formation of which is impor-
tant for stability of the enzyme [9;10] . Disorders of mitochondrial NADH:ubiquinone oxido-
reductase were identified in many neurodegenerative diseases, such as encephalomyopathies 
or Leigh syndrome, as well as in the process of aging [11-13]. Together with cytochrome bc1 
complex, complex I  is the  main  site of the reactive oxygen  species (ROS) production  in 
oxidative phosphorylation [14].  
 
Figure 1.1: Mitochondrial electron transfer chain.  
Complex I is the only member of the respiratory chain for which no detailed structure is available. The sites of 
reactive oxygen species production are shown by red arrows. Reprinted from [14]  
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1.1  SUBUNIT COMPOSITION OF COMPLEX I 
Eukaryotic complex I is composed of more than 40 subunits, resulting in a molecular mass of 
almost 1 MDa [15-18]. Among them, 14 central subunits are conserved in eukaryotes and 
prokaryotes and represent a minimal set required for functionality of the enzyme [19]. The 
central subunits comprise all redox centers known  for complex I:  flavine  mononucleotide 
(FMN) and up to nine iron-sulfur clusters (Fe-S) [20;21]. The central subunits can be divided 
into two classes. The  first class  is represented by  seven  highly  hydrophobic polypeptides 
(ND1 to ND6 and ND4L) encoded in most eukaryotes by the mitochondrial DNA and located 
in the membrane arm of the protein. These subunits are postulated to be involved in proton 
translocation. About 60 transmembrane helices have been predicted for the central hydro-
phobic subunits. Additionally, alkaline phosphatase fusions indicated that some of the pre-
viously predicted transmembrane helices form extended extramembraneous domains [22;23]. 
The remaining seven central subunits are hydrophilic proteins and contain distinct binding 
motifs for all redox centers and NADH. The additional, so called accessory subunits are cha-
racteristic only for the eukaryotes, but their role in energy conversion is unclear. Several ac-
cessory subunits located in the membrane arm were classified as single transmembrane do-
main subunits (STMD). These are small proteins containing a single transmembrane helix and 
highly  hydrophobic  domains  with  charged  residues  facing    both  sides  of  the  membrane 
[17;18]. Bovine complex I was predicted to contain fourteen STMD subunits [24]. It was 
postulated that the STMD proteins mediate assembly of the mitochondrially encoded subunits 
and stabilize the membrane portion of complex I [18].  
Purified bovine enzyme was shown to dissociate into subcomplexes upon treatment with de-
tergents and chaotropes like perchlorate [24-26]. The soluble, catalytically active flavoprotein 
subcomplex (FP) comprises the FMN molecule, the NADH binding site, one [2Fe-2S] and 
one [4Fe-4S] cluster (Figure 1.2) [27-29]. The iron-protein (IP) is composed of the 75-kDa, 
49-kDa, 30-kDa, TYKY and PSST subunits [30]. The last subcomplex is known as hydro-
phobic protein (HP) and was first characterized in [18]. Using the non-denaturing detergent 
lauryldimethylamine oxide (LDAO), followed by ion-exchange chromatography, the bovine 
complex I was resolved into subcomplexes Iα and Iβ (Figure 1.2) [25;31]. Iβ represents the 
major portion of the membrane part of complex I. Upon prolonged incubation in LDAO,  
fraction Iα releases the predominantly hydrophilic subcomplex Iλ [16]. The described sub-
complexes were used for identification and assignment of the particular subunits to different 
parts of complex I by means of Edman degradation, gel electrophoresis and mass spectrome-COMPLEX I – MYSTERIOUS MOLECULAR MACHINERY  
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try [32]. For excellent reviews on  mitochondrial complex I see [1] and  Zickermann et al 
(submitted).  
 
 
Figure 1.2: Subcomplexes and subunits of bovine heart mitochondria. 
Flavoprotein (FP) is a component of the Iλ subcomplex (light yellow).  Iλ and Iγ (yellow) together form  Iα. Iβ 
(grey blue) represents the major portion of the membrane arm of complex I. Central subunits are printed in blue, 
accessory subunits common to all eukaryotes – in red, and subunits characteristic for metazoa – in purple. Aste-
risk indicates subunits, for which a single transmembrane domain was predicted. Figure reprinted from [1]. 
 
1.2  FUNCTIONAL MODULES OF COMPLEX I  
Extensive phylogenetic studies of the complex I central subunits revealed unambiguous rela-
tionships with different types of hydrogenases [33;34] and three functional modules of com-
plex I were defined: the N module, comprising the electron entry site, the Q module or elec-
tron output module and the P module, responsible for proton translocation across the inner 
mitochondrial membrane.  
The N module comprises the 75-kDa, 51-kDa and 24-kDa subunits and is related to the α and 
γ subunits of NAD
+-reducing hydrogenases, as the one found in Alcaligenes eutrophus [35]. 
The electrons are transferred from NADH via FMN to a wire of iron-sulfur clusters. FMN is 
non-covalently bound to the 51 kDa subunit, which possesses an NADH-binding motif and a 
characteristic βαβ-nucleotide fold on its N terminus [12]. Additionally, the N module contains 
a set of eight iron–sulfur clusters bound by distinct binding motifs. In some bacteria, includ-COMPLEX I – MYSTERIOUS MOLECULAR MACHINERY  
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ing Escherichia coli, an additional tetranuclear cluster, bound to [CxxCxxxC-(x)27-C] motif 
was observed [36]. All the Fe-S clusters are present in the recently released X-ray structure of 
the peripheral arm of complex I from Thermus thermophilus [37]. Nevertheless, the assign-
ment of the electron paramagnetic resonance (EPR) signals to particular clusters is the subject 
of a current debate [38;39].  
The Q module mediates the transfer of electrons from the N module, via three further iron-
sulfur clusters to ubiquinone or menaquinone in case of some bacteria. The 49-kDa, 30-kDa, 
PSST and TYKY subunits are the building blocks of the Q module. The 49-kDa subunit and 
the PSST subunit display homology, respectively, to the large and small subunits of water-
soluble [NiFe] hydrogenases [40;41]. In E. coli, the 30-kDa subunit is fused to the 49-kDa 
subunit  [42].  Subunit  TYKY  comprises  binding  motifs  [CxxCxxCxxxCP-(x)27-
CxxCxxCxxxCP] for two further tetranuclear iron-sulfur clusters. Cluster N2, which is asso-
ciated with the PSST subunit [43;44] has the highest redox potential  that is pH dependent 
[20;45].  N2 is believed to be the direct electron donor to ubiquinone [46].  
The P module is composed of seven, mitochondrially encoded and membrane-embedded sub-
units, ND1, ND2, ND3, ND4, ND4L, ND5 and ND6. Homology studies have shown that the 
ND2/ND4/ND5 family of subunits have evolved from the mrp (multiple resistance and pH 
adaptation) type Na
+/H
+ antiporters known for Bacillus subtilis and other bacteria [19;22]. 
MrpA and MrpD represent proteins that are important for Na
+ resistance and homeostasis, and 
function as Na
+/H
+ antiporters. Remarkably, subunit ND4L displays homology to the MrpC 
protein of the mrpA-G operon [47]. These antiporters are commonly found in bacteria. It is 
likely that the ion translocation functions of the mrp proteins were retained by homologous 
complex I subunits embedded in the membrane. The topology of the proton pumping ele-
ments is still for the most part unclear. A review prepared by Zickermann et al., (submitted) 
summarizes the current knowledge on the architecture of complex I peripheral and membrane 
arm.  
1.3  STRUCTURE OF COMPLEX I 
Until recently, the structural information on complex I was exclusively obtained by electron 
microscopic single particle analysis and two-dimensional crystallography. Enzyme purified 
from Bos taurus, Yarrowia lipolytica, Neurospora crassa, Arabidopsis thaliana and E. coli 
showed typically an L-shaped structure, with the peripheral arm extending into the mitochon-
drial matrix or the bacterial cytoplasm, and membrane arm embedded in the lipid bilayer [3-
7]. A high resolution X-ray structure of the hydrophilic domain of complex I from Th. ther-COMPLEX I – MYSTERIOUS MOLECULAR MACHINERY  
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mophilus was presented by Sazanov and Hinchliffe [37]. The partial structure (PDB 2fug) 
contains eight subunits Nqo1-6, Nqo9, and Nqo15, as well as nine iron-sulfur clusters, togeth-
er with N7, which is found only in some bacteria (Figure 1.3).  
An extensive electron microscopic study of Y. lipolytica complex I provided a new, detailed 
model of the eukaryotic enzyme [6]. EM reconstructions of the yeast enzyme subcomplex, 
lacking the 51-kDa and the 24-kDa subunits, allowed unambiguous localization of these two 
central subunits within the N module [48]. The published bacterial X-ray partial structure was 
fitted into the 3D reconstruction of the holoenzyme. Out of six possible fits discussed in the 
study, fit 1, placing the N2 cluster roughly 60 Å above the membrane represents the most 
probable arrangement. This challenges the orientation of the peripheral arm with respect to 
the membrane as suggested by Sazanov et al., [37;49] (Figure 1.3). Moreover, fit 1 is in good 
agreement with the antibody  binding experiments, which  locate the 49-kDa subunit away 
from the membrane [50;51]. The proposed architecture of the eukaryotic enzyme raises fun-
damental questions concerning the energy coupling: How is the electron transfer related to the 
proton translocation and how are the electrons transferred to the hydrophobic ubiquinone? 
 
 
         
Figure 1.3: Structure of the hydrophilic domain of complex I from Th. thermophilus and 
electron microscopic reconstruction of Y. lipolytica enzyme. 
A: X-ray structure of the peripheral domain from Th. thermophilus [37]. The subunit Nqo4 (49-kDa) reaches the 
membrane arm and the H1 helix extends in the direction of the membrane distal part of the enzyme. B: Ar-
rangement of iron-sulfur clusters in the peripheral arm [37]. C: Fitting of the bacterial X-ray model (A) into 3D 
reconstruction of complex I from Y. lipolytica [48]. H1 is the helix of the PSST subunit, which extends towards 
the membrane arm. 
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1.4  ENERGY COUPLING HYPOTHESIS 
Quite contrary to the other complexes of the respiratory chain, all the known complex I redox 
groups are enclosed within the membrane extrinsic arm. This implies that all the redox chemi-
stry takes place in the peripheral arm, while the proton translocation is limited to the mem-
brane arm. How the energy is transferred over a distance of more than hundred Ångstroms, is 
still uncertain, but recent EM data of Y. lipolytica complex I shed light on a possible mechan-
ism of energy  coupling. The EM representations show the peripheral arm attached to the 
membrane arm via a ‘double stalk’, with a cavity in between (Figure 1.3 C) [6]. It was post-
ulated, that the first stalk (common stalk) corresponds to the connection seen also for the bac-
terial enzyme and is composed of central subunit domains, while the second stalk is formed 
by accessory subunit domains, possibly including the 39-kDa subunit [17]. Fitting of the Th. 
thermophilus structure into the 3D reconstruction of Y. lipolytica enzyme positions the PSST 
subunit and at the same time, the quinone binding pocket around 60 Å above the membrane. 
In this fit, only the H1 helix of the PSST subunit extends towards the membrane arm and fills 
up one of the stalks. It was speculated, that the 34 N-terminal amino acids of the 49-kDa sub-
unit and 32 N-terminal amino acids of the PSST subunits, which are disordered in the pub-
lished structure [37], might take part in the formation of the common stalk. It is likely that 
additional  contributions  come  from  the  ND1  subunit,  for  which  a  pronounced  portion  of 
extramembraneous domain was predicted [23]. Analogously, subunits ND2 and ND3, which 
are predicted to have large extramembraneous domains may provide enough protein mass to 
build the common stalk. The presence of an amphipathic junction between the peripheral and 
membrane arm offers a plausible pathway for the hydrophobic quinone to leave the membrane 
and to come in contact with cluster N2 Alternatively, large scale conformational changes, 
which would bring cluster N2 in the proximity of the membrane for reduction of quinone 
were discussed [52].  
The ambiguities about the orientation of the peripheral arm and the lack of structural informa-
tion on the membrane arm render elucidation of the energy coupling mechanism very diffi-
cult. A high resolution X-ray structure of the holocomplex will be required for understanding 
of the relationship between the redox chemistry entailed in the peripheral arm and the proton 
translocation taking place in the membrane arm of the NADH:ubiquinone oxidoreductase.   
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2  CRYSTALLIZATION OF MEMBRANE PROTEINS 
Integral membrane proteins mediate the functional properties of biological membranes, serv-
ing as the energy transducers, channels and receptors, which are essential components of nu-
merous fundamental cellular processes. Moreover, integral membrane proteins are targets of a 
large number of drugs. Comprehensive knowledge of membrane protein structures is essential 
for understanding their function, but also for the development of modern medicine through 
rational drug design. The first high resolution structure of a membrane protein, the photosyn-
thetic reaction centre from Rhodopseudomonas virdis was published in 1985 [53]. According 
to data of the Protein Data Bank, there are more than 49000 protein structures known up to 
date,  out  of  which  only  171  represent  structures  of  integral  membrane  proteins 
(http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html).  Taking  into  account,  that  be-
tween twenty and thirty-five percent of the genome encoded proteins are integral membrane 
proteins, the overwhelming imbalance in the statistics of solved protein structures is remarka-
ble. The major obstacle in the 3-D crystallization of membrane proteins is posed by the am-
phipathic nature of their surface. In vivo, the membrane proteins are embedded in a dynamic 
lipid bilayer, where the hydrophobic areas of the proteins are in contact with the acyl chains 
of the phospholipids, whereas the polar surfaces face the polar head groups of the lipids and 
the  aqueous  phase.  Detergent  molecules,  which  mimic  the  nature of  the  biological  mem-
branes, are used to solubilize the membrane proteins in their native conformation from the 
lipid bilayers. Each detergent is characterized by the so called critical micelle concentration 
(CMC). At concentrations below the CMC, the detergent molecules are present in the solution 
as monomers and form a monolayer at the water-air boundary. At concentrations higher than 
CMC, the detergents spontaneously form micelles, with the hydrophobic tails oriented to-
wards the centre (Figure 2.1). Driven by the hydrophobic effect detergents cover the hydro-
phobic surfaces of proteins in a belt-like manner, shielding them from the aqueous environ-
ment [54;55]. The water soluble protein detergent co-complex (PDC) is the starting material 
for further purification and crystallization and the solubilization process represents a crucial 
step in the purification procedure of membrane proteins.   
2.1  SELECTION OF A SUITABLE DETERGENT 
Selection of a suitable detergent is essential for successful crystallization of membrane pro-
teins. Detergents, fall into three main groups, with respect to the type of the head group they CRYSTALLIZATION OF MEMBRANE PROTEINS  
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possess: ionic, nonionic and zwitterionic. Using mild detergents, such as polyoxyethylenes or 
N-dodecyl-β-maltoside, the membrane proteins can be isolated from the lipid bilayers in their 
native conformation. In contrast, surfactants with charged polar head groups, like sodium-
dodecylsulfate, readily denature proteins [56]. Detergents display a complicated phase beha-
vior, which includes separation into detergent-rich and detergent-poor phases in some regions 
of their temperature/composition diagrams [57]. This phenomenon is called the ‘cloud point’ 
and is indicated by turbidity, of a previously clear, homogenous detergent solution, caused by 
temperature differences [55]. In fact, crystallization often takes place at the cloud point. The 
boundary between the detergent phase and the two immiscible aqueous phases is known as a 
consolute boundary and depends on the detergent type, salt, temperature and precipitant [58]. 
The length of the detergent acyl-chain plays an important role in the crystallization of mem-
brane proteins. An interesting example was provided by the case of the yeast cytochrome bc1 
complex, which crystallized in the presence of undecyl-maltopyranoside, whereas dodecyl-
maltopyranoside did not yield any crystals [59;60]. According to Martin Caffrey’s Membrane 
Protein Data Bank (http://www.mpdb.ul.ie), a great majority (around 75%) of membrane pro-
tein structures solved by X-ray diffraction up to date, originated from crystals grown in the 
presence of N-octyl-ß-D-glucopyranoside (OG), the alkyl chain of which is one of the shortest 
among all detergents. This implies that detergents forming small micelles that do not interfere 
with crystal packing are  most suitable  for crystallization of polytopic  membrane proteins. 
However, attractive interactions between polar head groups of the detergent micelles could be 
vital for crystal lattice stability. The properties of the hydrophilic heads showed also to be 
meaningful for the success of membrane protein crystallization. In the case of the two subunit 
cytochrome c oxidase from Paracoccus denitrificans, change from N-dodecyl-β-maltoside to 
6-cyclohexyl-hexyl-β-maltoside (Cymal-6) or undecyl-maltopyranoside resulted in a signifi-
cantly improved diffraction limit of the crystals (from 8 Å to 2.5 Å) [61]. Exchange of the 
detergent used in the solubilization procedure during the purification steps, seems to be a val-
uable technique supporting crystallization of membrane proteins. Moreover, the use of sec-
ondary detergents as additives in crystallization setups might be beneficial for crystal quality.  
2.2  TYPES OF MEMBRANE PROTEIN CRYSTALS 
There are three categories of membrane protein crystals (Figure 2.1). The first category is 
represented by 2D crystals, which are basically membrane proteins reconstituted into lipid 
bilayers. These crystals are amenable to structural studies by electron crystallography and 
atomic  force  microscopy  [62].  X-ray  structural  analysis  at  high  resolution  requires  well-CRYSTALLIZATION OF MEMBRANE PROTEINS  
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ordered 3D crystals. Three dimensional crystals fall into two groups: type I and type II crys-
tals. Type I crystals are basically stacked 2D crystals, where the hydrophobic and polar inte-
ractions are important in the two dimensions, whereas only the hydrophilic attractive interac-
tions stabilize the third dimension [56]. Lipid cubic phase has proven to be a useful method 
for generation of type I crystals. The three dimensional continuous lipid phase serves as a 
solvent  matrix  for  membrane proteins, which  allows direct contacts between  hydrophobic 
surfaces of the molecules. 
 
 
 
 
Figure 2.1: Solubilization of the membrane proteins by means of detergents.  
There are three types of membrane protein crystal, 2D crystals, type I 3D crystals and type II 3D crystals. The 
last type is best suited for structural analysis of membrane proteins. Modified after Michel [56].  
membrane 
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The method has been most successful for structural analysis of the related proteins, bacterio-
rhodopsin [63], halorhodopsin [64], sensory-rhodopsin II  [65;66] as well as the human adre-
noreceptor β2AR [67].  
Type II crystals are the most common category of membrane protein crystals. Solubilized in 
detergents, the membrane proteins acquire characteristics of soluble proteins, rendering crys-
tallization procedures similar to that employed for soluble proteins. The crystal contacts are 
exclusively built via polar interactions of the protein surfaces extending from the detergent 
micelles (Figure 2.1). Although attractive interactions between polar head groups of neighbor-
ing detergent micelles may stabilize the crystal lattice, these interactions do not provide robust 
crystal contacts. Lack of sufficient hydrophilic surfaces poses a major obstacle in crystallizing 
integral membrane proteins. In the case of many ion channels or transporters, most of the pro-
tein is represented by helices buried in the membrane, whereas only short loops exposed to 
the polar phase make up for the hydrophilic surface. Enlargement of the hydrophilic surfaces 
by attachment of polar domains represents a promising technique to generate well-ordered 
type II crystals. An attractive approach was proposed by Ostermeier et al., where Fv antibody 
fragments were used as specifically binding polar domains in the crystallization of bacterial 
cytochrome c oxidase (COX) [68]. Since then, the method attracted the attention of membrane 
protein crystallographers and was  successfully employed  in the structure determination of 
several integral membrane proteins.  
2.3  ANTIBODY  FRAGMENTS  FOR  CO-CRYSTALLIZATION  WITH  
MEMBRANE PROTEINS 
Complete antibodies are not suitable for co-crystallization experiments due to their internal 
flexibility of the hinge region and their bivalent character (Figure 2.2 A, B). Employment of 
the  fragments of  monoclonal antibodies,  such as  Fab or Fv, obviates these problems and 
serves as a promising tool in generation of high quality type II crystals. All the antibody 
fragments used in reported successful co-crystallization trials originated from antibodies ob-
tained using standard hybridoma technology [69]. To be suitable for co-crystallization, the 
IgG fragments must fulfill the following requirements: (1) binding the antigen in its native 
conformation,  (2)  having  a  high  binding  constant  and  (3)  forming  a  stable  and  rigid  co-
complex with the antigen. Apart from participation in the formation of crystal contacts, im-
munoglobulin fragments may stabilize a particular conformation of the protein of interest and 
facilitate crystallization. There is no rule as to whether Fab or Fv fragments would be more CRYSTALLIZATION OF MEMBRANE PROTEINS  
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suitable for successful crystallization with a particular target molecule. The best idea is thus 
probably to try both. In general, the antibody fragment (extended hydrophilic domain) must 
reach out of the detergent micelle in order to contribute to the formation of rigid crystal con-
tacts. The difference in size of Fab (~ 50 kDa) and Fv (~ 25 kDa) fragments may therefore be 
critical  for  successful  crystallization.  As  the  immunoglobulin  domain  fold  is  highly  con-
served, the Fab fragments can be employed for determination of the phases during structural 
characterization. In contrast to Fv fragments, which are small compact domains, Fab frag-
ments however display certain flexibility, referred to as the ‘elbow motion’ (Figure 2.2B), 
which can be detrimental for crystallization. The most important aspects related to the immu-
noglobulin fragments are described shortly below.  
 
       
Figure 2.2: Native antibody structure. 
A: Structure of a native antibody with its basic modules: Fv, Fab and Fc parts. B: diagram summarizing modes 
of  flexibility  of  an  IgG  molecule.  These  figures  were  taken  from  Dr.  Mike  Clark’s  resources 
(http://www.path.cam.ac.uk/~mrc7/mikeimages.html).  
 
 
 
 
Figure 2.3: Antibody fragments. 
The intact antibody and its basic fragments are depicted.  There are two forms of Fab fragment (antibody binding 
fragment): Fab and Fab’, where the Fab´ represents the Fab with an additional small polypeptide portion of the 
A  B 
IgG 
F(ab´)2  Fab´ Fab 
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heavy chain constant domain. scFv (single chain variable fragment) is composed of the variable domains of each 
of the light and heavy chains, linked by a polypeptide linker. Figure from [70].  
2.3.1  Fab and Fv fragments 
 Fab fragments contain the antigen binding region and represent a fully functional part of an 
immunoglobulin. The ~ 50 kDa molecule is composed of one constant and one variable do-
main of each of the heavy and the light chain (Figure 2.2, Figure 2.3). Fab fragments can be 
generated proteolytically by digestion of an intact antibody with cysteine proteases such as 
papain or ficin. The intact antibodies are produced in cell culture of murine hybridoma cell 
lines or obtained by ascites production. The monoclonal antibodies are subsequently purified 
by Protein A/G affinity chromatography. Pure Mabs (monoclonal antibodies) are then frag-
mented by proteases in the presence of cysteine. Papain was originally isolated from Carica 
papaya and is a nonspecific thiol-endopeptidase containing a sulfhydryl group in its active 
site that must be in the reduced state for the activity of the enzyme. When incubated with pa-
pain in the presence of cysteine, intact immunoglobulins are split at the hinge region, generat-
ing three fragments of similar size: two identical Fab fragments and one Fc (crystallizable 
fragment) fragment. The Fc fragments can be separated from the papain digestion mixture by 
Protein G/A affinity chromatography. Ficin also belongs to the cysteine proteases and is iso-
lated from fig latex. Depending on the concentration of the reducing agent required for its 
activity, ficin will generate F(ab´)2, in the presence of 1 mM cysteine, or Fab fragments in the 
presence of 10 mM cysteine. Care needs to be taken in order to obtain a homogenous Fab 
preparation. The presence of heterogeneous fragments like Fab´ still containing small parts of 
the hinge region constant domain and in some cases glycosylated regions, may prevent co-
crystallization. Digestion with papain may cause damage of the antigen binding sites of the 
Fab fragments, rendering them nonfunctional [71].  
Fv fragments (variable fragments) are soluble, globular, monovalent domains of roughly 25 
kDa and represent the smallest portion of an antibody retaining antigen binding ability (Figure 
2.2 A, Figure 2.3). The fragments are composed of the variable domains of the light and 
heavy chain. Well established genetic engineering protocols allow the preparation of pure and 
homogenous fragments of recombinant antibodies. Two forms of Fv fragments can be pro-
duced: Fv and scFv (single chain Fv). In case of the single chain Fv fragments, the light and 
heavy chain domains are linked by a short peptide linker, usually poly-serine or poly-glycin 
(Figure 2.3). scFv fragments have multiple applications, such as in immunochemistry, flow 
cytometry and medicine [72]. Historically, scFv fragments were introduced to facilitate phage 
display, where it is more suitable to express single peptide domains [73]. Phage display libra-CRYSTALLIZATION OF MEMBRANE PROTEINS  
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ries and ribosome display systems offer a convenient approach for the generation of Fab and 
Fv/scFv fragments against membrane proteins in their native conformation without need for 
immunization [74;75]. The first method involves cloning of an antibody fragment into the 
phage genome as fusion with one of the phage coat proteins. Multiple rounds of panning (af-
finity  selection process) are carried out to enrich appropriate binder phages, consequently 
identified by screening after each round of selection [76]. In ribosome display, the peptide of 
interest and its mRNA are covalently bound and associated with the ribosome. Affinity selec-
tion of the binder proteins is performed using a protein – ribosome – mRNA – complex (PRM 
complex) [77].  
Recombinant Fv and Fab fragments can be generated by cloning of the encoding genes from 
the hybridoma cell lines and subsequent expression in various systems [78-80]. A very well 
characterized E. coli expression system, introduced by Kleymann et al., [79] was employed 
for the generation of the Fv fragments used in the co-crystallization of the yeast cytochrome 
bc1 complex (QCR) from Saccharomyces cerevisiae [60] and the cytochrome c oxidase from 
P. denitrificans [68]. The Fv fragments are produced in an oxidizing periplasm ensuring ap-
propriate arrangement of the disulphide bonds. Nevertheless, the comparatively small volume 
of the periplasm is a limiting factor for the production of antibody fragments in high yields. A 
potentially interesting approach was described by Venturi et al., who used an E.coli strain 
with an impaired reducing system. This enabled high yield (10-30 mg/L of bacterial culture) 
production of Fab fragments in an oxidizing cytoplasm [81]. 
Cell-free expression systems represent an alternative method for antibody fragment produc-
tion.  Successful expression of Fab and Fv/scFv fragments were reported using E. coli based 
in vitro coupled transcription/translation systems [82-84]. Employment of reduced and oxi-
dized glutathione, protein disulphideisomerase (PDI) and molecular chaperones enhanced the 
protein solubility and increased antigen binding activity of the produced antibody fragments. 
The advantages of the cell-free expression over expression in microbial cells could be (1) pos-
sibility of simultaneous transcription and translation of two genes and (2) avoiding formation 
of inclusion bodies. 
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2.4  CRYSTALLIZATION  OF  MEMBRANE  PROTEINS  WITH  ANTI-
BODY FRAGMENTS 
Extension of the polar surface of polytopic membrane proteins can be achieved by attachment 
of antibody fragments. The first successful antibody fragment-mediated crystallization of a 
membrane protein was reported for the cytochrome c oxidase from P. denitrificans, where the 
Fv fragments were attached to a four-subunit complex (Figure 2.4 C). The Fv fragments parti-
cipated in all crystal contacts and the structure was determined to a resolution of 2.8 Å [68]. 
Since, the protein-protein contacts along the c-axis were limited, the diffraction pattern was 
anisotropic and the crystals not easily reproducible. Using the same approach, the authors 
crystallized a subcomplex of the two functionally most important subunits of COX. The crys-
tal lattice was formed by interactions between cytoplasmic and periplasmic surfaces of the 
neighboring COX molecules, in addition to Fv mediated contacts. 
 
 
 
Figure 2.4: High resolution structures of membrane proteins complexed with antibody 
fragments (shown in red circles).  
A: Fab-mediated crystallization of the KcsA K
+ channel. Crystal packing; Fab fragments are depicted in blue, 
whereas the KcsA K
+ is shown in yellow. PDB code: 1k4c [85]. B: Fv co-complex of yeast cytochrome bc1 com-
plex (QCR); the Fv fragment (in red circle) binds to the extrinsic domain of the Rieske protein. PDB code: 1ezv 
[60]. C: Fab complex of human adrenoreceptor β2AR. Left: asymmetric unit representation; right: packing of the 
β2AR-Fab in crystals formed in DMPC bicelles (β2AR in gold, Fab heavy chain in blue, Fab light chain in red). 
PDB  code:  2r4s  [67].  D:  Bacterial  cytochrome  c  oxidase,  four  subunit  crystallization,  with  Fv  fragments 
(magenta) as crystallization enhancers. PDB code: 1qle [68]. 
 
A 
B 
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The co-complex structure was determined at 2.7 Å [61]. In this example, the Fv fragments 
played a double role. Apart from, enhancing the crystallization, the strep-tag fused to the anti-
body fragments, was used to purify the COX-Fv co-complex by means of a streptavidin af-
finity chromatography [79]. The structure of the Fv fragment used in the crystallization of 
COX was determined at 1.28 Å resolution. Comparison of the free and antigen-bound Fv did 
not show significant structural differences [86].  
Another successful Fv-mediated crystallization of a membrane protein was recorded for the 
yeast cytochrome bc1 complex (QCR) from S. cerevisiae [60]. The antibody fragment origi-
nated from a conformational antibody binding to the extrinsic domain of the Rieske protein 
(Figure 2.4 B). The structure of the co-complex was solved to 2.3 Å resolution. The cyto-
chrome bc1 complex possesses two relatively large hydrophilic surfaces, one facing the inter-
membrane space (~ 46 kDa), the other protruding into the matrix (~ 86 kDa). Interestingly, 
yeast QCR crystals, suitable for X-ray structural study were obtained only for the protein co-
complexed with Fv fragments. Purification via streptavidin affinity chromatography, similar 
to the one applied for bacterial COX, was not possible for the yeast QCR-Fv co-complex. The 
Rieske protein is attached to the periphery of the transmembrane part of the QCR by a single 
helix. Binding of the co-complex to a streptavidin  column  via Rieske-bound  Fv  fragment 
caused disintegration of QCR [87]. Yeast QCR-Fv co-complex was also crystallized with its 
substrate cytochrome c bound. Confirming activity measurements structural analysis revealed 
that, the antibody fragments did not interfere with substrate binding [87;88] 
The potassium channel KcsA
 was the first example of successful crystallization of an integral 
membrane protein with Fab fragments [85]. The proteolytic Fab fragment originated from an 
antibody recognizing the native homotetrameric form of the channel and was bound to the K
+ 
channel on the extracellular surface. Furthermore, the bound Fab fragments did not hinder ion 
binding by leaving the passageway outside the pore wide open. The crystal contacts were ex-
clusively mediated by the Fab fragments, which created a spacious crystal lattice, leaving 
room for large decyl-maltoside micelles (Figure 2.4 A). The extra polar surface provided by 
the Fab fragments, was of a deciding value for the crystal quality. The co-complex crystals 
diffracted X-ray to a significantly better resolution (below 2 Å) when compared to the single 
subunit structure of the KcsA K
+ solved
 without antibody fragments, where the crystals dif-
fracted X-rays to a resolution of 3.2 Å
 [89]. Employment of the Fab fragments was also bene-
ficial for the crystallographic analysis. The phases were determined by molecular replacement 
using a previously published Fab structure as the search model. Thus, Fab fragment-mediated CRYSTALLIZATION OF MEMBRANE PROTEINS  
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crystallization offers an interesting approach for the structural investigation of channels and 
other membrane protein, which do not possess significant large hydrophilic surfaces.  
The complex of human adrenoreceptor β2AR is the second known case of Fab co-complex 
crystallization [67]. Inherent structural flexibility associated with the basal activity of the G-
protein-coupled receptors (GPCRs) has hindered their structural analysis. Proteolytic antibody 
fragments were generated to ensure conformational  stability. The deglycosylated complex 
bound  to  an  inverse  agonist  carazolol  was  crystallized  in  DMPC  bicelles  (10%  w/v 
DMPC:CHAPSO in 10 mM HEPES, pH 7.5, 100 mM NaCl). The Fab fragment was bound to 
the third intracellular loop, which is involved in activation of the G protein as well as in selec-
tivity of the GPCR-G protein interactions. The antibody fragment did not affect the activity of 
the receptor nor influenced the native structure. The structure was determined at 3.4 Å/3.7 Å 
resolution. 
2.5  ENLARGEMENT OF THE POLAR SURFACE – ALTERNATIVE TO 
THE ANTIBODY FRAGMENTS 
Essentially, every soluble protein that specifically binds to the target protein may be consi-
dered as a candidate for co-crystallization attempts. Engineered protein scaffolds were pro-
posed as an alternative for the antibody fragments [90;91]. Employing the phage display tech-
nique, the protein scaffolds could be applied to select for suitable binding partners. So far no 
examples of co-crystallization with membrane proteins were reported.  
Fusion partners employed for expansion of polar surfaces of membrane proteins represents a 
potentially promising approach. However, the fusion proteins are attached to the target protein 
via a linker. Flexibility introduced by the linker region may be detrimental for crystallization. 
In the crystallization of membrane-bound cytochrome bo3 ubiquinol oxidase from E. coli, 
protein Z was fused to the subunit IV at the C-terminus [92;93]. The resultant fusion protein 
crystallized in conditions similar to the native counterpart, but the crystals were even less or-
dered and it was not possible to employ molecular replacement as a structural method. In or-
der to avoid flexibility, the fusion protein – cytochrome b562 – was inserted into one of the 
inner cytoplasmic loops (between two transmembrane helices) of E. coli lactose permease 
[94]. Crystallization of the ‘red permease’ resulted in 2D crystals, which diffracted X-rays to 
a resolution of 20 Å [95].  
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3  GENERATION OF ANTIBODY FAB FRAGMENTS 
3.1  PRODUCTION  AND  PURIFICATION  OF  MONOCLONAL  ANTI-
BODIES 
The monoclonal antibodies used in this work were produced using the hybridoma cell culture 
technique as described in 13.2. The clones 1F5 and 44G10 were more sensitive to decreasing 
concentration of fetal calf serum in the growth medium in comparison to the antibody 31A8. 
These cell lines were cultivated in 1-2 % growth enhancing factor during the last stages of the 
antibody production. The cell culture supernatant was purified using Protein G affinity chro-
matography  (13.3).  Neutralization  with  1M  TrisCl,  pH  9.0  buffer  assured  non-denaturing 
condition after the low pH elution. The peak fractions were analyzed on SDS-PAGE as shown 
in Figure 3.1. Fractions represented by the most prominent IgG bands were pooled and con-
centrated.  
 
Figure 3.1: Purification of antibody 31A8. Fractions eluted from Protein G column. 
10% SDS-PAGE under reducing conditions. CI: complex I; fractions 34-44: peak fractions; FT: flow through; L: 
load on the column; C: control, purified 37F3. 
 
The functionality of the purified monoclonal antibodies was analyzed by binding of complete 
IgG to complex I (CI), in a 1: 1 molar ratio. The resultant mixture was applied to an analytical 
gel filtration column (TSK g4000swxl, 7.8 mm x 30 cm). The elution profile revealed the 
presence of four different species (Figure 3.2 A), representing CI at different IgG saturation 
levels (peaks 1-3) and antibody excess (peak 4). Peak 1 most probably resulted from forma-
tion of a ternary complex, where one antibody molecule bound two CI molecules. Peak 2 cor-GENERATION OF ANTIBODY FAB FRAGMENTS  
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responded to CI/IgG co-complexes, with one IgG molecule per complex I. Peak 3 was at the 
same elution volume as for the un-complexed enzyme (green trace, Figure 3.2 A) and most 
likely represented complex I without attached antibodies. The presence of antibody revealed 
by Western blotting in fraction 9 (peak 3) could be explained by a partial overlap with peak 2.  
The unbound antibody molecules contributed to peak 4, as revealed by SDS-PAGE and West-
ern blot. A Western blot of the peak fractions showed that the antibodies bound tightly to 
complex I (Figure 3.2 B, right panel). The binding of the immunoglobulins 1F5 and 44G10 to 
the native complex I was analyzed in an experiment similar to the one described for 31A8 and 
in each case the results were comparable (data not shown). 
 
               
Figure 3.2: Binding of complete IgG 31A8 to purified complex I.  
A: Gel filtration profile. The dark blue trace represents run of CI with bound intact antibody 31A8. The green 
profile corresponds to CI without antibody. B; left panel: 10% SDS gel, right panel: developed Western blot 
membrane. Fractions were prepared under reducing conditions. CI: complex I; A: IgG 31A8; 7-9, 12: peak frac-
tions. The CI subunits (75- kDa, 51/49-kDa and 39-kDa) were marked for comparison on the Western blot mem-
brane. The bands were stained in a chromogenic reaction with NBT and represent pseudo positive signals in 
Western blot (Figure 3.2 B, lane ‘CI’). 
 
The 1F5 antibody showed only limited solubility at low temperatures. As the affinity purifica-
tion step was carried out at 4
oC, the antibody precipitated in the collection tubes. The precipi-
tate  disappeared  without  additional  treatment  upon  sample  transfer  to temperatures  above 
18
oC. Antibodies are very robust proteins and re-nature easily from mild denaturing condi-
tions. Also in this case the 1F5 antibodies remained intact upon precipitation. The precipitated 
and subsequently re-dissolved samples were analyzed using SDS-PAGE (Figure 3.3). The 
bands in the region of 100 kDa presumably represent not fully reduced sample. The precipi-
A  B
51/49 kDa 
30 kDa 
             fractions              fractions  
CI   A  7   8   9  12   CI A 7  8  9  12 
1 
3 
2 
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tated samples (F) and the precipitate itself (PR) were shown to bind to complex I in a manner 
similar to the control (C) and un-precipitated fractions (P) (data not shown). In a concentrated 
sample the whitish precipitate would re-appear upon transfer to low temperatures.  
  
                           
Figure 3.3: 1F5 precipitation at low temperatures. 
10% SDS-PAGE under reducing conditions. M: molecular mass marker (SeeBlue® Plus2, Invitrogen); C: con-
trol, purified 31A8; P: pooled fractions 35-44, without 38 and 39; F: fractions 38 and 39; S: supernatant of the 
centrifuged fractions 38 and 39; PR: precipitate of the centrifuged fractions 38 and 39; DP: room temperature 
dissolved fractions 38 and 39. 
 
Typical yields of the purification procedure are summarized in Table 3.1. The purified antibo-
dies were frozen in 0.1 M PBS, pH 7.0 buffer and stored in liquid nitrogen. The storage condi-
tions did not affect the functionality of the antibodies as verified by ELISA tests and binding 
experiments, similar to those described before (data not shown). 
 
Clone  Yield/ L of cell culture 
 
31A8 
mg 
55 
1F5  35 
44G10  30 
Table 3.1: Average yield of the purified monoclonal antibodies.  
 M     C      P      F     S    PR   DP 
105 kDa 
55 kDa 
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3.2  GENERATION OF PROTEOLYTIC ANTIBODY FRAGMENTS 
Production of pure and functional Fab fragments was an essential part of this project. Since, 
the fragmentation result depended strongly on the immunoglobulin type and may even be 
clone specific, several techniques were employed in order to find an optimal procedure which 
would give reproducible and reliable result. The following section is focused on fragmenta-
tion of the monoclonal antibodies. Initially the Fab fragments were not separated from Fc 
parts, which have the same molecular mass (~50 kDa). It is worth mentioning at this point 
that a fraction of the IgG molecules, Fab fragments, and most probably the Fc fragments fall 
apart into light and heavy chain or two heavy chains (respectively) on SDS-PAGE, even  un-
der non-reducing conditions (R. MacKinnon, personal communication). As a result a pure Fab 
sample may be represented by two bands on an SDS gel: a ~ 48 kDa band corresponding to 
whole Fab, and a 24 kDa band, representing the portion where the inter chain disulphide 
bonds were broken (Figure 3.4). This phenomenon is not a sign of general antibody instabili-
ty, since the gel filtration experiment showed that the Fab fragments remained intact under 
native conditions and small molecular weight fragments were not observed (see below). In 
some cases, under SDS conditions, the intra chain disulphide bonds are broken, but the chains 
are not fully unfolded leaving some non-covalent interactions intact. The SDS-PAGE migra-
tions  of  these  fragments  are  different to those  where  the  domains  are  fully unfolded  (H. 
Schägger, unpublished). Because of that, additional bands may occur.  
 
 
Figure 3.4: Migration of IgG and IgG fragments in SDS-PAGE. 
10% SDS-PAGE. 1: IgG 1F5 non-reduced; 2: IgG 1F5 reduced with mercaptoethanol; 3: immobilized papain 
digestion mixture under non-reducing conditions; 4:  purified Fab 1F5 under non-reducing conditions.  
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Crystalline papain,  immobilized papain,  immobilized  ficin and trypsin were employed  for 
generation of the antibody Fab fragments. The trypsin digestion protocol was not reproducible 
and is not presented in the following section. The serine proteases were activated with 10 mM 
cysteine. Inactivation of the crystalline papain was carried out using alkylating agents, like N-
ethylmaleimide or 2-iodoacetamide. Use of the immobilized forms obviated the need to inac-
tivate the enzymes and separation was simply done by centrifugation. Immobilized papain 
was chosen for standard preparation of Fab fragments due to straight forward protocol and 
reproducibly of the results. 
Purification of the proteolytic fragments was performed initially by ion-exchange chromato-
graphy. It was not possible to resolve the papain digestion mixture by cation exchange chro-
matography. The fragments purified by anion exchange chromatography were most probably 
the  Fc  fragments.  Use of  unpurified  IgG  digest  was  not optimal,  since  presence  of  large 
amounts of undigested or partially digested antibody fragments posed a critical problem for 
further crystallization trials. Double gel filtration chromatography ensured elimination of high 
molecular weight species (un- and partially digested immunoglobulins), but did not remove 
the Fc parts. The most optimal method of isolation of pure antibody Fab fragments from pro-
teolytic digestion mixture was use of Protein G affinity chromatography followed by size ex-
clusion chromatography. In the first step, the Fc and Fc-containing fragments were removed, 
while the second step resulted in preparation of homogeneous Fab fragments.  
The following chapters describe the procedures of generation and purification of functional 
proteolytic Fab fragments in detail. 
3.2.1  Crystalline papain 
Digestion  of  the  purified  antibody  31A8  was  performed  as  described  (13.5.1.2)  and  the 
amount of the protease was optimized. Use of papain at concentration lower than 2% (w/w) 
resulted in a low fragmentation yield (Figure 3.5). The high molecular weight fragments (un- 
or partially digested immunoglobulins) were less abundant for enzyme concentrations higher 
than 2%. Slight over digestion of the immunoglobulins was observed for 5% w/w ratio of 
papain to antibody. Use of 15% of papain resulted in a complete fragmentation of the antibo-
dies, but at the same time the over digestion was most pronounced (lane 4, Figure 3.5). A 2% 
w/w papain to protein ratio was used in further experiments in order to avoid over digestion.  
The digestion time was another important factor in the optimization procedure. The minimal 
time range required for an efficient fragmentation of the monoclonal antibodies was 2 hours 
(Figure 3.6). GENERATION OF ANTIBODY FAB FRAGMENTS  
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Figure 3.5:  Papain concentration for optimal IgG fragmentation.  
10 % SDS-PAGE, non-reducing conditions. CI: complex I used as a molecular weight marker; 1, 2, 5, 15:  the 
values represent percent of w/w ratio of papain to IgG.  
 
When using shorter reaction times, large proportions of undigested or partially digested anti-
body molecules were observed rendering the method unproductive. In a standard experiment 
papain was inactivated with 30 mM NEM after 3-4 hours. 2-iodoacetamide (50 mM) could 
alternatively be used as an alkylating agent without changing the fragmentation pattern (data 
not shown).  Papain was activated by cysteine in the presence of EDTA. Purified monoclonal 
antibodies were incubated with 1% (w/w) papain activated with different concentrations of 
cysteine. 
    
Figure 3.6: Time course of the digestion of 31A8 IgG with crystalline papain. 
10% SDS-PAGE. M: complex I non-reduced; 1: IgG 31A8 reduced; 2: IgG 31A8 non-reduced (0 min); 3: 30 
min; 4: 60 min; 5: 90 min; 6: 120 min; 7: 240 min. Samples 2-7 were not reduced. 
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The enzyme was inactivated according to a standard procedure after 120 minutes. Change of 
the cysteine concentration (5 - 10 mM) did not influence IgG fragmentation (data not shown). 
10 mM cysteine was used in the standard fragmentation protocol for the crystalline papain 
activation. . 
3.2.2  Immobilized ficin 
Fragmentation of antibodies with ficin was performed for two pH values, pH 6.0 and pH 7.0 
following the manufacturer’s suggestions. The reaction carried out at pH 7.0 (50 mM phos-
phate buffer) resulted in poor fragmentation. Most of the protein stayed intact after 4 hours of 
digestion (Figure 3.7 B, lane 3). It was not possible to resolve the resulting fragments using an 
anion exchange chromatography with the Mono Q column (GE Health Care; Figure 3.7 A). 
The sample eluted after one third of the gradient as a homogenous peak, representing mainly 
the undigested immunoglobulin molecules (Figure 3.7 B, lanes 3 and 4). When the immobi-
lized ficin was activated with 10 mM cysteine in 0.1 M citrate buffer pH 6.0, the main prod-
ucts were 48 kDa fragments (Figure 3.8, B). The digestion mixture was purified using ion 
exchange chromatography (Figure 3.8 A). The peak number 1 (lane 1, Figure 3.8 B) presum-
ably represents the undigested IgG molecules. 
 
 
                          
Figure 3.7: IgG digestion with immobilized ficin at pH 7.0. 
A: Mono Q column elution profile. The chromatography was performed as described in13.5.2.1. B: 10% SDS-
PAGE; M: molecular mass standard (SeeBlue®, Invitrogen); 1: ficin digest reduced; 2: load on Mono Q column; 
3: peak fraction 11; 4: peak fraction 12. 
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The (Fab’)2 fragments and other partially digested antibody fragments contribute to the peak 2 
(lane 2, Figure 3.8 B).  Lane 3 corresponds to the third peak and is the fraction with the high-
est abundance of the 48 kDa fragments, most likely Fab and Fc fragments. Additionally, a 
band of around 54 kDa is present, which could account for a proteolytic fragment with altered 
SDS migration properties due to broken internal disulphide bonds (as described before). The 
fourth peak exclusively contained pure fragments of a mass of 48 kDa. The presence of the 
lower bands was discussed in the introduction to this section 3.2 (page 22). 
 
                                              
Figure 3.8: IgG digestion with immobilized ficin at pH 6.0. 
A: elution profile from a Mono Q column. The chromatography was performed as described in 13.5.2.1. B: sil-
ver stained 10% SDS-PAGE, non-reducing conditions; M: molecular mass standard (SeeBlue®, Invitrogen); 10-
13: corresponding peak fractions.  
 
3.2.3  Immobilized papain 
The digestion was performed as described in 13.5.1.3. After 14 hours, most of the immunog-
lobulin sample was digested. The digestion mixture gave a positive signal in the native ELISA 
test (data not shown). In contrast to the two IgG digestion methods described above, the im-
mobilized papain digestion (IPD) resulted in a slightly different digestion pattern. Instead of 
one, two bands are observed in the range of 50 kDa (Figure 3.9, lane 4). Both bands are rec-
ognized by anti-mouse IgG in western blot. One explanation would be the presence of another 
isoform of Fab like Fab’, which is only 2 kDa larger. In order to distinguish between the two 
isoforms, a gel filtration step was employed in the purification procedure (described in greater 
detail below). Secondly, the double band may be the consequence of differential migration 
due to cleavage of intra-chain disulphide bonds. Use of the immobilized form of the enzyme 
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eliminated the need of inactivation of the protease, as well as facilitated the separation proce-
dure. Thus, the immobilized papain method was chosen as a standard technique for further 
experiments.  
 
Figure 3.9: Digestion of IgG 1F5 with immobilized papain.  
The enzyme: substrate ratio was1:160 w/w and the reaction time12 hrs. A. 10% SDS-PAGE, Coomassie stain. 
M: molecular mass standard (SeeBlue®, Invitrogen); 1: IgG 1F5 reduced; 2: complex I reduced; 3: IgG 1F5 non-
reduced; 4: digestion mixture non-reduced. B: developed Western blot membrane. Legend as in A. 
 
3.3  PURIFICATION OF FUNCTIONAL FAB FRAGMENTS  
3.3.1  Cation exchange 
The IPD (immobilized papain digestion) mixture of IgG 31A8 was purified using cation ex-
change chromatography (S Hyper D column, Bio Sepra) as described in 13.5.2.2.  The result-
ing separation was poor and it was not possible to isolate pure IgG fragments (Figure 3.10 A 
and B). 
 
                                    
Figure 3.10: Purification of immobilized papain digest of IgG 31A8 using cation ex-
change chromatography.  
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A: S Hyper D column elution profile.  B: 10% SDS-PAGE, Coomassie stain. M: molecular mass standard (See-
Blue®, Invitrogen); A: IgG 31A8 reduced; D: digestion mixture (control); 6-9: peak fractions (see A); HS: high 
salt elution product. 
 
3.3.2  Anion exchange 
The IPD mixture of 31A8 IgGs was purified by anion exchange chromatography (Mono Q 
column, GE Health Care) with good separation yields. The undigested and partially digested 
antibody fragments contributed to peak 1 in Figure 3.11A and represent the flow-through 
sample. The peak 2, which eluted in the middle of the salt gradient, could represent a mixture 
of the Fab and Fc parts. The corresponding fractions (11 and 12) were pooled and purified by 
size  exclusion  chromatography  as  described  in  13.5.2.5.  The  elution  profile  was  uniform 
(Figure 3.12A) and the sample was exclusively represented by a 50 kDa IgG fragment (Figure 
3.12B, lanes 25-30). To check the functionality of the purified fragment, the concentrated 
sample (pooled fractions 25-28, Figure 3.12) was mixed with complex I and the mixture was 
applied to an analytical gel filtration column (TSK G3000swxl, TOSOHaas Science). The size 
exclusion chromatography profile was represented by two distinct peaks (Figure 3.13 A).  
 
 
 
                                              
       
Figure 3.11: Purification of the papain digestion mixture of antibody 31A8 by anion ex-
change chromatography.  
A: Anion exchange column elution profile. B: 10% SDS gel, non-reducing conditions. M: molecular mass stan-
dard (SeeBlue®, Invitrogen); D: papain digestion mixture of 31A8 IgG; 1-3: first three fractions eluted from the 
column (flowthrough portion); 10-13: fraction of the peak 2. The fractions were not concentrated.  
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Figure 3.12: Gel filtration of pooled fractions after ion exchange chromatography.  
A: gel filtration profile. B: 10% SDS PAGE, non-reducing conditions. M: molecular mass standard (SeeBlue®, 
Invitrogen); D: papain digestion mixture of 31A8; L: Mono Q fractions (11+12 Figure 3.11 A); 25-30: main 
peak fractions, see A. 
 
The  fractions  were  analyzed  by  SDS-PAGE  under  reducing  and  non-reducing  conditions 
(Figure 3.13 B). Immunodetection with the use of the alkaline phosphatase conjugate assay 
showed that the purified antibody fragments did not bind to purified complex I. As proven by 
Western blot (Figure 3.13), peak 1 (Figure 3.13 A) represented by lane 3 on Figure 3.13 (B 
and C) corresponded to complex I alone. 
All the unbound antibody fragments eluted as peak 2, and were detected with anti-mouse IgGs 
(Figure 3.13 C). In the left panel of the Figure 3.13 B, the antibody fragments were fully re-
duced and were detected in Western blot in the region of 25 kDa. The right panel shows frac-
tions, which were not reduced with mercaptoethanol. The proteolytic fragments dissociated 
partially into light and heavy chain and for the fractions 9 and 12 (Figure 3.13 B, C) two 
bands were detected. The binding experiment showed that the prepared antibody fragments 
were not functional.  The ability to interact with complex I was lost during the preparation 
procedure, since the intact immunoglobulins were shown to bind tightly to the purified com-
plex I from Y. lipolytica (3.1). The same Fab production and purification procedure was ap-
plied in the case of the immunoglobulins 1F5 and 44G10. It was found that the purified anti-
body fragments did not bind complex I (data not shown). We concluded that the IgG antigen 
binding ability was lost after the anion exchange chromatography step (Mono Q column). 
Most probably the isolated fragment was the Fc part of the antibody. 
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More unlikely, the antigen binding region of the proteolytic fragments was disturbed during 
the ion exchange purification. As a consequence the Mono Q column purification step was 
excluded from the standard procedure of the Fab preparation.  
 
 
 
                             
Figure 3.13: Binding of 31A8 IgG fragments to complex I. 
A: Gel filtration profile. B: 10% SDS-PAGE. Left panel shows reduced fractions, right panel, shows the same, 
non-reduced fractions. Red boxes indicate the region shown in C. CI: complex I; A: IgG 31A8; F: pure antibody 
fragment 31A8; f.9: fraction 9; f.12: fraction 12. C: Western blot insets.  
 
 
3.3.3  Immobilized papain digestion mixture as Fab source 
Since it was not possible to isolate functional Fab fragments using ion exchange chromato-
graphy, the immobilized papain digestion (IPD) mixture was used as a Fab source. The anti-
body fragments were prepared as described in 13.5.1.3. The IPD mix was added to complex I 
and the sample was purified using size exclusion chromatography only. The resulting elution 
profile displayed a shoulder on the left side of the main peak, which indicated the presence of 
some high molecular mass impurities (Figure 3.14 A).  
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Figure 3.14: Binding of immobilized papain digest (IPD) 1F5 to complex I. 
A: Gel filtration profile of complex I/IPD mixture of 1F5. B: left panel: 10% SDS-PAGE, Coomassie stained; 
right panel: developed Western membrane. Antibody fragments were detected using goat anti-mouse, alkaline 
phosphatase conjugate antibodies in dilution 1:5000. M: molecular mass standard (SeeBlue®, Invitrogen); 1: 
1F5 antibody reduced; CI: complex I; 2:  1F5 antibody non-reduced; D: immobilized papain digestion mixture; 
mix: complex I mixed with the digest D in two fold molar excess of Fabs; 6-8: peak fractions 6-8. 
   
 
 
Although the antibody fragments were detected by Western blot in the peak fractions, the 
Coomassie stained polyacrylamide gel revealed only minor bands in the region around 50 kDa 
(Figure 3.14 B, lanes: mix and fractions 6-8). The underrepresentation of the bands may mir-
ror sub-stochiometric binding of the antibody fragments to complex I The use of the immobi-
lized papain digestion mixture without purification has its limitation due to possible presence 
of un- und partially digested antibody fragments. Moreover, presence of the Fc fragments may 
lead to incorrect calculation of the amount of Fab fragments needed to saturate complex I in a 
1:1 ratio. 
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3.3.4  Isolation  of  pure  Fab  fragments  from  the  immobilized  papain 
digestion mixture 
3.3.4.1 Double gel filtration 
Sample homogeneity and purity is critical for successful protein crystallization. In order to 
eliminate the co-complexes of complex I and un- and partially digested antibodies, a new pu-
rification strategy was designed. The IPD mixture was purified via double gel filtration chro-
matography using a HiLoad Superdex 16/60 prepgrade 75 column (GE Healthcare). The col-
umn resolution (3,000 – 70,000 Da) allowed good separation of the proteolytic fragments ac-
cording to an SDS gel (Figure 3.15 B).  
 
 
 
   
                          
Figure  3.15:  Purification  of  proteolytic  antibody  fragments  via  double  size  exclusion 
chromatography. 
A: Gel filtration elution profile, comparison of run I (dark blue trace) and run II (turquoise trace), described in 
the text. B: 10% SDS-PAGE. M: molecular mass standard (PageRuler™ Prestained Protein Ladder, Fermentas). 
Run I fractions correspond to fractions eluted in the first run (see A, blue trace). 
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In the first gel filtration experiment (run I, Figure 3.15 A blue trace) the un- and partially di-
gested IgGs (peak 1) were separated from lower molecular mass fragments (peaks 2 and 3). 
Antibody fragments of molecular mass of ~52 kDa contribute to peak number 2 (fractions 24-
26, Figure 3.15 B) probably corresponding to Fab’ or Fc fragments. The slightly smaller Fab 
Fragments were predominantly found in fractions 27-31 (peak 3) which were pooled, concen-
trated and reapplied to the column. In the second run (assigned as run II, Figure 3.15 A, tur-
quoise trace) only a small portion of peak 2 was observed at the left shoulder of the main 
peak. Fractions 26-31 were combined and used for preparation of the CI/Fab co-complexes.  
3.3.4.2 Protein G spin columns followed by gel filtration 
IgG as well as (Fab)2 parts, both possessing antigen binding sites, were removed from the IPD 
mixture by including a gel filtration step in the purification procedure. The Fc fragments, hav-
ing similar molecular mass as Fab fragments, could not be removed completely in this man-
ner. To assure the highest purity of the proteolytic fragments used for crystallization trials, the 
Fc parts were separated from the Fab fragments by means of Protein G NAb™ Spin columns 
(Pierce). The antibody fragments were prepared using immobilized papain as described in 
13.5.1.3  and  affinity  chromatography  was  performed  according  to 13.5.2.4.  The  fractions 
were analyzed in SDS-PAGE and on Western blot. The migration of the IgG 1F5 sample 
(lane A, Figure 3.16) was altered, probably due to reduction of the disulphide bonds. Most of 
the IPD mixture (lane D) was detected as ~25 kDa band. This might have been due to disinte-
gration of the antibodies during prolonged storage in the presence of cysteine. The unbound 
fragments, the flow-through (ft) and wash fractions (w1-w3) contained the Fab fragments. 
The Fc fragments and whole IgGs were eluted from the column using low pH and were de-
tected in a Western blot using anti-mouse alkaline phosphatase conjugate antibodies (Figure 
3.16, e1-e3, right panel). Summarizing, apart from removal of the Fc parts, the protein G 
chromatography eliminates other Fc-containing molecules, such as the un-digested IgGs. The 
flow-through as well as all three wash fractions were pooled and applied to the gel filtration 
column for a final purification step. The peak fractions, (26-30, Figure 3.17) were pooled, 
concentrated and analyzed by SDS-PAGE and Western blotting (Figure 3.16, lane F). It is 
remarkable, that all  antibody species were recognized  by anti-mouse alkaline phosphatase 
conjugate antibodies. When anti-mouse alkaline phosphatase conjugate antibodies supposed 
to be specific for Fab fragments were used, the result was identical (data not shown), indicat-
ing low specificity of the immunoglobulins used for analysis of antibody fragmentation.  GENERATION OF ANTIBODY FAB FRAGMENTS  
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The Fab fragments prepared using the procedure described in this section were used in the co-
crystallization trials.  
 
 
 
Figure 3.16: Purification of the 1F5 IPD mixture over protein G NAb™ Spin Columns. 
Left: 10% SDS-PAGE, non-reducing conditions. Right: developed Western membrane. M: molecular mass stan-
dard (PageRuler™ Prestained Protein Ladder, Fermentas), A: mAb 1F5; D: 1F5 IPD mixture; ft: flow-through 
sample; wash 1-3: wash fractions; elute 1-3: eluted fractions; F: Fab 1F5.  
 
 
 
Figure 3.17: Final gel filtration step in the Fab preparation procedure. 
Elution profile (HiLoad Superdex 16/60 prepgrade 75, GE Healthcare). Turquoise lines indicate pooled fractions 
(26-30) and the sample is shown in Figure 3.16, lane F.  
 
 
The 44G10 and 31A8 Fab fragments were prepared according to the same procedure as de-
scribed for antibody 1F5. A comparative elution profile is shown in Figure 3.18 A. Different 
elution maxima indicated differences in the masses of the antibody fragments. The presence 
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of dissimilar papain digestion sites within the immunoglobulins under investigation is also 
seen in SDS-PAGE and Western blot (Figure 3.18 B). The proteolytic fragments originating 
from the clones 31A8 and 44G10 eluted from the gel filtration column at the same volume, 
whereas 1F5 Fab seemed to be of a lower molecular mass. It is also remarkable, that the ~25 
kDa band is most prominent in case of the clone 31A8, whereas negligible for 1F5. It may be 
speculated, that the 31A8 fragment was in some way disrupted during the papain digestion, 
resulting in higher sensitivity of the Fab towards SDS (Fab fragments separate more easily 
into the light and heavy chain under non-reducing conditions in the presence of  SDS). The 
proteolytic fragment of the antibody 44G10, eluted from the gel filtration column as a uniform 
peak. The same sample, when analyzed in SDS-PAGE displayed presence of a double band in 
the ~ 50 kDa region.  
 
      
 
Figure  3.18:  Purified  Fab  fragments  used  in  co-crystallization  trials:  31A8,  1F5  and 
44G10.  
A: Comparative gel elution profile for all three Fab fragments used for crystallization trials in this work. B: Left: 
10% SDS-PAGE under non-reducing conditions. Right: developed Western blot membrane. M-molecular mass 
standard (PageRuler™ Prestained Protein Ladder, Fermentas); 1: Fab 31A8; 2: Fab 1F5; Fab 44G10. 
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4  SURFACE PLASMON RESONANCE MEASUREMENTS  
4.1   AFFINITIES  OF  THE  MONOCLONAL  ANTIBODIES  AND  THE 
Fab FRAGMENTS TO COMPLEX I 
The affinities of the monoclonal antibodies towards complex I were assessed by surface plas-
mon resonance using two different protocols. In the first approach, the antibody was used as 
the ligand and complex I as the analyte. The immunoglobulins were indirectly immobilized 
on the CM5 sensor chip via an anti-mouse capture antibody, which in turn was covalently 
bound to the carboxymethylated dextran surface by amine coupling. Since the monoclonal 
antibody  was  immobilized  on  the  surface,  thereby  avoiding  avidity  effects,  the  responses 
could be described by a simple 1:1 interaction model. The experiments were performed as 
described in 13.4. The affinity data obtained using this approach, were verified by a different 
technique. In the second protocol, complex I, used as the ligand, was attached to the NTA 
sensor chips via a His-tag, whereas the antibodies were used as analytes. The measurements 
were done according to the protocol described in 13.4. The affinity of the Fab fragments to-
wards complex I was measured using only the second immobilization system. The results 
obtained by the two approaches were very similar and reproducible. The highest affinity, in 
the picomolar range, was measured for the monoclonal antibody 1F5. Its corresponding Fab 
fragment, bound to the antigen with only slightly lower affinity, but still with the same order 
of magnitude. The antibody 44G10 and its Fab fragment displayed nanomolar affinity towards 
complex I. The lowest response was measured in the case of the antibody 31A8, which was 
reflected by the highest Kd value. It was not possible to measure the affinity of Fab 31A8 to 
complex I, due to a very weak binding signal. This result was in agreement with the data ob-
tained for gel filtration chromatography of the CI/Fab co-complexes, where it was not possi-
ble to detect significant binding of the Fab 31A8 to complex I (see Figure 5.3 and Figure 5.4) 
4.2  INFLUENCE  OF  CONFORMATION  ON  THE  BINDING  OF  THE 
MONOCLONAL ANTIBODIES TO COMPLEX I 
The antibody 44G10 is Western blot negative, which indicates its conformational specificity. 
The same seems to be the case for the 31A8 antibody. In contrast, antibody 1F5 recognizes 
only a linear epitope and is Western blot positive. In order to address the binding of the anti-
bodies to complex I displaying different conformations, NADPH that had shown to change 
the pattern fragments of peptides obtained by limited proteolysis of complex I [96;97] was SURFACE PLASMON RESONANCE MEASUREMENTS  
   
 
 
  37 
included in the experiments. To this end, antibodies were immobilized on the sensor chip via 
a capture antibody and complex I was used as the analyte. The substrate was pre-incubated 
with complex I, at final concentrations of 0.1, 1, 5, and 10 µM for at least 30 minutes on ice, 
as described in 13.4. In the first cycle complex I without bound NADPH was used as a con-
trol. The relative plasmon resonance response at the end of each injection was plotted against 
the NADPH concentration for all immunoglobulins. For both conformation specific antibo-
dies 44G10 and 31A8 no effect on the binding to the enzyme was observed upon incubation 
with NADPH (Figure 4.1). In contrast, a significant drop in the binding signal of the 1F5 was 
observed for NADPH concentrations above 1 µM.  
An interesting observation was recorded for the binding experiments, where an ‘aged’ com-
plex I sample was used. The complex I dilutions were kept at 4
oC for several days. The data 
collected during subsequent days indicated that the affinity of 31A8 and 44G10 antibodies to 
the enzyme decreased constantly with time, until it reached a constant level of approximately 
70 % of the initial readings. In the case of the immunoglobulin 1F5 no correlation between 
age of the antigen sample and affinity towards it, was observed.  
 
Figure 4.1: Effect of NADPH on binding of the monoclonal antibodies to complex I.  
No effect of NADPH on binding to complex I was observed for the monoclonal antibodies 31A8 and 44G10. In 
contrast, the response upon binding of antibody 1F5 to complex I was decreased by approximately 40 % when 
NADPH was present at concentrations above 1µM. 
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5  PREPARATION OF THE CI/Fab CO-COMPLEXES 
The functionality and stability of the prepared Fab fragments was verified in a standard bind-
ing experiment (13.7).  
5.1  CI/1F5 Fab CO-COMPLEXES 
The Fab fragments of antibody 1F5 were prepared using immobilized papain. The digestion 
mixture was purified by protein G chromatography (protein G NAb™ Spin Columns, Pierce), 
followed by gel filtration (HiLoad Superdex 16/60 prepgrade 75, GE Healthcare). The pure 
Fab was added to complex I in a 1.3:1 molar ratio. The stability of the co-complex was ana-
lyzed using size exclusion chromatography and Western blotting. The gel filtration profile of 
the CI/Fab 1F5 co-complex exhibited a shift towards the higher molecular weight region as 
compared to the native complex I (Figure 5.1 A). As the mass attached to CI was 20 times 
smaller than the enzyme, the shift was relatively small. The Fabs 1F5 were shown to bind 
tightly to CI, as proven by Coomassie stained SDS PAGE and Western blotting (Figure 5.1 
B). 
 
                
Figure 5.1:  Preparation of a CI/Fab 1F5 co-complex. 
A: Gel filtration profile; CI (red) vs. CI/Fab (blue). B: 10% SDS PAGE and developed Western membrane inset. 
1: pure Fab 1F5; 2: mixture of Fab and CI in 1.3:1 molar ratio; 3: complex I; 4: CI/Fab 1F5 co-complex after gel 
filtration. 
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5.2  CI/Fab 44G10 CO-COMPLEXES 
The immobilized papain digest of antibody 44G10 was purified by gel filtration, without sub-
sequent Protein G affinity chromatography. The Fab fragments were mixed with complex I at 
a 2:1 molar ratio. The amount of the Fab fragments needed for the two fold molar excess of 
the fragments over complex one was calculated taking into account the presence of the Fc 
parts. The stability of the resultant mixture was analyzed by size exclusion chromatography. 
The peak fractions were shown to represent co-complex fractions and the 44G10 Fab frag-
ments were detected by Western blot using anti-mouse alkaline phosphatase conjugate anti-
bodies. The unbound antibody fragments eluted as a minor peak and were also detected by 
Western blot (data not shown).  CI/Fab 44G10 co-complex was also prepared with Fab frag-
ments generated following to an improved procedure. This method included a Protein G affin-
ity purification step following the papain digestion to remove the Fc parts. These Fab 44G10 
proteolytic fragments were incubated with complex I, in 3 fold molar excess, to assure satura-
tion of the enzyme with the fragments. The CI/Fab 44G10 co-complex was stable and the Fab 
fragment could be detected under non-reducing conditions in Western blot using anti-mouse 
alkaline phosphatase conjugate antibodies after gel filtration chromatography (Figure 5.2 A, 
B). 
 
 
Figure 5.2: Preparation of s CI/Fab 44G10 co-complex. 
A: 10% SDS PAGE under non-reducing conditions. CI: complex I; 1: mixture of Fab and CI in 3:1 molar ratio; 
2:  CI/Fab 44G10 co-complex after gel filtration; 3: Fab 44G10 used for the preparation of the co-complex. B: 
Western blot. 
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Both, Coomassie stain and Western blot indicated the presence of two bands in the region of 
~50 kDa (Figure 5.2 A/B, lane 3). The double band was present in the mixture of complex I 
and the antibody fragment (Figure 5.2 A, B, lane 1), but absent in the sample after gel filtra-
tion chromatography (Figure 5.2 A, B, lane 2), where only the upper band (marked with pink 
arrow) was detected. This may indicate presence of two isoforms in the Fab 44G10 prepara-
tion with only one isoform binding to complex I.  
5.3  CI/Fab 31A8 CO-COMPLEXES 
The antibody 31A8 was fragmented using immobilized papain. The digestion mixture was 
purified using Protein G magnetic beads according to the manufacturer’s procedure. The un-
bound sample containing Fab fragments (without further purification) was mixed with pure 
complex I in a ratio corresponding to 2.5 molar excess of the Fab fragments. The co-complex 
eluted from a gel filtration column as a homogenous peak (Figure 5.3 A) and the preparation 
was analyzed on an SDS gel and by Western blotting. The Fab bands of the peak fractions 
(Figure 5.3 B, lanes 7-8) were much less prominent than the complex I subunits, what indi-
cated a sub-stochiometric binding of the Fab fragments to complex I. Additionally, there was 
a double band observed in the region of 50 kDa for the Fab sample (Figure 5.3 B, lane F) as 
well as for all the peak fractions.   
 
                   
 
 
Figure 5.3: Sub-stochiometric binding of the Fab 31A8 fragments to complex I. 
A: gel filtration elution profile. B: upper panel: 10% SDS-PAGE; lower panel: developed Western blot mem-
brane. M: molecular mass standard (PageRuler™ Prestained Protein Ladder, Fermentas); F: protein G magnetic 
beads unbound fraction. CI: complex I; mix: mixture of fraction F and complex I in a 2,5 molar excess of Fab; 6-
11: peak fractions.   
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The antibody fragment excess eluted behind the main peak as a double peak. The main com-
ponents of fractions 10 and 11 were shown to have a different molecular mass (Figure 5.3 B, 
lanes 10 and 11) possibly cooresponding to Fab’ and Fab fragments. Ideally, the Fc parts 
would have been removed in the magnetic beads protein G chromatography. The effect of the 
sub-stochiometric  binding of  Fab to complex I  on co-complex crystallization  will  be dis-
cussed in the last chapter. 
In an optimized procedure the Fab fragments were prepared by immobilized papain digestion 
of IgG 31A8, followed by protein G affinity chromatography and subsequent gel filtration. 
The Fab 31A8 was used in a 3 fold molar excess to form the co-complex. The CI/Fab mixture 
was applied to a gel filtration column in order to examine the stability of the co-complex and 
remove the unbound sample. The elution maximum of the resultant peak corresponded to the 
retention time of the native enzyme (Figure 5.4 A). Western blot analysis of the co-complex 
after  size  exclusion  chromatography  showed  no  signal  in  the  range  of  the  Fab  fragment 
(Figure 5.4 B, lane CI/Fab). Lack of binding of the Fab 31A8 to complex I most probably 
resulted from damage of the antigen binding region, caused by papain digestion. Under native 
conditions, the non-complexed Fab (Figure 5.4B, lane 4) disassembles into light and heavy 
chain more easily than the Fab bound to complex I (Figure 5.4, lane 2).  
 
                         
 
Figure 5.4: Preparation of a CI/Fab 31A8 co-complex. 
A: Comparison of the gel filtration profiles for the co-complex (blue) and the native complex (orange). B: 10% 
SDS PAGE (left panel) and a developed Western membrane (right panel). M: molecular mass standard (PageRu-
ler™ Prestained Protein Ladder, Fermentas); 1: complex I; 2: CI/Fab co-complex with 3 fold molar Fab excess; 
3: the CI/Fab 31A8 mixture after gel filtration; 4: Fab 31A8 used for the co-complex preparation.  
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5.4  ACTIVITY  ASSAYS  AND  PHOSPHATE  DETERMINATION  OF 
CI/Fab CO-COMPLEXES 
To test whether binding of the Fab fragment affected catalytic activity, pooled complex I frac-
tions eluted from the Ni
2+ NTA column (Ni
2+ NTA pool) were divided into two equal parts. 
The first half was subjected directly to further purification steps (gel filtration and concentra-
tion). To the second part 1F5 Fab fragments were added in a molar excess of 2:1. This co-
complex was purified in parallel to the native enzyme. Activity assays were performed as de-
scribed in 13.6.6. The presence of the Fab complexes did not significantly affect the measured 
specific NADH:HAR  oxidoreductase activity at any stage of the preparation (Table 5.1). Ta-
ble 5.2 shows that also the specific dNADH:DBQ oxidoreductase activity was not affected by 
the presence of the Fab fragment. 
 
Purification stage 
 
Protein 
mg 
 
%                    
dNADH:HAR activity  
[µmol min
-1] 
  
[µmol min
-1 mg
-1] 
Yield 
% 
Membranes  4576  100  5678  1,2  100 
Lauryl maltoside extract  2252  50  6280  2,8  110 
Ni 
2+ NTA Pool  69  1,5  1969  29  35 
TSKgel G4000sw pool  12/9,5  0,5/0,4  689/623  57/66  24/22 
Complex I  10/9  0,45/0,4  610/588  60/64  21/20 
Table 5.1: Purification table of complex I vs. complex I/Fab 1F5 co-complex (red).  
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NADH:HAR 
[µmol min
-1 mg
-1] 
dNADH:DBQ 
[µmol min
-1 mg
-1] 
 
Complex I  56  6,1 
 
Co-complex  60  6,4 
 
Table 5.2: NADH:HAR and dNADH:DBQ activities of the 1F5 co-complex and the native 
enzyme. 
 
The results obtained for the co-complexes of Fab 31A8 and 44G10 were similar to those rec-
orded for Fab 1F5 complex (not shown). Determination of organic phosphor taken as a meas-
ure for the phospholipid content of preparations of complex I and the co-complexes was per-
formed as described in 13.6.9. Typical values obtained for the co-complex preparation were 
between 100-180 nmol phosphor/mg enzyme and were similar to the values obtained for the 
complex I in the absence of antibody fragments (data not shown).   
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6  CRYSTALLIZATION OF CI/Fab CO-COMPLEXES 
6.1  CI/Fab 31A8 CO-COMPLEX CRYSTALLIZATION 
Preparation of the CI/Fab 31A8 co-complexes was difficult due to impeded binding of the 
Fabs to CI (see previous chapter). It was concluded, that the antigen binding region of the 
31A8 antibody fragments became distorted during the proteolytic digestion procedure. De-
pending on the batch and/or technique used for the Fab preparation, either weak or no binding 
to pure complex I was observed for the 31A8 antibody fragments. Figure 6.1 represents initial 
crystallization conditions for the co-complex for which a weak binding of the Fab fragments 
was observed. The conditions were selected after screening with the PEG/Ion™ crystalliza-
tion screen (Hampton Research). The quality of the crystals was not satisfying. Twinning, 
crystal shower and other undesirable features resulted most probably from non-homogeneous 
mixture of CI particles with and without Fab fragments. Crystals from the experiments pre-
sented in Figure 6.1, A were cryoprotected by soaking in cryosolution (11% PEG 3350, 100 
mM sodium formate, 30% glycerol, pH 6.0) and shock frozen in liquid nitrogen. 
 
 
Figure 6.1: Initial conditions for CI/Fab 31A8 co-complex crystallization.  
PEG/Ion crystallization screen (Hampton Research) was used for screening for suitable conditions. A: 9% PEG 
3350, 100 mM sodium formate, 10% glycerol, pH 6.0; B: 8% PEG 3350, 100 mM ammonium acetate, 10% 
glycerol, pH 7.1; C: 9% PEG 3350, 100 mM sodium formate, 10% glycerol, pH 6.4; D: 9% PEG 3350, 100 mM 
sodium potassium phosphate, 10% glycerol, pH 5.2. 
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The frozen crystals did not diffract X-rays when measured in cryo-conditions at the ID14 
beamline at the European Synchrotron Radiation Facility (ESRF) in Grenoble, France. Next, 
the conditions identified in the initial crystallization screen were optimized by varying preci-
pitant concentration and pH values in different directions. It was possible to control the nuc-
leation process by manipulating the pH value of the crystallization solution. As an example, 
crystallization conditions for 0.1 M sodium potassium phosphate, 8% PEG 3350, 10% glyce-
rol are depicted in Figure 6.2. At pH 5.0-5.2 the sample crystallized as crystal shower (Figure 
6.2, A), whereas only minimal increments of pH resulted in growth of only several crystals 
(Figure 6.2 B and C). Nevertheless, the quality of the crystals was not improved. 
 
 
Figure 6.2: Controlled nucleation of crystallization of CI/Fab 31A8 co-complex.  
0.1 M sodium potassium phosphate, 8% PEG 3350, 10% glycerol pH 5.0-5.6. Minimal changes in the pH of the 
crystallization buffer significantly influence on the nucleation process. A: pH 5.0-5.2; B: pH 5.4; C: pH 5.6. 
 
 
The CI/Fab 31A8 sample described in 5.3 was crystallized, although no binding of the proteo-
lytic fragments was detected. Screening for appropriate conditions was carried out using the 
Mosquito  crystallization  robot  and  commercial,  as  well  as  self  designed  crystallization 
screens. Additionally, an additive screen (Hampton Research) was performed for crystalliza-
tion conditions working with the native protein. The conditions for which crystals were ob-
served in the nano scale were transferred to the 24-well scale. The crystals, regardless whether 
grown as sitting or hanging drops, were similar in form to those observed for the same condi-
tions for the un-complexed CI. In order to verify their composition, the crystals (Figure 6.3A) 
were dissolved and analyzed in SDS-PAGE and Western blot (Figure 6.4). The signal ob-
tained for the CI/Fab 31A8 crystallization sample (Figure 6.4, lane 2) shows the presence of 
minor amounts of the Fab 31A8 fragments in the complex I sample.  
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Figure 6.3: Crystallization of CI with Fab 31A8.  
The CI/Fab 31A8 co-complex was crystallized under standard conditions for the crystallization of the native 
complex. A: hanging drop, 24-well plate scale - 7% PEG 3350, 40 mM calcium acetate, 12% glycerol, pH 7.3; 
B: sitting drop, nanoliter scale - 7% PEG 3350, 40 mM calcium acetate, 12% glycerol, pH 7.3 + 10 mM urea; C: 
hanging drop, 24-well plate scale - 8% 3350, 40 mM calcium acetate, 12% glycerol, pH 7.3; D: sitting drop, 24-
well plate scale - 8% 3350, 40 mM calcium acetate, 12% glycerol, pH 7.3.  
 
 
   
      
Figure 6.4: Verification of the CI/Fab 31A8 co-complex crystals. 
Upper panel: 10% SDS-PAGE; lower panel: developed Western membrane; non-reducing conditions. 1: Fab 
31A8, 2: CI/Fab 31A8 co-complex sample after gel filtration; 3: dissolved CI crystals (Fig 6.3A); 4: CI/Fab 
31A8 sample dissolved crystals. 
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The signal for the Fab fragments in the dissolved crystals was even less pronounced (Figure 
6.4, lane 4). This indicated that the binding of the antibody fragment to the antigen was neg-
ligible and most probably the Fab did not participated in the crystal contacts formation. The 
detected antibody domains could be present in the aqueous regions within crystal lattice. As 
speculated earlier in this work, the antigen binding region was most likely disrupted during 
the proteolytic digestion procedure using the immobilized papain. Furthermore, the crystals 
presented in the Figure 6.3 were analyzed by means of x-ray crystallography at the ESRF in 
Grenoble, beam line ID14. The crystallographic characteristic of the crystals were identical to 
those obtained for complex I without bound antibody fragments (data not shown).   
6.2  CI/Fab 44G10 CO-COMPLEXES CRYSTALLIZATION 
The Fab fragment of the antibody 44G10, as well as its co-complex with complex I was pre-
pared according to the procedure described in 5.2. The Fab fragment 44G10 was shown to 
bind tightly to the purified complex I. The crystallization sample was prepared in a dilution 
buffer  containing  0.015%  C12E9  and  0.4%  Cymal4  ™/phosphocholine  or  0.4%  Cym-
al4™/DQA. An extensive screening for suitable crystallization conditions was performed for 
the prepared sample. The crystallization robots Mosquito™ (TPP Labtech) and Cartesian Mi-
croSys™ (Genomic Solutions) were employed for high throughput screening of ~1200 com-
mercially available crystallization solutions (listed in Materials and Methods section). Crystal-
lization was performed at 18
 oC and 4 
oC for the sample at a concentration of 35 mg/ml.  
In the 4
 oC setups amorphous precipitate was much more abundant in comparison to the crys-
tallization plates that were prepared and incubated in 18
 oC. 
 
 
Figure 6.5: Initial crystallization results for CI/Fab 44G10 co-complex. 
A: 18% PEG 400, 0.1 M MES pH 6.5, 0.1 M MgCl2; B: 2 M MgCl2, 0.1 M Bicine pH 9.0; C: 30% [w/v] PEG 
4000. 
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For three out of more than thousand tested crystallization solutions small crystals could be 
observed after 24 hours from setting the drops (Figure 6.5). Self-designed crystallization buf-
fers, based on the initial screening procedure, were prepared for optimization and scale-up of 
the results. Only in case of the solution 18% PEG 400, 0.1 M MES pH 6.5, 0.1M MgCl2 it 
was possible to grow crystals at the 24-well scale. Nonetheless, the crystals shown in Figure 
6.5 A were proven to be Ugp1p crystals (see 10, page 80). It is likely, that the crystals pre-
sented in Figure 6.5 C were PEG crystals. Reproducible crystals of CI/Fab 44G10 co-complex 
at the 24-well plate scale were observed for the standard conditions used for crystallization of 
the un-complexed enzyme (8% PEG 3350, 40 mM calcium acetate, 12% glycerol, pH 7.3). In 
comparison to complex I crystals, the co-complex crystals were much smaller and not well 
defined (Figure 6.6 A). In order to improve crystal quality, phosphocholine (PC) was directly 
added to the crystallization samples. Upon addition of ~10-20 molecules of PC per complex I 
particle, no difference was observed between the co-complex crystals and those of complex I 
alone.  When ~ 30 molecules of PC/CI were added, the resultant crystals were smaller and 
irregular (Figure 6.6). Further addition of lipids abolished crystallization and only heavy pre-
cipitate was observed in the setups regardless of the pH used. Subtle changes of the PEG con-
centration in the crystallization sample and/or bottom solution were used in the following 
screening procedure. To influence the nucleation process, the co-complex crystallization sam-
ple was mixed with the precipitant solutions (7-8% PEG 3350, 40 mM calcium acetate, 12% 
glycerol, pH 7.3) and placed over wells containing buffers with increasing concentration of 
PEG (7-10%).  
 
 
Figure 6.6: Influence of lipids on the crystallization of a CI/Fab 44G10 sample.  
A: CI/Fab 44G10 co-complex crystals grown from 8% PEG 3350, 40 mM calcium acetate, 12% glycerol, pH 
7.3; B: CI/Fab 44G10 co-complex crystals grown from 8% PEG 3350, 40 mM calcium acetate, 12% glycerol, 
pH 7.3, where ~ 30 PC molecules/CI were added to the crystallization sample.  
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Although an extensive screening procedure was applied in search for suitable crystallization 
conditions for the Fab 44G10 co-complex of complex I, it was not possible to grow crystals of 
satisfying quality.  It is likely that the Fab fragment 44G10 has a detrimental influence on the 
crystallization of complex I. Even if the antibody fragment represents only a twentieth of the 
complex I mass, it may greatly influence the formation of crystal contacts. In the case of the 
CI/Fab 44G10 co-complex, it seems that the Fab fragments introduced significant disorder 
into the system and as a result impeded the crystallization process.  
 
6.3  CI/Fab 1F5 CO-COMPLEXES CRYSTALLIZATION 
6.3.1  Initial crystallization conditions 
CI/Fab 1F5 co-complex was prepared and purified according to the technique described in 
5.1. Using SDS-PAGE and Western blotting it was shown that the 1F5 antibody fragment 
formed a stable co-complex with complex I. The CI/Fab co-complex crystallization sample 
was prepared in a buffer containing 0.015% C12E9 in addition to 0.2% Cymal 4™/0.072% PC 
or 0.12% Cymal 5™/0.072% PC. The  initial crystallization conditions were based on the 
standard complex I crystallization buffers and the experiments were carried out at 18 
oC. The 
characteristics of the crystallization sample and the growth conditions are summarized in Ta-
ble 6.1. The sample remained soluble at 10 mg/ml for all tested buffers. At a concentration of 
20 mg/ml small crystals grew in the wells where the PEG 3350 concentration was more than 
10%. The largest crystals grew at a sample concentration of 35 mg/ml during the third day 
after setting the drops and achieved their maximal size by the sixth day.  It seemed, that the 
equilibration took place very fast resulting in large crystals (up to 1 mm) of miscellaneous 
forms independent of the system used (hanging/sitting drop) (Figure 6.7). Use of Cymal 5 
instead of Cymal 4 resulted in crystals of similar appearance. Western blot analysis proved the 
presence of Fab fragments in re-dissolved crystals. The crystals were cryoprotected by se-
quential transfer into growth buffers with increasing concentrations of glycerol (20%, 25%, 
30% glycerol) and were finally shock frozen in liquid nitrogen or liquid propane. Data col-
lected at the ID14 beamline at the ESRF in Grenoble, France, did not reveal any significant 
difference between the data qualities of the crystals frozen using either method. At low tem-
peratures the crystals diffracted X-rays up to a resolution of 15 Å. When removed from the 
cryo-stream, the crystals annealed rapidly and no diffraction pattern could be observed. The 
following crystallization buffers were preselected for further screening procedure: CRYSTALLIZATION OF CI/FAB CO-COMPLEXES  
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 * 9% PEG 3350, 10% glycerol, 100 mM sodium potassium phosphate, pH 5.2  
 * 8% PEG 3350, 12% glycerol, 40 mM calcium acetate, pH 7.3 
 
 
Figure 6.7: Initial crystals of CI/Fab 1F5 co-complex. 
A: 10% PEG 3350, 10% glycerol, 100 mM sodium potassium phosphate, pH 5.2, drop 2µl (1+1); B: 11% PEG 
3350, 10% glycerol, 100 mM sodium potassium phosphate, pH 5,2; C: 10% PEG 3350, 10% glycerol, 100 mM 
sodium potassium phosphate, pH 5.2, drop 2+1; D: 10% PEG 3350, 12% glycerol, 100 mM lithium acetate, pH 
7.8; E: 8% PEG 3350, 12% glycerol, 40 mM calcium acetate, pH 7.3; F: 9% PEG 3350, 12% glycerol, 100 mM 
magnesium formate, pH 5.9.  
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Sample characteristic   
Protein concentration  10, 20 and 35 mg/ml 
Phospholipid content 
Native lipids 
Added lipids 
nmol /mg co-complex 
162 
55 
Total  217 
Specific activity 
NADH:HAR oxidoreductase 
dNADH:DBQ oxidoreductase 
µmol min
-1 mg
-1 
61 
3.5 
Crystal growth conditions   
Temperature  18 
oC 
System  Vapor diffusion, hanging and sitting drop 
Drop volume  1-3 µl 
Reservoir volume  1 ml 
Detergent  0.015%  C12E9 
Additive 
0.2% Cymal 4/0.072% PC  
0.12% Cymal 5/0.072% PC 
Table 6.1: Characteristics of CI/Fab 1F5 crystallization samples after initial screening. 
 
6.3.2  Optimization of crystallization conditions 
6.3.2.1 Additive screen 
As the obtained crystals appeared in irregular shapes, the optimization procedure was aimed 
at growing crystals in regular forms. The crystallization conditions selected from the initial 
experiments were employed for an additive screen (Hampton Research). The sample characte-
ristics were similar to those presented in Table 6.1. Use of sitting and hanging drop systems 
had little or no effect on the crystallization results. Upon addition of salts (10 mM), only 
amorphous precipitate was observed in all wells. 10 mM phenol promoted growth of rock-like 
crystals, in contrast to a different dissociating agent, dimethyl sulfoxide (3%) which resulted 
in precipitation of the protein. Linkers generally abolished formation of crystals. Addition of 
10 mM urea amounted in growth of large irregular crystals.  
For the oxidized, but not for the reduced form of L-glutathione crystals of flower- and rock-
like shapes could be observed. Non detergent sulfobetaines (NDSB) caused protein precipita-CRYSTALLIZATION OF CI/FAB CO-COMPLEXES  
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tion. Heavy precipitate was observed in wells where detergents like LDAO or n-octyl-β-D-
glucoside were used as an additive. When non-volatile organic compounds were included in 
the crystallization buffer, this led to sample precipitation. In contrast, addition of volatile or-
ganic compounds such as acetone (4%) or 1,4-dioxane (3%) promoted formation of single, 
large crystals. The experiments were easily reproducible, but the presence of the additives in 
the crystallization buffers did not influence the form of the crystals, which were similar to 
those obtained without additives (Figure 6.8).  
 
 
Figure 6.8: Crystallization of CI/Fab 1F5 co-complex in presence of additives. 
The crystals grew in hanging drops at 18 
oC from 8% PEG 3350, 10% glycerol, 100 mM sodium potassium 
phosphate, pH 5.2, supplemented with additives: A: 3% 1,4-dioxane; B: 4% acetone; C: 0.12% Cymal 5. 
 
6.3.2.2  Oils in crystallization of CI/Fab co-complexes 
Judging from the irregular forms and size, the CI/Fab 1F5 crystals grew too fast. Oils were 
employed during crystallization of the co-complexes to reduce the growth rate and to control 
the  nucleation  process.  In  the  microbatch  experiments  using  the  72  well  Terasaki  plates 
(Hampton Research) heavy whitish precipitate was observed in all wells. The experiments 
were performed at 18 
oC. Presence of oils in the setups abolished crystallization, regardless of 
the oil type and volume. The results were similar when crystallization was carried out in 96 
Well  IMP@CT™  plates  (Greiner  Bio-One),  with  controlled-evaporation-rims,  filled  with 
crystallization buffer. Furthermore, introduction of an oil layer into standard vapor diffusion 
experiments, where the protein drop was not in contact with the oil, caused formation of a 
similar precipitate. Most likely the oils interfered with detergents present in the protein drop 
and/or glycerol present in the crystallization buffers. To sum up, addition of oils was not suit-
able for crystallization of CI/Fab co-complexes.   
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6.3.2.3 Seeding  
In order to obtain CI/Fab 1F5 crystals of a better quality seeding experiments were performed 
in three variants described in 13.9.6. Both, sitting and hanging drop systems were tested. In 
the seeding experiments, self-nucleated crystals appeared already after several hours indepen-
dent of the seed stock dilution used. The quality of the crystals was similar to those observed 
under standard conditions. 
6.3.2.4 Lipids and the crystals quality 
 A strict relationship between the crystals’ quality and the amount of the native lipids
1 was 
observed for the CI/Fab 1F5 co-complex. It was possible to grow crystals from 8% PEG 3350, 
10% glycerol, 100 mM sodium potassium phosphate, pH 5.2 in a reproducible manner at 18 
oC. However, the best quality crystals originated from preparations, where the amount of li-
pids
1 was around 150 nmol lipids/mg co-complex (Figure 6.9).   
 
 
Figure 6.9: High quality crystals of the CI/Fab co-complex.  
The crystals grew from 8% PEG 3350, 10% glycerol 100 mM sodium potassium phosphate, pH 5.2, in hanging 
drops (A, C, D) and sitting drops (B). The crystallization sample contained ~ 150 nmol PC/mg co-complex what 
was a quality-determining factor.  
                                                 
1 Determined by malachite green assay described in 13.6.9. 
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Single, large (~ 0.4 x 0.4 x 0.3 mm) and regular crystals appeared after 24 hours and achieved 
their maximum size by the fifth day after setting the drops. Generally, the crystals grew more 
eagerly in the sitting drop setups, although they were smaller and rarely only a single crystal 
was formed. The hanging drop setups, on the other hand, yielded large, single crystals. Prepa-
rations where the phospholipid content was below 110 nmol /mg co-complex did not crystall-
ize. In case of the co-complex crystals from batches with more than 190 nmol phospholi-
pids/mg co-complex grew as irregular forms of non-satisfying quality. The amount of the na-
tive lipids depended strongly on the purification procedure, and was not easily predictable or 
controllable. If a batch of complex I had a low lipid-content, external PC was added to bal-
ance the difference. The degree of delipidation correlated with the amount of detergent mole-
cules per complex I during the Ni
2+-NTA affinity as well as size exclusion chromatography. 
The differences in the sample characteristics are obvious from comparing Table 6.1 and Table 
6.2. First of all, the amount of total lipids was significantly higher for the initial conditions. 
Secondly, although the amounts of native lipids were the same, the specific dNADH:DBQ 
oxidoreductase activity was almost two times higher for the sample giving rise to high quality 
crystals, when comparing to the initial crystals. 
6.3.2.5 Temperature 
Without doubt, the lipid content played a key role in the crystallization of the CI/Fab 1F5 co-
complex. Temperature appeared to be second important factor. Interestingly at 18 
oC, CI/Fab 
1F5 high quality crystals grew readily from 8% PEG 3350, 10% glycerol 100 mM sodium 
potassium phosphate, pH 5.2 but not 8% PEG 3350, 12% glycerol, 40 mM calcium acetate, 
pH 7.3. The situation was opposite at 10 
oC, where large, high quality crystals grew generally 
from the acetate buffer conditions.  
 
6.3.2.6 Crystal growth using pH gradient  
It was possible to grow CI/Fab 1F5 crystals using pH gradient
2. When the phosphate buffer 
was used (8% PEG 3350, 10% glycerol 100 mM sodium potassium phosphate, pH 4.5) the 
CI/Fab 1F5 crystals, although under heavy precipitate, were similar to these obtained, when 
grown in constant pH conditions (Figure 6.10 A). The same experiments conducted with cal-
cium acetate buffer (6% PEG 3350, 12% glycerol, 40 mM calcium acetate, pH 6.0) resulted in 
growth of irregular crystals (Figure 6.10 B). No crystals were observed, when the protein was 
mixed with crystallization buffer containing PEG 3350 at concentration lower than 7%. 
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Sample characteristic   
Protein concentration  35 mg/ml 
Phospholipid content 
Native lipids 
Added lipids 
nmol/mg co-complex 
148 
0 
Total  148 
Specific activity 
NADH:HAR oxidoreductase 
dNADH:DBQ oxidoreductase 
µmol min
-1 mg
-1 
66 
6.8 
Crystal growth conditions   
Temperature  18 
oC 
System  Vapor diffusion, hanging and sitting drop 
Drop volume  1-3 µl 
Reservoir volume  1 ml 
Detergent  0.015%  C12E9 
Additive  0.2% Cymal 4/0.072% PC  
0.12% Cymal 5/0.072% PC 
Table 6.2: Characteristics of a CI/Fab 1F5 crystallization sample yielding high quality crys-
tals.  
 
 
 
 
 
 
Figure 6.10: Growth of CI/Fab 1F5 crystals under pH gradient conditions.  
A: Reservoir solution: phosphate buffer, pH 4.5, Drop solution: phosphate buffer, pH 5.2; B: Reservoir solution: 
acetate buffer, pH 6.0, Drop solution: acetate buffer, pH 7.0.  
 
A  BCRYSTALLIZATION OF CI/FAB CO-COMPLEXES  
   
 
 
  56 
6.3.2.7 Dehydration of co-complex crystals 
The aim of the dehydration experiments was to improve the diffraction properties of the co-
complex crystals. Due to the fragility and temperature-sensitive  nature of the co-complex 
crystals
3, the trials were performed at 10 
oC. As revealed by microscopic inspection, the crys-
tals exposed to the dehydration solution for more than two hours suffered from dehydration 
damage. Crystals not displaying any signs of damage (dehydrated for 1,5 hours) were frozen 
in liquid nitrogen at 20 minutes intervals in the absence of additional cryoprotectant. When 
measured at the ESRF in Grenoble, France, the dehydrated crystals did not diffract x-rays. 
This was most likely due to excessive water removal and collapse of the crystals packing. An 
alternative  to  this  experiment,  would  be  controlled  dehydration  by  means  of  a  humidity 
chamber as the one described by Reiner Kiefersauer et al,. [98]. 
6.3.2.8 Soaking of the co-complex crystals in Ta6Br12
2+  
The CI/Fab 1F5 crystals remained stable upon soaking in Ta6Br12
2+ solution. The compound 
was added to the drops containing crystals either as a solid (a couple of crumbs added directly 
to the drop) or as 10 mM solution in water. Microscopic inspection of the crystals did not re-
veal any cracks or damage after 24 hours incubation. An example crystal was measured at the 
ESRF in Grenoble, France. Unfortunately, no diffraction pattern was observed for this par-
ticular crystal. As the crystal was already over one month old, this might have been the reason 
for lack of diffraction. The experiments will be repeated with freshly grown crystals.  
 
 
Figure 6.11: CI/Fab 1F5 co-complex crystals after soaking in Ta6Br12
2+. 
A: Crystal grew from 11% PEG 3350, 12% glycerol, 40 mM calcium acetate, pH 7.3 with 0.12% Cymal 5 as 
additive. B: Crystal grew from 19% PEG 3350, 12% glycerol, 40 mM calcium acetate, pH 7.3 with 0.12% Cym-
al 5. The crystals were soaked in 10 mM Ta6Br12
2+ for 24 hours at 10 
oC.  
                                                 
3 The CI/Fab 1F5 crystals melted fast when exposed to air at room temperature.  
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6.3.3  Diffraction of CI/Fab 1F5 crystals 
The screening of the CI/Fab 1F5 co-complex crystals was performed at the ESRF beamline 
ID 14-2 in Grenoble, France, whereas the data sets were collected at the Swiss Light Source, 
beamline PXII in Switzerland. The best crystals diffracted X-rays to below a resolution of 7 
Å. It was possible to collect a data set composed of 600 diffraction images from a single crys-
tal without significant loss in data quality. An example diffraction image is depicted in Figure 
6.12. Data collection parameters are summarized in the Table 6.3. The images were processed 
with the HKL suite package (Otwinowski, Minor). The preliminary results suggest that the 
crystal lattice is of the cubic type and display space group different from the one observed for 
native crystals.   
 
Data collection parameters   
Detector  MAR 225 mm CCD  
Wavelength  0.99187 Å 
Detector to crystal distance  700 mm 
Oscillation range  0.3˚ 
Oscillation start  0˚ 
Beam centre  x 103 y 112.1 
Table 6.3: Parameters of the data collection for a CI/Fab 1F5 crystal. 
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Figure 6.12: Diffraction image of CI/Fab 1F5 co-complex crystal.  
The X-ray diffraction data were collected at the Swiss Light Source, beamline PX II. The crystal diffracted X-
rays to a resolution of 7.2 Å. The shadow present on the image resulted from a detector defect, and at this stage 
was of a minor significance. 
 
The unit cell dimensions calculated from indexing of the images with DENZO (HKL pack-
age) seem to be as follows: a = 471 Å, b = 471 Å, c = 472 Å, α = 90˚, β = 90˚, γ = 90˚. Such 
an extremely large volume of the primitive cell is rarely seen for the protein crystal systems, 
but common  for ribosomes [99]. Another  interesting observation concerns the reflections, 
which lay in a close neighborhood to each other. This may be explained by the large unit cell 
dimensions. In order to address these questions, further processing of data and optimization of 
the crystal quality is required.   
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7  SOLVING  THE  X-RAY  STRUCTURE  OF  MITOCHON-
DRIAL COMPLEX I 
Until recently the structural information on complex I was derived mainly from electron mi-
croscopic studies [6;100-102].  Electron microscopic (EM) reconstruction of the E. coli com-
plex I showed that the peripheral and the membrane arms are connected via a thin junction 
[3]. The peripheral arm of the  bacterial enzyme was crystallized and a partial X-ray structure 
of the complex I from Th. thermophilus was solved [37]. Although the prokaryotic protein 
represents the minimal model of complex I, the peripheral arm structure from Th. thermophi-
lus does not answer the key questions regarding the energy coupling. The available structural 
information on the membrane arm is very limited and the proton pumping mechanism has not 
been elucidated yet. The architecture of complex I has also been addressed using methods, 
such as studies of subcomplexes [25], site directed mutagenesis [103;104] and structure pre-
diction. The tremendous structural and functional complexity of the enzyme is mirrored by 
extreme difficulties with its purification and crystallization. The L-shaped protein displays 
significant internal flexibility including bending motions of the peripheral and the membrane 
arm and other possible functional conformational changes [6]. This renders generation of high 
quality crystals diffracting to high resolution difficult, if not impossible. Nevertheless, a high 
resolution X-ray structure of the holoenzyme will be prerequisite for understanding the mole-
cular machinery of the energy coupling by complex I. A well established purification protocol 
of Y. lipolytica complex I yields a highly pure and active enzyme in quantities suitable for 
crystallization attempts (protocol modified after [105]). In contrast to the bacterial enzyme, 
complex I from Y. lipolytica is very stable and crystallizes as a holocomplex. However, the 
quality of the native protein crystals is limited.  
The role of antibody fragments as tools for structural studies has become increasingly impor-
tant over recent years. Following the successful cases of the cytochrome c oxidase from P. 
denitrificans [61;68], cytochrome bc1 complex from Saccharomyces cerevisiae [60], human 
β2 adrenergic G-protein coupled receptor [67] and KcsA K
+ ion channel from Streptomyces 
lividans [85], attempts were undertaken to apply the antibody fragment-mediated crystalliza-
tion  for complex I structural characterization.  SOLVING THE X-RAY STRUCTURE OF MITOCHONDRIAL COMPLEX I  
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7.1  PREPARATION OF HOMOGENOUS Fab FRAGMENTS 
Preparation of highly pure Fab fragments of IgG molecules suitable for crystallization trials 
was one of the important parts of this project. After a set of proteolytic enzymes and different 
fragmentation conditions were tested, an immobilized papain-based protocol was developed. 
Since the first reports in the late fifties [106] generation of antibody fragments by proteolytic 
digestion of γ immunoglobulins become a standard technique [107;108]. The mechanism of 
fragmentation by means of diverse proteolytic enzymes has been studied for antibodies from 
different species. Nevertheless, preparation of homogenous Fab fragments is not straightfor-
ward and has to be optimized separately for each antibody. Papain is a thiol protease with 
broad substrate specificity, which can give rise to undesired heterogeneous fragments. Varia-
ble digestion of the IgG molecule in the hinge region results in a mixture of Fab and Fab’ 
fragments. The latter contains an additional small portion of the heavy chain constant domain. 
In some cases the impurity represented by this extra portion may disturb crystallization, while 
in other cases it may play an insignificant role. For example, the Fab fragment and the ten 
amino acids longer Fab’ fragments from human myeloma IgG1 proteins were crystallized. 
Identical crystalline forms and diffraction patterns were observed, regardless of the size of the 
proteolytic fragment [109]. On the other hand, it can be anticipated, that the presence of oli-
gosaccharides (derived from the Fc part heavy chain) in the Fab’ fragment may introduce a 
significant inhomogeneity and abolish crystallization.   
During the initial crystallization of the CI co-complexes, an un-purified papain digestion mix-
ture was used as a source of Fab fragments. The resultant crystals were of low quality and 
difficult to reproduce. The most important step in the preparation of Fab fragments was sepa-
ration of the un- and partially digested antibodies. Although whole antibody molecules were 
crystallized and their X-ray structures were solved [110-112], the flexibility in the hinge re-
gion is detrimental for crystallization. Furthermore, the bifunctionality of the un- and partially 
digested  antibodies  is  undesired  in  crystallization  experiments,  since  it  introduces a  pro-
nounced  inhomogeneity to the sample. With a size exclusion column  having a separation 
range of 3-70 kDa it was not possible to resolve fragments with a mass difference smaller 
than 1 kDa. In order to separate proteolytic fragments with small mass differences, prepara-
tive isoelectric focusing (IEF) could be employed. Crystallization trials of the CI/Fab 1F5 co-
complex included Fab fragments derived from a Protein G purified papain digest. The undi-
gested and partially digested antibody fragments (F(ab)2  or F(ab’)2) were separated from the 
mixture using gel filtration. A second round of size exclusion chromatography was employed SOLVING THE X-RAY STRUCTURE OF MITOCHONDRIAL COMPLEX I  
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to achieve the highest possible purity of the sample. This procedure ensured production of 
homogenous Fab fragments as judged from size exclusion chromatography and SDS PAGE 
(Figure 3.18)  
It has also been shown, that the mouse IgG subclasses display variable susceptibility to papain 
or pepsin [107;113;114]. The mouse IgG1 subclass exhibits the highest resistance to papain 
and the presence of 10 mM cysteine is necessary for Fab formation. Results of liquid chroma-
tography-electrospray ionization mass spectrometry (LC/ESI-MS) of IgG1 papain digest indi-
cated a two-step fragmentation mechanism [115]. During the first step IgG1 is cleaved to 
F(ab’)2 and Fc fragments. In the second stage, thiol reduction of the interchain disulphide 
bonds in the hinge region is crucial in the formation of the Fab fragments. The same study 
revealed that, the subclass IgG2a was easily cleaved to Fab and Fc fragments in the absence 
of cysteine.  
The antibodies used in this project belonged to the subclass IgG1 (31A8 and 44G10), and to 
the subclass IgG2a (1F5). SDS-PAGE and gel filtration showed different papain–sensitive 
sites for all three monoclonal antibodies used. The largest Fab fragment (~50 kDa) resulted 
from fragmentation of the 44G10 antibody. Though the elution profile of Fab 44G10 was 
represented by a single, uniform peak, a double band in the region of 50 kDa was observed by 
SDS-PAGE (Figure 3.18). After incubation with complex I and subsequent size exclusion 
chromatography only the polypeptide corresponding to the upper band did bind to complex I 
and was detected in the co-complex, by Western blot (Figure 5.4). Most probably, proteolytic 
digestion produced two isoforms of Fab fragments, where only one (the upper one) possessed 
the ability to bind the antigen. The Fc fragment was removed from the sample during the Pro-
tein G affinity chromatography and could not account for the polypeptide represented by the 
lower band.  
Antibody Fab 31A8 released the smallest Fab fragment (~ 46 kDa) compared to the 1F5 and 
44G10. Interestingly, this fragment dissociated easily into light and heavy chain when incu-
bated in SDS under non-reducing conditions. This indicated low stability, or even loss of na-
tive conformation which in turn may explain negligible binding to complex I. The affinity of 
31A8 Fab fragments towards the antigen was almost undetectable in the SPR experiments 
confirming the binding data, where the Fab fragment could be separated from complex I on a 
gel filtration column. It was concluded, that the antigen binding site was most probably dam-
aged during papain digestion.  
Fragmentation of immunoglobulin 1F5 produced Fab fragments (~ 48 kDa), which appeared 
to be the most useful ones. Dissociation into light and heavy chain was minor (Figure 3.18) SOLVING THE X-RAY STRUCTURE OF MITOCHONDRIAL COMPLEX I  
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and at the same time the affinity towards the antigen (measured using SPR) was the highest 
among  analyzed  Fab  fragments.  This  fragment  was  successfully  employed  in  co-
crystallization trials with complex I.  
7.2  Fab-MEDIATED CRYSTALLIZATION OF COMPLEX I  
The first co-crystallization experiments of complex I were carried out in the presence of Fv 
fragments. The recombinant Fv fragments of antibodies 31A8 were produced in the bacterial 
periplasm.  Using  Western  blot  it  was  shown  that  the  Fv  fragments  formed  a  stable  co-
complex with complex I. Nevertheless, low yield of the bacterial expression was the limiting 
factor in the co-crystallization attempts [116]. Moreover under the tested conditions, no im-
provement in the crystal quality upon Fv binding was observed (Zickermann unpublished). 
Most probably the extra hydrophilic portion delivered by the Fv fragments was too small for 
formation of new crystal contacts. The Fv fragments represent the smallest portion of an im-
munoglobulin, which possess antigen binding ability, but the mass is roughly 30-40 times 
smaller than that of complex I.  
The aim of this project was co-crystallization of complex I with proteolytic Fab fragments and 
structural characterization of the co-complexes. The monoclonal antibodies used for prepara-
tion of the fragments bind different epitopes within the complex I membrane arm at the inter-
membrane space site (Figure 7.1). The epitopes appear to be very attractive for the crystalliza-
tion experiments, since they offer formation of possible crystal contacts involving the mem-
brane part of the protein. The antibodies 44G10 and 31A8 are Western blot negative and were 
classified as conformation specific antibodies (Zickermann, unpublished). In contrast, the IgG 
1F5 recognizes a linear epitope [17]. The immunoglobulins were digested using immobilized 
papain to gain Fab fragments, suitable for co-crystallization attempts.  SOLVING THE X-RAY STRUCTURE OF MITOCHONDRIAL COMPLEX I  
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Figure 7.1: Electron microscopy of complex I from Y. lipolytica decorated with monoc-
lonal antibodies (Bostina et al. unpublished).  
 
The upper images represent average of the statistical analysis of the representations shown in the lower panel 
images. A: antibody 30C12 binding NESM subunit (analogously to antibody 1F5) [17]; B: conformation specific 
antibody 44G10. C: conformation specific antibody 31A8.  
 
The major difference to the published co-complexes is the size ratio of the antibody fragment 
to the antigen. In case of the KcsA potassium channel, the Fab fragment comprises about 2.5 
times the mass of the antigen, providing a hydrophilic domain reaching far beyond the deter-
gent micelle and leading to formation of spacious crystal packing. The monomer of complex I 
from Y. lipolytica is roughly 20 times larger than the binding antibody fragment. Nonetheless, 
it was possible to grow crystals of Fab co-complexes of the NADH:ubiquinone oxidoreduc-
tase from Y. lipolytica, with X-ray diffraction properties indicating a different space group 
when compared to the native enzyme.     
7.2.1  CI/Fab 1F5 crystals 
Data presented in this study suggest that the Fab 1F5 participates in crystal contact formation, 
since the co-complex crystallized in a space group different to the one observed for the native 
enzyme under the same conditions. The initial diffraction data suggested even crystal packing 
of a higher symmetry, when compared to the un-complexed protein. The Fab fragment binds 
to the NESM subunit in the distal part of the membrane arm. Significant improvement in dif-
fraction quality of the CI/Fab 1F5 crystals was achieved. The initial crystals grown in condi-
tions identical to the native protein diffracted X-rays to a resolution of 20 Å. Use of Fab 
fragments prepared according to the optimized protocol enhanced crystal quality. Further im-
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provements involved optimization of the lipid content of the crystallization sample. Finally, 
the mentioned procedures together with growth under a pH gradient led to production of crys-
tals diffracting X-rays to a resolution of 7 Å. Nevertheless, further enhancements of the crys-
tal quality will be required in order to obtain structural information. 
To this end, screening for better cryoprotection conditions will be employed in ongoing expe-
riments. Preliminary optimization of the cryoconditions indicated that freezing in liquid pro-
pane is superior to freezing in liquid nitrogen. An improvement of diffraction limit from 16 Å 
to 12 Å resolution was observed. However, these results need to be verified, since it is well 
known that even crystals coming from the same drop may display very different diffraction 
quality.  
 For further expansion of the hydrophilic domain, a combinatorial crystallization technique 
could be considered [117;118]. Attachment of Fab binding domains such as protein L from 
Peptostreptococcus  magnus  (PpL),  protein  A  from  Staphylococcus  aureus  (SpA)  and  the 
streptococcal protein G (SpG), would provide an additional hydrophilic part, which in turn 
could greatly enhance crystallization. The disadvantage of this method could be internal flex-
ibility resulting from the attachment of an extra polypeptide chain. This would be detrimental 
for crystallization trials.   
Employment of a humidity chamber, which allows a controlled dehydration process, seems to 
be a promising technique for improvement of the diffraction quality of protein crystals [98]. 
In non-controlled dehydration experiments of CI/Fab 1F5 crystals using high concentrations 
of polyethylene glycol in the bottom solution a substantial amount of solvent was withdrawn 
from the crystals. As a result, the crystal lattice was most probably disrupted, since no diffrac-
tion pattern was observed when the crystals were measured at synchrotron radiation facility.   
Once crystals of higher quality will be obtained, the structural characterization of the co-
complexes is expected to be a valuable source of information on the structural architecture 
and function of eukaryotic complex I.  
7.2.2  Crystallization with conformation specific antibody fragments  
If possible, co-crystallization with  antibody  fragments derived  from  conformation specific 
antibodies offers a unique approach of trapping a protein molecule in a particular conforma-
tional state. In the case of NhaA, a bacterial Na
+/H
+ antiporter, conformation specific antibo-
dies were used for functional and structural studies [119]. The pH-mediated regulation of the 
activity was shown to be accompanied by a conformational change in the hydrophilic amino-
terminus. Moreover, antibody 1F6 was  shown to bind only to the alkaline  state of NhaA SOLVING THE X-RAY STRUCTURE OF MITOCHONDRIAL COMPLEX I  
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[120]. The crystals of the Fab co-complexes of the E. coli NhaA diffracted X-rays to a maxi-
mum resolution of 7.9 Å [Venturi, PhD thesis].  
In another example HIV gp120 envelope glycoprotein was neutralized with antibodies recog-
nizing the native protein [121]. The Fab fragments were used to identify two molecular sur-
faces with immunogenic potential, one competitive with the CD4 receptor and the other com-
petitive with the chemokine receptors. A structure of the ternary complex of a partially degly-
cosylated HIV-gp120 core bound to a two-domain fragment of the CD4 cellular receptor and 
to Fab fragment against a CD4i (CD4-induced) epitope was solved at 2.5 Å resolution [122]. 
This work provided evidence for a conformational change upon CD4 binding, the nature of 
CD4-induced antibody epitope, and a specific mechanism of immune evasion.  
Structural studies of the potassium channels using the Fab approach became almost a standard 
technique in the group of Roderick MacKinnon. In addition to expanding the hydrophilic do-
main, the antibody fragments were employed for determination of the phases to solve the 
structures. To address the function of the voltage-dependent KvAP potassium channel from 
Aeropyrum pernix, conformational Fab fragments were attached to the voltage sensor paddles 
to detect their motions. Combining results from the crystal structure, electrophysiological as-
says [123;124] and electron microscopic analysis [125] the authors proposed a new model of 
voltage-dependent gating, where the voltage-sensor paddles move across the membrane carry-
ing the load of gating charges through the electric field [124]. 
Conformation specific antibodies used in this study (31A8 and 44G10) gave positive signals 
in the native ELISA test. It is however not known if these antibodies indeed stabilize a specif-
ic conformation of the native enzyme. Surface plasmon resonance (SPR) experiments (see 4) 
show, that presence of NADPH did not influence binding of the antibodies 31A8 and 44G10 
to complex I. In contrast, the relative response of antibody 1F5 dropped significantly above 
NADPH concentrations of 1µM. This suggests that binding of antibody1F5 to the complex I 
conformation exerted by NADPH is limited. When an ‘aged’ sample of complex I was used in 
SPR measurements, the affinity of the antibodies 31A8 and 44G10 decreased with time, until 
it reached a constant value of approximately 70 % of the initial records. This was not the case 
for antibody 1F5, which affinity towards complex I did not change regardless to the age of the 
sample. This result correlates with the fact that 1F5, in contrast to the other two antibodies, 
recognizes a linear epitope within complex I.    
Although, various  fragmentation  methods were  employed,  it was  not possible to generate 
functional Fab fragments of the antibody 31A8. It was deduced, that the antigen binding site 
of the IgG 31A8 was distorted during the papain digestion step.  SOLVING THE X-RAY STRUCTURE OF MITOCHONDRIAL COMPLEX I  
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The Fab 44G10 was shown to bind tightly to complex I. Even though an extensive screening 
(over 2500 conditions at 4
 oC and 18 
oC) was carried out, no suitable crystallization conditions 
were found. The quality of the initial crystals obtained for CI/Fab 44G10 co-complex was not 
sufficient for crystallographic analysis. It was concluded that the Fab 44G10 fragments had a 
deleterious effect on the crystallization process. The IgG fragment, which binds possibly to 
the 39-kDa subunit (Zickermann, unpublished), must impose an unfavorable crystal packing, 
which abolishes crystallization.  PRÉCIS  
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8  PRÉCIS  
Fab fragments suitable for co-crystallization with complex I were generated using an immobi-
lized papain-based protocol. The binding of the antibody fragments to complex I was verified 
using Surface Plasmon Resonance and size exclusion chromatography. The binding constants 
of the antibodies and their respective Fab fragments were found to be in the nanomolar range.  
This work presents the first report on successful crystallization of complex I (proton pumping 
NADH:ubiquinone oxidoreductase) from Yarrowia lipolytica with proteolytic Fab fragments. 
The quality of the crystals was significantly improved when compared to the initial experi-
ments and the best crystals diffracted X-rays to a resolution of ~7 Å. The activity of complex 
I remained uninfluenced by antibody fragment binding. The initial diffraction data suggest 
that the complex I/Fab co-complex crystals represent a space group different to the one ob-
served for the native protein. Ongoing experiments are aimed at further enhancements of the 
diffraction quality of the crystals.  
Providing a different space group the CI/Fab co-complexes may become a very useful ap-
proach for structure determination of the enzyme. Moreover, the bound Fab offers an addi-
tional  possibility  to  generate  phase  information.  The  antibody-mediated  crystallization 
represents a valuable tool in structural characterization of the NADH:oxidoreductase subcom-
plexes or even single subunits.  
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9  UGP1P –INTRODUCTION 
9.1  UDP-GLUCOSE PYROPHOSPHORYLASE – THE REACTION ME-
CHANISM 
UDP-glucose  pyrophosphorylase  (UGP1,  Ugp1p,  UTP:α-D-glucose-1-phosphate  uridylyl-
transferase, UDPGP, EC 2.7.7.9) catalyzes the Mg
2+-dependent formation of UDP-glucose 
and pyrophosphate, from glucose-1-phosphate and UTP  [126] (Figure 9.1). The ΔG˚΄ of the 
phosphoanhydride exchange between glucose-1-phosphate and UTP is close to zero. Thus the 
reaction is thermodynamically readily reversible. 
 
 
 
Figure 9.1:  The reaction catalyzed by UDP-glucose pyrophosphorylase.  
In the readily reversible reaction the phosphoryl-oxygen of glucose-1-phosphate attacks the α-phosphorus atom 
of UTP. As a result, UDP-glucose and pyrophosphate are formed. Pyrophosphatase hydrolyzes the inorganic 
pyrophosphate in a highly exergonic reaction, which renders the formation of UDP-glucose energetically favora-
ble and physiologically irreversible.  
Glucose-1-phosphate 
pyrophos-
phatase 
UTP 
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Nevertheless,  hydrolysis of the  formed PPi (pyrophosphate) by the omnipresent inorganic 
pyrophosphatase is highly exergonic (ΔG˚΄= - 33.5 kJ*mol
-1) and as a result the overall reac-
tion of UDP-glucose formation is physiologically irreversible. The reaction kinetics follow an 
ordered bi-bi mechanism, which involves formation of a ternary enzyme/substrate complex, 
where the nucleoside phosphate binds prior to pyrophosphate or glucose-1-phosphate [127-
129].  A  similar  uridylyl  transfer  reaction  is  catalyzed  by  galactose-1-phosphate-uridyl-
transferase (see following chapter). In contrast to UDP-glucose pyrophosphorylase, the kinet-
ics of this enzyme display double-displacement characteristics (ping-pong kinetics), with par-
ticipation of a free uridyl enzyme intermediate [130-132]   
9.2  UDP-GLUCOSE AT THE CROASSROADS OF SUGAR METABOL-
ISM 
The universal distribution of UDP-glucose pyrophosphorylase in nature results from a global 
need for its major catalysis product UDP-glucose. UDP-glucose represents an activated form 
of glucose which due to the presence of the high energy bonds can transfer glucosyl units in 
numerous cellular reactions. In S. cerevisiae, UDP-glucose serves as a glucosyl donor for the 
synthesis of β-glucan (1,6-β-glucan and 1,3-β-glucan), which represents about 55% of the 
total cell-wall carbohydrates. This polymer is believed to be the key factor in determining the 
morphology and in maintaining the osmotic integrity of the yeast cells [133]. It was shown, 
that deletion of the UGP1 gene in S. cerevisiae, was lethal for the yeast cells [134]. Addition-
ally, UDP-glucose is involved in trehalose synthesis in yeast. In animal cells UDP-glucose 
plays an  important role  in the synthesis of glycogen. Direct polymerization of glucose-1-
phosphate units to glycogen under phosphate-release is thermodynamically impossible (posi-
tive ΔG˚΄). Since the discovery of Luis Leloir in 1957 it is known that glucose can be trans-
ferred onto the non-reducing end (atom C4) of the growing glycogen chain only in its acti-
vated form, as UDP-glucose. The transfer of glucosyl units of UDP-glucose to the glycogen 
chain results in formation of α(1→4) gylcosidic bonds and is catalyzed by glycogen synthase. 
Although the synthesis of glycogen  is  not exclusively dependent on the activity of UDP-
glucose  pyrophosphorylase,  malfunction  of  the  enzyme  may  affect  polysaccharide  levels 
[135]. In plants, UDP-glucose is an important precursor in the synthesis of sucrose [136] and 
direct or indirect precursor in the synthesis of cellulose, pectines and hemicellulose [137]. 
Moreover,  in  the  reaction  coupled  to  ADP-glucose  pyrophosphorylase  (AGPase)  activity, 
UDP-glucose is directly converted to ADP-glucose, which participates in starch biosynthesis UGP1P –INTRODUCTION  
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[138]. The crystal structure of ADP-glucose pyrophosphorylase from potato tuber was solved 
by Jin et al. [139] without substrate and in co-complexes with ADP-glucose and ATP respec-
tively (PDB 1YP2, 1YP3, 1YP4).  Recently, a new structure from Agrobacterium tumefaciens  
was deposited in the PDB [140]. In all eukaryotes, UDP-glucose is involved in the synthesis 
of the carbohydrate moiety of glycolipids and glycoproteins as it participates in the formation 
of Glc3Man9GlcNac2, which is necessary for N-glycosylation of proteins [141] [142]. Accord-
ing to some studies, UDP-glucose may participate in the synthesis of glucomannoproteins, 
which are present in the yeast cell wall [143]. The role of UDP-glucose in the synthesis of 
proteoglycans was described by [144]. It was also shown that UDP-glucose pyrophosphory-
lase is necessary for the production of the capsular polysaccharide, the virulence factor of 
Streptococcus pneumonia [145]. UDP-glucose pyrophosphorylase is also crucial for galactose 
metabolism. In order to utilize galactose in glycolysis, it has to be converted into glucose, or 
more precisely to glucose-6-phosphate. The two monosaccharides are epimers with different 
configuration only at the C4 atom, but the conversion of glucose to galactose is not a simple 
one step epimerization reaction. It requires the action of four enzymes: galactokinase, galac-
tose-1-phosphate uridylyl transferase, UDP-galactose-4-epimerase and phosphoglucomutase. 
The so called Leloir pathway is represented schematically in Figure 9.2. In the first step of 
this pathway, galactose is ATP-phosphorylated at C1 by galactokinase. Next, galactose-1-
phosphate uridylyl transferase transfers the uridylyl group of UGP-glucose to galactose-1-
phosphate  yielding  glucose-1-phosphate  and  UDP-galactose.  The  latter,  is  epimerized  to 
UDP-glucose by means of UDP-galactose-4-epimerase. This step is NAD
+ dependent indicat-
ing incolvement of a sequential redox mechanism at C4 atom of the monosaccharides. In the 
final reaction, glucose-1-phosphate is converted to glucose-6-phosphate, which can directly 
enter glycolysis. Malfunctioning of the enzymes of the Leloir pathway causes severe metabol-
ic disorders, collectively referred to as galactosemia. The disease was first described by Gop-
pert in 1917 [146]. Defects in the gene encoding galactose-1-phosphate uridylyl transferase 
(classic galactosemia) lead to poor growth in children, speech abnormality, mental retarda-
tion, cataract and liver damage (which may be lethal). UGP1P –INTRODUCTION  
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Figure 9.2: Interconversion of galactose and glucose in the Leloir pathway. 
Galactose can enter glycolysis only after it is epimerized to glucose. This is achieved in the Leloir pathway, 
where galactokinase, galactose-1-phosphate uridylyl transferase, UDP-galactose-4-epimerase and phosphoglu-
comutase mediate the outlined reactions of galactose/glucose interconversion. Gal-galactose; Glc-glucose; P-
phosphate; UDP-uridylyl diphosphate. The figure is based on Biochemistry, 2
nd edition, Voet & Voet, p. 478, 
Figure 16-35.  
 
 
 
Elimination  of  lactose  and  galactose  from  the  diet  can  induce  regression  of  the  cataract 
(clouding of the eye lenses), but neurological complications are permanent. Overexpression of 
human UDP-glucose pyrophosphorylase (hUGP2) in S. cerevisiae was reported to rescue ga-
lactose-1-phosphate uridylyl transferase-deficient yeast [147]. Galactokinase deficiency (ga-
lactosemia type 2 or GALK deficiency), is characterized by an accumulation of galactose and 
galactitol as a consequence of disabled conversion of galactose to galactose-1-phosphate by 
galactokinase. Buildup of galactitol, a toxic sugar alcohol causes cataract [148;149]. Imple-
mentation of a galactose-free diet alleviate the symptoms of this genetic disorder. Galactose-
mia type 3 is very rare and results in clinical symptoms similar to classical galactosemia and 
also severe delays in both motor and cognitive skills [150].  UGP1P –INTRODUCTION  
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9.3  UGPASES  
UGPases are ubiquitous cytosolic proteins which were purified from a variety of sources since 
their discovery [151]. The molecular mass of a monomer varies between 40 and 60 kDa de-
pending on the species. The enzymes are most abundant in tissues displaying high polysac-
charide synthesis activity. In the protein extractable from calf liver, the UGPases account for 
up to 0.2% [152], and they represent 1% of the total slime mold protein [153]. In tumor tissue, 
where the glycolytic activity is increased compared to normal cells, UGPase content is de-
creased by up to 50% [154].  In higher animals, the highest concentrations of UDP-glucose 
pyrophosphorylase are found in liver, while brain, spleen, lung and fat tissues contain rather 
low amounts of the enzyme [155]. In higher plants, UGPases activity  levels are typically 
linked to the demand for starch and sucrose [126]. Chloroplasts and starch granules may also 
contain high concentrations of the enzyme.  
Together with other glycosyltransferases, UGPases  belong to the SGC superfamily (SpsA 
GnT I core domain), which was defined on the basis of structural similarity of Bacillus subti-
lis  glycosyltransferase  (SpsA)  and  N-acetylglucosaminyltransferase  from  rabbit  (GnT  I) 
[156]. The proteins, although possessing low sequence identity, are characterized by the pres-
ence of a signature called SGC fold [156;157] . An SGC fold is characterized by an eight-
stranded β-sheet, flanked with α-helices (Figure 9.3). Furthermore, UGPases posses a charac-
teristic motif in their active site (LxxGxGTxxxxxxPK) that is conserved throughout the super-
family. 
 
Figure 9.3: Rabbit GnT I protein-the representative of SGC domain (SpsA GnT I core 
domain)  
GnT I ribbon diagram (Fig. 1. Unligil et al., 2000 [156]). The protein is composed of two domains: domain 1 
(cyan) and domain 2 (orange). UDP-GlcNAc (UDP-N-acetylglucosamine) binding loop is shown in red, the 
linker connecting the domains in green. UDP-GlcNAc and Mn
2+ are depicted in yellow.  UGP1P –INTRODUCTION  
   
 
 
  75 
Although eukaryotic UGPases catalyze the same reaction as their bacterial counterparts, the 
proteins show no similarities in the amino acid sequences, nor in the three-dimensional struc-
ture [134;158]. The sequence similarity within eukaryotic enzymes lies between 42 to 95%. 
The UDP-glucose pyrophosphorylase from Y. lipolytica shows 70 % sequence identity to the 
protein from baker’s yeast and 51% to the one from A. thaliana (Figure 9.4). A second iso-
form of UGPase, UGPA2, was found in the S. cerevisiae genome. The two isoforms display 
41% sequence identity [159]. 
 
S.cerevisiae      ----------TYAFESNTNSVAASQMRNALNKLADSSKLDDAARAKFENELDSFFTLFRR 50 
Y.lipolytica      MSKHHLKTQSAVAFDNSATTVAASQMRNALNKLSDS-VEDPAQKRRFENEMDNFFSLFRR 59 
A.thaliana        ---------------MAATTENLPQLKSAVDGLTEM----------SESEKSGFISLVSR 35 
                                   :.:   .*::.*:: *::            *.* ..*::*. * 
 
S.cerevisiae      YLVEKSSRTTLEWDKIKSPNPDEVVKYEIIS----QQPENVSNLSKLAVLKLNGGLGTSM 106 
Y.lipolytica      YLVDKAKGNALDWDRIQPPKAEQVIDYKDID----QDVG-AEFLNKLAVLKLNGGLGTSM 114 
A.thaliana        YLSGEAQH--IEWSKIQTPTDEIVVPYEKMTPVSQDVAETKNLLDKLVVLKLNGGLGTTM 93 
                  **  ::.   ::*.:*:.*. : *: *: :     :     . *.**.**********:* 
 
S.cerevisiae      GCVGPKSVIEVREGNTFLDLSVRQIEYLNRQYDSDVPLLLMNSFNTDKDTEHLIKKYSAN 166 
Y.lipolytica      GCVGPKSVIEVRDGKSFLDLSVRQIEHLNRQYNVDVPFILMNSFNTDEDTQTIIKKYQGH 174 
A.thaliana        GCTGPKSVIEVRDGLTFLDLIVIQIENLNNKYGCKVPLVLMNSFNTHDDTHKIVEKYTNS 153 
                  **.*********:* :**** * *** **.:*. .**::*******..**. :::**    
 
S.cerevisiae      RIRIRSFNQSRFPRVYKDSLLPVPTEYDSPLDAWYPPGHGDLFESLHVSGELDALIAQGR 226 
Y.lipolytica      KINIKTFNQSRFPRVFKDSNLPVPKSFDDRIDAWYPPGHGDLFESLHNSGVLDELIAEGK 234 
A.thaliana        NVDIHTFNQSKYPRVVADEFVPWPSKGKTDKEGWYPPGHGDVFPALMNSGKLDTFLSQGK 213 
                  .: *::****::***  *. :* *.. .   :.********:* :*  ** ** ::::*: 
 
S.cerevisiae      EILFVSNGDNLGATVDLKILNHMIETGAEYIMELTDKTRADVKGGTLISYDGQVRLLEVA 286 
Y.lipolytica      EIIFVSNVDNLGAVVDLSILKHMSTTGSEYIMELTDKTRADVKGGTLIDYDGQVRLLEIA 294 
A.thaliana        EYVFVANSDNLGAIVDLTILKHLIQNKNEYCMEVTPKTLADVKGGTLISYEGKVQLLEIA 273 
                  * :**:* ***** ***.**:*:  .  ** **:* ** *********.*:*:*:***:* 
 
S.cerevisiae      QVPKEHIDEFKNIRKFTNFNTNNLWINLKAVKRLIESSNLEMEIIPNQKTITRDGHEINV 346 
Y.lipolytica      QVPKEHTEEFKSIKKFKYFNTNNLWINLKAIKRVVENNELDSEIIPNEKSITIGKNDIPV 354 
A.thaliana        QVPDEHVNEFKSIEKFKIFNTNNLWVNLKAIKKLVEADALKMEIIPNPKEVDG----VKV 329 
                  ***.** :***.*.**. *******:****:*:::* . *. ***** * :      : * 
 
S.cerevisiae      LQLETACGAAIRHFDGAHGVVVPRSRFLPVKTCSDLLLVKSDLFRLEHGSLKLDPSRFGP 406 
Y.lipolytica      LQLETAVGAAIRHFKGCMGVNVPRRRFLPVKTCSDLLLVKSDLYTLHAGRLEMDPSRFGG 414 
A.thaliana        LQLETAAGAAIRFFDNAIGVNVPRSRFLPVKASSDLLLVQSDLYTLVDGFVTRNKARTNP 389 
                  ****** *****.*... ** *** ******:.******:***: *  * :  : :* .  
 
S.cerevisiae      -NPLIKLGSHFKKVSGFNARIPHIPKIVELDHLTITGNVFLGKDVTLRGTVIIVCSDGHK 465 
Y.lipolytica      -SPLIKLGGHYKKVSDFQKRIPHMPKILELDHLTITGNVMLGKGVTLKGTVICVCEEGKK 473 
A.thaliana        SNPSIELGPEFKKVATFLSRFKSIPSIVELDSLKVSGDVWFGSSIVLKGKVTVAAKSGVK 449 
                   .* *:** .:***: *  *:  :*.*:*** *.::*:* :*..:.*:*.*  ....* * 
 
S.cerevisiae      IDIPNGSILENVVVTGNLQILEH 488 
Y.lipolytica      IDIPNGSVLENVVITGSLSILEH 496 
A.thaliana        LEIPDRAVVENKNINGPEDL--- 469 
                  ::**: :::**  :.*  .:    
 
Figure 9.4: UDP-glucose pyrophosphorylase sequence alignment; S. cerevisiae, Y. lipoly-
tica and A. thaliana.         
The sequence identity between the plant and yeast enzymes is 51% for Y. lipolytica and 52% for S.cerevisiae, 
whereas the sequence identity between the yeast proteins amounts to 70%. The nucleotide binding loop sequence 
is enclosed in the blue box, whereas the C-terminal region important for the oligomerisation-in red box. The 
sequence alignment was done using ClustalW2, EMBL-EBI tools. UGP1P –INTRODUCTION  
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The oligomerisation state of UDP-glucose pyrophosphorylases depends on the origin as well 
as environmental conditions. In E. coli, the UGPase that is a product of the galU gene was 
shown to be active in its tetrameric state [160]. The active Ugp1p from S. cerevisiae was puri-
fied as an octamer with a an apparent molecular mass of 448 kDa [161]. In case of the plant 
enzyme, the most active form was typically found as monomer. Dimers and higher order oli-
gomers displayed very little or no catalytic activity. Therefore, it has been proposed that the 
oligomeric state of plant UGPases may regulate enzymatic activity [162]. 
9.4  REGULATION  OF  THE  ENZYMATIC  ACTIVITY  OF  UDP-
GLUCOSE PYROPHOSPHORYLASE  
While yeast UDP-glucose pyrophosphorylase is subject to product inhibition, little is known 
on regulation of its metabolic activity. Glycogen synthesis is regulated at the level of glyco-
gen synthase and glycogen phosphorylase and the regulation mechanism involves phosphory-
lation and allosteric interactions. In case of the mammalian enzyme, regulation of glycogen 
synthesis entails hormone-mediated substrate cycles and enzyme-catalyzed covalent modifi-
cations [163;163]. The activity of phosphoglucomutase determines the glucose-1-phosphate 
pool. In baker’s yeast paralogous PAS kinases Psk1 and Psk2, additionally to glycogen syn-
thase phosphorylate also Ugp1p [164]. Phosphorylation of a single residue Ser11 exerts a con-
formational change in Ugp1p, which is required for targeting the enzyme to the site of glucan 
synthesis in the cell periphery. Two forms of Ugp1p were isolated: isoform 1 (unphosphory-
lated) and isoform 2 (phosphorylated). Cells lacking the phospho-Ugp1p (either due to im-
pairment of PAS kinase genes or mutation of the PAS kinase phosphorylation site) displayed 
a pronounced glycogen hyperaccumulation and a decrease in β-(1,6)-glucan, which is the ma-
jor component of the cell wall. It was hypothesized, that isoform 1 is preferentially used for 
the glycogen synthesis, whereas the phospho-Ugp1p mediates synthesis of UDP-glucose for 
structural carbohydrates [165].  
9.5  UGPASES – STRUCTURAL ANALYSIS 
UDP-glucose pyrophosphorylase was purified and successfully crystallized from a variety of 
organisms. Up to now there are five sources for which high resolution structures were depo-
sited in the PDB. The structure of UDP-glucose pyrophosphorylase from A. thaliana was 
solved for the native enzyme (2q4j, 1z90), in complex with UTP (2icx) and UDP-glucose 
(2icy), which resulted in the highest resolution data set (1.64 Å) [166]. The structure of the UGP1P –INTRODUCTION  
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enzyme from the parasite Leishmania major, was solved to a resolution of 2.3 Å and there are 
two entries in the PDB: 2oef and 2oeg [167]. There are two structures available for the bac-
terial enzyme; from E. coli (2e3d) [168] and from Corynebacterium glutamicum (2pa4) [169]. 
The structure of Ugp1p from baker’s yeast was solved by molecular replacement using the 
structure of the plant enzyme as a template [161]. As mentioned before, the amino acid se-
quence identity between the two proteins is 52%. A superposition of the monomers of the two 
structures (Figure 9.5) exhibits high structural similarity, especially in the SGC domain. The 
C-terminal region, which is important for oligomerisation, lacks the β18 sheet in case of the 
A. thaliana monomer, which is replaced by a short α-helix (blue trace, Figure 9.5). The C-
terminus of yeast and metazoa is characterized by highly conserved hydrophobic residues, 
which are replaced by polar and charged amino acids in the plant enzyme sequences (Figure 
9.4) [161;166]. The β18 sheet participates not only in the oligomerisation event, but also in 
the  formation of a dimeric protomer. While UGPases  from different species display  high 
structural similarity in the active site region, the C-terminus shows pronounced differences.  
 
 
Figure  9.5:  Superimposition  of  the  X-ray  monomer  structures  of  UDP-glucose  pyro-
phosphorylase from A. thaliana (blue) and S. cerevisiae (red).  
The high sequence identity correlates well with the structural similarity. The major difference is observed at the 
C-terminal (marked with an asterisk) of the monomer. In place of the β-sheet β18 in the yeast structure, a shorter 
310-helix is present in the plant enzyme. The figure was prepared using the CCP4 alignment tool (The CCP4 
Suite: Programs for Protein Crystallography. Acta Cryst. D50, 760-763). 
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In the recently solved structure of Ugp1p from baker’s yeast, C-terminal hydrophobic interac-
tions of the monomers mediate the formation of a dimeric protomer per unit cell (Figure 9.6 
A) as well as the association of the protomers into an octameric assembly (Figure 9.6 B). The 
native crystals diffracted X-rays to a resolution of 3.1 Å and were classified to belong to the 
I222 space group [161].  
Ugp1p from Y. lipolytica has not been characterized so far. The protein displays 70% and 
52% sequence identity to the one from S. cerevisiae and the plant enzyme respectively. It is 
likely that the domain architecture is similar to the one observed for other SGC domain pro-
teins. Since the sequence of the active site of the yeast enzyme is conserved, one may assume 
that the secondary structures of this region should be very similar.  It will be interesting to see, 
if and how the protein forms oligomers and what will be the mechanism of regulation of the 
enzymatic activity. In order to address at least some of these questions a structural characteri-
zation of the enzyme will be required.   
 
 
 
   
 
Figure 9.6: Crystal structure of UDP-glucose pyrophosphorylase from S. cerevisiae. 
A: An asymmetric unit contains a dimeric protomer formed by hydrophobic interaction of the C-terminal β 
sheets. B: Side view of octameric Ugp1p. The N-terminal domain is shown in green, the central (SGC) domain 
in yellow, the C-terminal domain in blue. UDP-glucose in ball-and-stick representation was modeled into the 
presumed active site. Figure reprinted from Roeben et al., 2006 [161]. 
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10 UGP1P - RESULTS  
UDP-glucose pyrophosphorylase from S. cerevisiae displays affinity towards Ni
2+-NTA (prof. 
Andreas Bracher, personal communication). The same was observed for Ugp1p from Y. lipo-
lytica and the enzyme was co-purified during affinity chromatography of His-tagged complex 
I. Ugp1p was detected in the CI/Fab 44G10 co-complex preparation, after it crystallized in a 
crystal form different from those observed for the co-complexes before. MALDI mass spec-
trometry (MS/MS) in collaboration with Benjamin Rietschel (AG Karas, Goethe University 
Frankfurt) was employed to characterize the dissolved crystals. 20 small crystals were col-
lected for SDS-PAGE composition analysis. To remove precipitate the crystals were washed 
thoroughly in a stabilizing buffer, which was the growth solution supplemented with 10% 
glycerol. No crystal damage was observed upon crystal soaking in the stabilizing solution.  
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C 
10% SDS, 6 M urea 
1
6
%
 
S
D
S
 
Figure 10.1: 2D SDS-PAGE analysis of 
Ugp1p crystals. 
A: dissolved crystals. The red arrow indicates the 
Ugp1p band; B: complex I from strain PIPO; C: 
crystallization sample co-complex CI/Fab 44G10. 
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The washed crystals were dissolved in water and the same amount of SDS-PAGE loading 
buffer was added. The dissolved crystals were analyzed by 2D SDS-PAGE as described in 
13.6.5. In the first dimension the bands were separated by SDS-PAGE (10% acrylamide, 6M 
urea) and a 16% SDS gel was used to resolve the protein bands in the second dimension [170] 
(Figure 10.1).Residual amounts of protein precipitate produced a slight background of com-
plex I subunits (Figure 10.1). The band marked with a red arrow was cut out and analyzed by 
mass spectrometry. The band was unambiguously identified as UDP-glucose pyrophosphory-
lase with sequence coverage of 72%. The monomer mass calculated on the basis of the MS 
polypeptide was 55614 Da. In the 2D SDS-PAGE (Figure 10.1 A) Ugp1p migrates slightly 
above the 49/51-kDa subunits of complex I. The band was absent in the complex I control 
sample (Figure 10.1 B).  
10.1  PURIFICATION OF UGP1P 
Ugp1p co-purified with complex I during the Ni
2+ NTA affinity chromatography step. The 
protein eluted from the size exclusion column following complex I. The elution volume cor-
responded to a mass of roughly 450 kDa, which would indicate an octameric state of the en-
zyme (Figure 10.2 A). The fractions were analyzed by 10% Laemmli gel and pooled accor-
dingly (Figure 10.2 B).  
 
 
                           
Figure 10.2: Co-purification of Ugp1p with complex I.  
A: gel filtration elution profile. Fractions 47-49 (marked by turquoise bars) were pooled for ion exchange purifi-
cation. B: 10% Laemmli gel [171]. M: molecular mass standard (PageRuler™ Prestained Protein Ladder, Fer-
mentas); CI: complex I; fractions 45-58: fractions eluted from a gel filtration column (see A). 
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Figure 10.3: Purification of Ugp1p using ion exchange chromatography.  
A: Mono Q elution profile. B: 10% Laemmli gel [171]. M: molecular mass standard (PageRuler™ Prestained 
Protein Ladder, Fermentas); P1: peak 1; P2: peak 2; P3: peak 3. 
 
 
 
                             
Figure 10.4: Western blot detection of purified Ugp1p. 
Left: 10% SDS-PAGE. M: molecular mass standard (PageRuler™ Prestained Protein Ladder, Fermentas); 1: 
CI/Fab 1F5 co-complex; 2: CI/Fab 1F5 crystallization sample; 3: purified Ugp1p; 4: Fab 1F5; 5: Fab 44G10.  
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The pooled  fractions were purified using anion  exchange chromatography as described  in 
13.8. The resultant peaks were analyzed on a 10% Laemmli gel (Figure 10.3 A, B). Peak 1 
represented a highly pure Ugp1p fraction. The Ugp1p band migrated in the Laemmli gel with 
an apparent molecular mass below the 55 kDa marker band (Figure 10.3 B, lane P1). The pu-
rified Ugp1p was detected in a Western blot using anti-Ugp1p antibodies directed against the 
baker’s yeast enzyme (courtesy of dr. Jared Rutter, University of Utah, USA; Figure 10.4). 
The low molecular weight Western blot signals observed for lanes 1 and 2 in the Figure 10.4 
and marked with brackets (*) represented an unspecific cross-reaction.  
10.2  OLIGOMERS OF UGP1P FROM Y. LIPOLYTICA 
A purified sample of Ugp1p was analyzed using laser-based mass spectrometry method LIL-
BID (laser-induced liquid bead ion desorption) in collaboration with Lucie Sokolova (AG 
Brutschy, Goethe-University, Frankfurt).  
 
Figure 10.5: Ugp1 from Y. lipolytica forms octamers as indicated by MS LILBID.  
A: (MS) LILBID spectrum of Ugp1p. The blue bars represent a charge distribution of an octamer of Ugp1p. The 
yellow ones represent a charge distribution of a monomer. Theoretical charge distributions for the Ugp1p, calcu-
lated in B for an octamer and C for a tetramer. 
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The sample in 30 mM ammonium acetate buffer of pH 7 was measured at ultrasoft conditions. 
The peaks in the spectrum corresponded to a charge distribution of a molecule of a mass 
about 450 kDa, which implies that Ugp1p is an octamer of a total mass 448 kDa (Figure 
10.5).    
10.3  CRYSTALLIZATION OF UGP1P 
10.3.1 Initial crystallization conditions  
The initial crystals of the purified Ugp1p grew in 300 nL hanging drops in vapor diffusion 
experiments carried out using Mosquito crystallization robot (TTP Labtech, UK). The crystals 
grew as thin needles (Figure 10.6 A). The mother liquor was composed of 18% PEG 400, 0.1 
M MES, pH 6.5, 0.1 M MgCl2. In order to facilitate crystal handling and analysis the crystal-
lization conditions were scaled up to 4 µl drops set up in 24 well plates. In the larger scale 
crystals appeared more eagerly in the sitting drop setups, as thicker better defined needles, not 
longer than 100 µm (Figure 10.6 B).  
Further screening for suitable crystallization conditions was conducted using the Mosquito 
crystallization  robot  and  commercial  crystallization  screens:  Crystal  Screen  and  Crystal 
Screen 2 (Hampton Research). Out of 96 conditions, three resulted in good quality crystals.   
 
        
Figure 10.6: Initial crystals of Ugp1p from Y. lipolytica. 
The crystals grew from 18% PEG 400, 0.1 M MES, pH 6.5, 0.1 M MgCl2. A: Crystals which appeared in 300 nL 
hanging drops setups, prepared using Mosquito crystallization robot (TPP Labtech). B: The initial conditions 
were scaled up to standard conditions (24 well plates, 4 µl drops). The crystals grew in sitting drop setups up to 
100 µm (black bar). 
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Figure  10.7:  Crystals  obtained  using  Mosquito  crystallization  robot  and  commercial 
screens. 
A: 0.2 M calcium chloride , 0.1 M HEPES sodium, pH 7.5, 28% PEG 400 (Crystal Screen solution 14); B: 0.5 M 
ammonium sulfate, 0.1 M sodium citrate tribasic pH 5.6, 1 M lithium sulfate (Crystal Screen 2 solution 15). 
 
Figure 10.7 represents crystals grown in 300 nL sitting drops.  It was not possible to repro-
duce the crystals in the 24 well plate scale. The results obtained in the third condition (20% 
PEG MME 550, 0.1 M NaCl, 0.1M BICINE, pH 9.0) selected from the screening procedure 
could be easily reproduced at larger scale. The initial crystals appeared in a sitting drop sys-
tem (Figure 10.8 A). In the upscaled conditions, larger crystals were observed in the hanging 
drops in comparison to sitting ones (Figure 10.8 B, C). The crystals appeared to be very frag-
ile and became easily damaged during fishing with a nylon loop. 
 
 
  
Figure 10.8: Ugp1p crystals grown from 20% PEG MME 550, 0.1 M NaCl, 0.1 M BI-
CINE, pH 9.0. 
A: Initial crystals obtained using Mosquito crystallization robot-sitting drop; B: crystals grown in 24 well plate 
in sitting drop; C: crystal grown in 24 well plate in hanging drop. Black bar indicates approximately 100 µm.  
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10.3.2 Optimization of the crystallization conditions 
It was possible to control the nucleation process by manipulating the pH of the mother liquor 
together with precipitant concentration. The basic condition used in this experiment was 18% 
PEG 400, 0.1 M MES, pH 6.5, 0.1 M MgCl2. The nucleation process was slower when the 
PEG (precipitate) concentration increase was accompanied by higher pH values of the crystal-
lization buffer. At 14% PEG 400 the optimum for crystallization was found for 0.1 M MOPS 
pH 7.0 (Figure 10.9 A). There were fewer crystals present in the drop. At the same time, the 
crystals were longer and thicker in comparison to the ones observed for pH 6.5. For PEG con-
centrations of 16 and 18% the pH optimum was shifted towards 7.0 (0.1 M MOPS)/7.5 (0.1 M 
HEPES) (Figure 10.9 B and C). The largest crystals grew at pH 7.5, whereas a crystal shower 
was recorded for pH 6.5. No crystals were observed for solutions containing PEG at pH 8.0 
and above.   
 
         
 
         
 
         
Figure 10.9: Controlled nucleation process of Ugp1p crystals. PEG/pH dependence.  
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10.3.3 Ugp1p crystallization under oil 
Microbatch experiments were carried out as described in 13.9.5, page 117. In these experi-
ments the crystallization drop is sealed with an oil layer consisting of Al’s oil or mixtures of 
silicon and paraffin used at different ratios. In addition to Al’s oil, a 65% paraffin: 35 % sili-
con mixture was selected for further experiments. The screening for suitable conditions was 
performed around the standard precipitant solution (14-18% PEG 400, pH 6.5-7.5, 0.1 M 
MgCl2). The equilibration of the supersaturation state was significantly slowed down by the 
oil barrier, resulting in larger size of the Ugp1p crystals. Regardless of the oil or oil mixture 
used, the best results were observed for 12% PEG and pH 7.0 (0.1 M MOPS). The largest 
crystals (up to 200 µm) grew under a layer of paraffin/silicon mixture (65%/35%).  
 
 
Figure 10.10: Ugp1p crystals grown using microbatch technique. 
A: Crystals grown under Al’s oil; B: crystals grown under a mixture 65% paraffin : 35% silicon. The crystals 
grew up to 200 µm.  
 
 
Introduction of an oil barrier into vapor diffusion experiment (13.9.2.6, page 116) significant-
ly improved the crystal size. A 500 µl film of an equal mixture of paraffin and silicon was 
placed on the top of 1 ml crystallization solution in a 24 well plate sitting drop experiment. 
The equilibration process was slower and the crystals grew longer and thicker in comparison 
to wells without the oil layer (Figure 10.11 A, B).  
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Figure 10.11: Ugp1p crystals grown in vapor diffusion sitting drop experiments with an 
oil barrier.  
Well conditions: 14% PEG 400, 0.1 M MOPS, pH 7.0, 0.1 M MgCl2. A: Crystals, which grew without an oil 
barrier. B: 500 µl Al’s oil layer was placed over the well solution White bar represents ~ 100 µm.  
 
 
10.4  DIFFRACTION OF UGP1P CRYSTALS 
The Ugp1p crystals were  frozen and stored in  liquid  nitrogen. Use of 22 % PEG 400 in 
growth  solution  was  a  good  cryoprotection  agent.  The  diffraction  data  were  collected  on 
beamlines ESRF, ID 14, France and SLS, PX II, Switzerland. The crystals displayed high 
stability and the quality of the diffraction images remained unchanged after prolonged exposi-
tion to X-ray radiation. The best crystals diffracted X-rays to a resolution of 3.2 Å. The calcu-
lated space group was I4 and the unit cell dimensions as follows: a = 295 Å, b = 295 Å, c = 
110 Å, α = 90˚, β = 90˚, γ = 90˚.  
 
Figure 10.12: Ugp1p crystal used for the X-ray data collection. 
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Figure 10.13: Diffraction image of Ugp1p crystal. 
The data were collected at beamline ID14, ESRF, France. Data collection parameters: distance 300 mm, exposi-
tion time: 5 sec, oscilation range 0.4˚, wavelength 0.933 Å. 
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11 DISCUSSION 
11.1  CO-PURIFICATION OF UGP1P 
Due to some affinity towards Ni
2+-NTA Ugp1p was co-purified with complex I during the 
affinity purification step. In the following gel filtration experiment, the proteins were sepa-
rated from each other and Ugp1p could be purified according to the procedure described in 
Materials and Methods. This phenomenon was also observed for UDP-glucose pyrophospho-
rylase from S. cerevisiae (Prof. Andreas Bracher, personal communication).  The reason for 
nickel binding is unclear. Analysis of the surface residues of the structural model did not re-
veal any obvious histidine motifs that could be responsible for metal binding.  
11.2  DOMAIN ARCHITECTURE OF UGP1P FROM Y. LIPOLYTICA 
UDP-glucose pyrophosphorylase  form Y. lipolytica displays a  high  sequence similarity to 
other  known  UGPases.  It  contains  a  signature  motif  LX2GXGTX6PK,  which  is  typically 
found in the active site of the SGC-domain proteins (Figure 11.2) [156;172-175]. The closest 
homologues with known structures are the enzyme from S. cerevisiae with 70 % sequence 
identity, followed by UDPGP from Arabidopsis thaliana with 52 % sequence identity. Based 
on the amino acid similarity, a structural model was built using the structure of the baker’s 
yeast protein with the QuickPhyre server [176] and CCP4 Molecular Graphics [177] (Figure 
11.1: Model of Ugp1p from Y. lipolytica.). It was possible to superpose the predicted structure 
of Ugp1p from Y. lipolytica with the solved structure of UDPGP from A. thaliana (PDB code 
1z90) with a root mean square deviation (r.m.s.d) of only 1.22 Å over 437 C
α atoms. The 
model shows α/β architecture characteristic for pyrophosphorylases and consists of three do-
mains: the amino-terminal domain, the SGC domain (central domain) and carboxy-terminal 
domain. The domains are arranged in a linear manner, where the N- and C-terminal domains 
are on opposite sides of the protein and do not contact each other (Figure 11.1). The N-
terminal domain is the smallest one and is formed by two long α-helices and a β-hairpin struc-
ture. The central domain shows characteristics of the SGC domain family and is built of eight-
stranded β-sheets, which are flanked by six α-helices [156]. In addition, a β-hairpin structure 
formed by a small two-stranded antiparallel β-sheets is observed in the core domain of the 
eukaryotic enzymes.  
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 Figure 11.1: Model of Ugp1p from Y. lipolytica. 
Ugp1p from Y. lipolytica displays a domain architecture characteristic for UGPases, with core domain typical for 
the SGC family proteins.  The active site is located at the interface of the depicted domains. The model was 
based on the known structure of baker’s yeast enzyme (PDB code 2i5k). The sequence similarity of the two 
proteins equals 70 %. The modeling was performed using QuickPhyre [176] and CCP4 Molecular graphics 
[177]. 
 
The sugar-binding domain
4 (Thr 268 - Ile 282) is conserved between baker’s yeast and Y. li-
polytica, and highly similar to the protein from A. thaliana. It is composed of α-helices and a 
four-stranded, antiparallel β-sheet. The interface of the four domains builds the active site of 
the enzyme which will be discussed in detail in the following paragraphs. The SGC domain 
signature motif harbors the nucleotide binding loop (Leu 105 – Lys 119) which is conserved 
throughout in eukaryotes (Figure 11.2). This loop is involved in conformational rearrange-
ments upon substrate binding. The carboxy-terminal domain is characterized by the presence 
of a left-handed β-helix structure. This is formed by parallel β-strands, which clasp around a 
triangular core of hydrophobic side-chains. The β-helix arrangement is interrupted by an α-
helix and a loop insertion in case of both yeast proteins and the A. thaliana enzyme. The ter-
minal β-strand β18, which seem to be important for oligomerisation, is absent in the plant 
                                                 
4 Regarded as a part of the central domain in the case of S. cerevisiae [161] and a separate domain in the case of 
the A. thaliana enzyme [166]. 
nucleotide binding 
loop 
amino-terminal 
domain 
carboxy-terminal 
domain 
SGC domain 
sugar binding 
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structure. This is in agreement with the fact that the active plant proteins were found exclu-
sively as monomers.  
 
Figure 11.2: Sequence alignment of the signature motif typical for SGC-domain pro-
teins. 
The signature motif LX2GXGTX6PK resides the nucleotide binding loop (Leu 105 – Lys 119) of the UDP-
glucose pyrophosphorylases. Residues important for substrate or metal binding are conserved (red) in the active 
centre of the SGC-family proteins. Sequence alignment was performed using ClustalW2, EMBL-EBI tools. 
 
11.3  ARCHITECTURE OF THE ACTIVE SITE OF UGP1P 
The model of Ugp1p from Y. lipolytica was constructed on the basis of the sequence similari-
ty to the baker’s yeast protein (PBD 2i5k), of which structure had been solved by molecular 
replacement using the known structure of UDPGP from Arabidopsis thaliana.  The following 
chapter will refer to the original plant structure which was solved as the native enzyme (PDB 
code 1z90), with  bound UDP-glucose (PDB code 2icy) and with  bound UTP (PDB code 
2icx). Since the residues involved in substrate binding are conserved between Ugp1p and 
UDPGP and the secondary structure displays high similarity, it seems very likely that the ar-
chitecture of the active sites is conserved. The residues are numbered according to the A. tha-
liana structure of the chain A and the numbering of the predicted model of Y. lipolytica en-
zyme is included in brackets.  
11.3.1 Active site with bound UDP-glucose 
The interior of the substrate binding pocket is laid-out with positively charged amino acids 
(Figure 11.3 A). The amino-terminal residues involved in UDP-glucose binding include Gln 
162 (182) and Gly 191 (211) coordinating the uridyl group and His 192 (212) coordinating the 
β-phosphate. The central-domain residues binding UDP-glucose are Asn 220 (240) and Asn 
293 (313) coordinating the glucosyl unit, Gly 87 (107) coordinating the uridyl group, Leu 85 
(105) coordinating the ribose group, and Lys 99 (119) coordinating the α-phosphate. The 
three residues Gly 87 (107), Leu 85 (105) and Lys 99 (119) are found on the nucleotide bind-
ing loop. Sugar binding domain residues involved in UDP-glucose binding, are Gly 258 (278) DISCUSSION  
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and Glu 271 (291) coordinating the glucose portion and Lys 256 (276) coordinating the β-
phosphate. The only C-terminal residue in contact with UDP-glucose is Lys 360 (382) coor-
dinating the α-phosphate.  
11.3.2 Active site with bound UTP 
Coordination of the uridine portion in the UTP complex is similar to the one observed for 
UDP-glucose complex. The sugar binding loop displays a conformation which is analogous to 
the one seen in the native structure. Temperature factors of this area recorded for chains A and 
B are higher when compared to neighboring residues indicating enhanced structural flexibility 
of the loop, when UTP is present [166]. Coordination of the α-phosphate is mediated by Lys 
360 (382) and Lys 99 (119) similar to the situation for UDP-glucose, whereas the β-phosphate 
is no longer coordinated by His 192 (212).  
 
 
 
 
Fig 11.3 A DISCUSSION  
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Figure 11.3: Architecture of the active site of UDP-glucose pyrophosphorylase from A. 
thaliana with bound UDP-glucose.  
A: electrostatic representation of the substrate binding pocket; B: the active site close-up; Numbering corres-
ponding to Y. lipolytica model is included in brackets. The amino terminal amino acids are depicted in blue, SGC 
domain amino acids-green, nucleotide-binding loop-yellow, sugar-binding domain-magenta, carboxy-terminal 
domain-red. UDP-glucose is shown in coral. The images were prepared using CCP4 Molecular Graphics. 
 
11.4  CONFORMATIONAL CHANGES UPON SUBSTRATE BINDING 
UDP-glucose pyrophosphorylase from A. thaliana undergoes a conformational change upon 
substrate binding [166]. The functional equivalent from Y. lipolytica displays high sequence 
and structure similarity and is likely to show the same conformational modifications exerted 
by binding of the substrates. As the reaction catalyzed by UDPGP follows an ordered bi-bi 
mechanism, the nucleoside phosphate or UDP-glucose bind prior to glucose-1-phosphate or 
pyrophosphate. This mechanism is mirrored by a conformational change, where the nucleo-
tide binding loop (Gly 87 - Lys 99, A. thaliana numeration) moves towards the nucleotide 
component of the substrate when UDP-glucose or UTP are present. This involves displace-
ment of the β-helix structure in the direction of the substrate. In the native structure the nuc-
leotide  binding  loop  is relaxed and placed away  from the  nucleotide  binding site (Figure 
11.4). The second structural alteration is observed for the sugar binding loop (Thr 248 - Ile 
261, A. thaliana numeration), which is in a closed conformation only in the presence of UDP-
glucose. The Y. lipolytica Ugp1p model built on the basis of known S. cerevisiae structure 
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(2i5k) is in agreement with the native conformation (data not shown). Crystallization of the 
protein in the presence of the substrates is planned for Ugp1p.  
 
Figure 11.4: Conformational changes of the UDPGP from A. thaliana upon substrate 
binding.  
Superposition of native (1z90, blue), UDP-glucose complex (2icy, green) and UTP complex (2icx, red) struc-
tures. The most evident conformational changes concern the nucleotide binding loop and the sugar binding loop. 
The image was prepared using PyMol, DeLano Scientific LLC. 
 
11.5  OLIGOMERISATION OF UGP1P FROM Y. LIPOLYTICA 
Plant UDP-glucose pyrophosphorylases were  found to be active exclusively as  monomers 
[178], whereas the active mammalian counterparts displayed different oligomerisation states. 
Ugp1p from S. cerevisiae was shown to be active only as an octamer [161]. Comparison of 
the carboxy-terminal regions of UGPase representatives from yeast, plant and protozoa re-
vealed the presence of highly conserved hydrophobic residues. Ugp1p from baker’s yeast was 
crystallized as a dimeric protomer. Analysis of the oligomerisation interface disclosed a set of 
hydrophobic residues His 448, Thr 450, Ile 469, Val 470, Val 489 and Thr 491 (S. cerevisiae 
numbering). In the plant sequences, the residues are exchanged for polar and charged amino 
acids such as Ser 434, Lys 450, Thr 468, Asp 489, Asn 491, P 493 and Glu 494, which pre-
vent formation of oligomers. Additionally, the C-terminal β18 strand, which was identified as 
being important for protomer formation, is replaced by a short α-helix in the plant structures. 
A  characteristic  C-terminal  sequence  Leu-Glu-His,  with  His  499  at  the  end  is  conserved 
throughout yeast and metazoa, but not in plants. The β18 strand as well as the hydrophobic 
nucleotide 
binding loop 
sugar-binding 
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residues identified at the oligomerisation interface are conserved in Ugp1p from Y. lipolytica. 
Gel  filtration  experiments  and  initial  LILBID  data  indicated  that  Ugp1p  forms  octamers.PRÉCIS  
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12 PRÉCIS 
UDP-glucose  pyrophosphorylase  from  Yarrowia  lipolytica  displays  affinity  towards  Ni
2+ 
NTA and was first detected in a contaminated sample of complex I. Following, separation 
from complex I, Ugp1p was purified using anion exchange chromatography. Sequence simi-
larity studies revealed high identity to other known pyrophosphorylases. As indicated by la-
ser-based mass spectrometry method (LILBID) Ugp1p from Y. lipolytica builds octamers si-
milarly  to  the  enzyme  from  Saccharomyces  cerevisiae.  The  initial  crystals  grew  as  thin 
needles favorably in sitting drop setups. The size of the crystals was increased by employment 
of a micro batch technique. The improved crystals diffracted X-rays to a resolution of 3.2 Å at 
the  synchrotron  beamline.  Structural  characterization  is  under  way  using  a  molecular  re-
placement approach based on the published structure of baker’s yeast UGPase.   
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13 MATERIALS AND METHODS 
13.1  MATERIALS 
13.1.1  Cell culture materials 
PANSERIN 401, serum free allround medium (Pan Biotech, P04-710401) 
Hybridoma express medium, animal derived component free (PAA, U15-001) 
Hybridoma cloning factor, growth adjunct (PAA, S05-015) 
Hybridoma enhancing factor (Sigma-Aldrich, H2900) 
L-Glutamine 200mM (Sigma-Aldrich, G7513) 
Fetal bovine serum (Sigma-Aldrich, F2442) 
Interleukin-6 (Sigma-Aldrich, I9646) 
Water, cell culture grade (Sigma-Aldrich, W3500) 
D-(+)-Glucose monohydrate (Fluka, 49159) 
Dimethyl sulfoxide (Sigma, D2650) 
Trypan blue 0.5% (Biochrom AG, L 6323) 
MycoAlert, mycoplasma detection assay (Cambrex, LT07-118) 
ELISA reagents (NaCl, Na2CO3, TrisCl, BSA, MgCl2, Tween 20) 
N-Dodecyl-β-maltoside (Glycon, D97002C) 
Diethanolamine (Sigma-Aldrich, D8885) 
Alkaline phosphate yellow liquid substrate for ELISA-pNPP (Sigma-Aldrich, P 7998) 
Anti-mouse IgG (whole molecule) alkaline phosphatase conjugate (Sigma-Aldrich, A5153) 
Anti-mouse IgG (Fab specific) alkaline phosphatase conjugate (Sigma-Aldrich, A2179) 
Protein G Sepharose™ 4 Fast Flow (GE Healthcare, 17-0618-01) 
Ni-NTA HisSorb Strips™ (Qiagen, 35023) 
13.1.2  Proteolytic Fab production 
Immobilized ficin (Pierce, 44881) 
Crystalline papain (Roche Diagnostics, 10108014001) 
L-Cysteine HCl (Sigma, C7477) 
N-Ethylmaleimide (Pierce, 23030) 
Immobilized papain (Pierce, 20341) 
Mono Q HR 5/5 (GE Health Care, 1ml, 17-0546-01) 
S Hyper D (Bio Sepra, 142310) MATERIALS AND METHODS  
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Dynabeads® Protein G (Dynal Biotech, 100.03) 
NAb™ Protein G Spin Columns (Pierce, 89957) 
HiLoad 16/60 Superdex 75 prep grade (GE Health Care, 17-1068-01) 
13.1.3  Protein chemistry  
Bacto™ Peptone (BD, 211820) 
Bacto™ Yeast Extract (BD, 212720) 
Agar (BD, 212304) 
HAR (hexa-ammine-ruthenium III-chloride) (Sigma, 262005) 
dNADH (Sigma, N8129) 
DBQ (Alexis, 270-293-M010) 
NADPH (Sigma, N7505) 
Dodecyl-nonaethylene-glycol-ether – C12E9 (Sigma, P9641) 
Viva Spin concentrators 30, 000 MWCO (Sartorius, VS0424) 
Viva Spin concentrators 100, 000 MWCO (Sartorius, VS0444) 
Centriprep YM-50 concentrators 50,000 MWCO (Millipore, 4310) 
Chelating Sepharose™ Fast Flow (GE Health Care, 17-0575-01) 
Gel filtration column TSK G4000sw, 21,5 mm x 30 cm (TOSOH Bioscience, 06729) 
PVDF membrane (Millipore, IPVH07850) 
Serva Blue G (Serva, 35050) 
p-Coumaric acid (Sigma, C9008) 
Luminol sodium salt (Sigma, A4685) 
SigmaFast™BCIP®/NBT tablets (Sigma, B5655) 
Anti-mouse IgG (Fab specific) alkaline phosphatase conjugate (Sigma, A2179) 
Anti-mouse IgG alkaline phosphatase conjugate (Sigma, A5153) 
Ani-rabbit IgG peroxidase conjugate (Sigma, A0545) 
Anti-mouse IgG peroxidase conjugate (Sigma, 2554) 
SeeBlue® Plus2 Pre-Stained Standard, molecular mass standard (Invitrogen, LC5925) 
PageRuler™ Prestained Protein Ladder, molecular mass standard (Fermentas, SM 0671)  
13.1.4  Surface plasmon resonance  
Sensor chip CM5 (BR-1000-14, Biacore) 
Sensor Chip NTA (BR-1000-34, Biacore) 
NSB reducer (BR-1006-91, Biacore) MATERIALS AND METHODS  
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Mouse antibody capture kit (BR-1008-38, Biacore) 
13.1.5  Crystallization materials 
24 well VDX™ plates (Hampton Research, HR3-172) 
72 well microbatch plates (Hampton Research, HR3-122) 
96 Well IMP@CT™ plates (Greiner Bio-One, 673 170) 
AxyGem™ 96-well plates (Axygen Biosciences, CP-AxyGem-96-50) 
Greiner CrystalQuick 96-well plates (Sigma, Z666130) 
Siliconized cover slides (Hampton Research. HR3-215) 
Micro-bridges™ (Hampton Research, HR3-342) 
Silicon (Hampton Research, HR3-415) 
Paraffin oil (Hampton Research, HR3-411) 
Al’s oil (Hampton Research, HR3-413) 
Glycerol anhydrous (Fluka, 49767) 
PEG 3350 (Hampton Research, HR2-591) 
PEG 400 (Hampton Research, HR2-603) 
QuikOptimize™ (Hampton Research, HR2-576) 
Seed Bead™ (Hampton Research, HR2-320) 
 
Commercial crystallization screens 
JBScreen Membrane 1-3 (Jena Biosciences, CS-306L) 
MembFac™ (Hampton Research, HR2-114) 
PEG/Ion Screen™ (Hampton Research, HR2-126) 
MemStart™ (Molecular Dimensions, MD1-21) 
Structure Screen 1 (Molecular Dimensions, MD1-01) 
Structure Screen 2 (Molecular Dimensions, MD1-02) 
Crystal Screen™ (Hampton Research, HR2-110) 
Crystal Screen 2™ (Hampton Research, HR2-112) 
NexTal MbClass Suite I (Qiagen, 130711) 
NexTal MbClass Suite II (Qiagen, 130712) 
Crystallization Kit for Membrane Proteins (Fluka, 73513-1KT-F) 
Additive Screen™ (Hampton Research, HR2-428) 
StockOptions™ (Hampton Research, HR2-245) MATERIALS AND METHODS  
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13.1.6  Monoclonal antibodies 
Mouse hybridoma clones used in this work (Table 13.1) were provided by Dr. Volker Zick-
ermann. 
 
Antibodies  Subtype  Binding epitope 
1F5  G2a  NESM 
31A8  G1  conformation specific 
44G10  G1  conformation specific 
Table 13.1 Cell lines used in the project 
 
13.2  HYBRIDOMA CELL CULTURE TECHNIQUES 
13.2.1  General aspects 
Cell lines used in this work were grown according to standard suspension cell culture tech-
niques. Use of growth enhancing factors was dependent on the clone. Monoclonal antibodies 
were produced at low concentrations of fetal calf serum (1%) to minimize amount of immu-
neglobulins of external origin. It was possible to cultivate the clones in the absence of antibio-
tics. 
 
Medium composition 
PANSERIN 401 (Pan Biotech) or hybridoma express medium (PAA) 
18-1%   fetal calf serum 
2 mM    L-glutamine 
100 U/ml  interleukin-6 
1-2%     enhancing factor (optional) 
1%    D-(+)-glucose (below fetal calf serum concentration of 2%) 
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13.2.2  Thawing of frozen stock cultures 
Frozen stock cultures were thawed fast in a 37
oC water bath. Directly after thawing, the vial 
was briefly immersed in methanol before transfer to a laminar flow bench. Ice cold standard 
medium was added to thawed cells in a drop wise manner and transferred to a 15 ml tube. The 
cells were centrifuged for 5 minutes at 200 x g. The supernatant was removed, the sediment 
was resuspended gently and 37
oC standard medium was added drop wise. Cells were cultured 
in 6 well plates.  
13.2.3  Single cell cloning 
Single cell cloning by serial dilution in a 96 well plate was conducted for all of the clones. 
This was done according to standard technique. In short; 100µl of standard medium was add-
ed to all (except A1) of the wells in 96 well plate. 200µl of cell suspension was added to well 
A1. Using the same tip, 100µl from A1 were transferred to B1 and mixed. In the same manner 
serial dilution proceeded in direction of H1. Next, using an eight-channel pipettor, an addi-
tional 100µl of standard medium was added to every well in column 1 giving a final volume 
of 200µl. Then, using the same tips 100µl from the wells of first column were transferred to 
those in the second column (A2-H2). Such repetitions were carried out for the entire 96 well 
plate resulting in 100µl of cell suspension in each well. The wells were fed with an additional 
100 µl of standard medium and the plate was incubated at 37
oC in a humidified CO2 incuba-
tor. After 7-10 days single cell colonies were selected by ELISA test and subsequently trans-
ferred to 24, and finally 6 well plates.  
13.2.4  Cell vitality determination 
The trypan blue stain was used to determine the vitality of the cells [179]. Equal amounts of 
cell suspension and 0.5% Trypan blue were mixed and analyzed by means of a hemocytome-
ter. The intact cell membrane of living cells remains impermeable for this diazo-dye. Dead 
cells in contrast absorb it and become dark blue. The ratio between blue and colorless cells is 
a measure for cell vitality.  
13.2.5  Monoclonal antibody production 
The hybridoma cultivation was conducted according to a common strategy for all clones, first 
in 6 well plates and finally in 75 ml bottles in upright position (C. Hunte, personal communi-
cation). The fetal calf serum concentration was decreased, starting with 18%, followed by 9%, 
4%, 2% and finally 1%. Clones 1F5 and 44G10 required growth enhancing factors at and be-MATERIALS AND METHODS  
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low fetal calf serum concentrations of 4%. At this point standard medium was supplemented 
with 1% glucose. At 1% fetal calf serum cells were transferred to standing bottles and diluted 
1:2 with standard medium (1% fetal calf serum, 1% glucose). Dilution was repeated after 2 
days and clones grew undisturbed for the following 10-14 days. Cell culture supernatant con-
taining monoclonal antibodies was harvested, sterile filtered and stored at -80 
oC.   
13.2.6  Freezing of cells  
Only vital cells were frozen for stock collection. 3 ml of cell suspension (one well of a six 
well plate) were sedimented at 200 x g. The pellet was resuspended in 1 ml of cold cryo me-
dium in a drop wise manner. Cryovials were placed in a pre-cooled styrofoam box and stored 
for one hour in -20
oC. Afterwards the vials were moved to -80
oC to further cool down slowly. 
After one day, vials were frozen and stored in liquid nitrogen. 
 
Cryo medium composition 
PANSERIN 401 (Pan Biotech) or hybridoma express medium (PAA) 
10% fetal calf serum 
10% DMSO 
100U/ml interleukin-6 
2 mM L-glutamine 
2% supplement (optional) 
 
13.2.7  ELISA 
Functionality of the produced monoclonal antibodies was verified by ELISA. Each of the 
wells in a 96-well plate was coated with 100µl complex I (10 µg/ml in 0.2M Na2CO3 buffer). 
After  one  hour,  the  plate  was  washed  three  times  with  200  µl  of  wash  buffer  (0.9% 
NaCl/0.1% Tween 20). Blocking was done with 200 µl of blocking buffer (150 mM NaCl, 1% 
BSA, 50 mM TrisCl, pH 7.5) for 15 minutes. The plate was washed as before. Non-diluted 
cell culture supernatant (50-100 µl) was added to each well and incubated for 60 minutes. A 
wash step was carried out to remove any unbound material. Secondary antibodies, anti-mouse 
alkaline phosphatase conjugate (1:1000 in 150 mM NaCl, 0.5% BSA, 0.05% Tween, 50 mM 
Tris-Cl, pH 7.5) were incubated with primary antibodies for an hour. The plate was washed 
thoroughly. 100 µl of substrate solution (10% diethanolamine pH 9.8, 0.5  mM MgCl2, 1 MATERIALS AND METHODS  
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mg/ml pNPP) was applied to the wells. After 30 minutes, the results were analyzed in a mi-
croplate reader at 405/450 nm. 
13.2.8  Native ELISA 
Adsorption of the antigen on a plastic surface can result in its denaturation. To assure native 
conditions, Ni-NTA HisSorb Stripes (Qiagen) were used to immobilize Complex I by means 
of the His-Tag. Coating was done with 100µl complex I 15µg/ml in coating buffer (50mM 
potassium phosphate, pH 7.5, 300 mM NaCl, 0.1% N-dodecyl-β-maltoside). After an hour the 
plate was washed three times with 200 µl wash buffer (20 mM Tris-Cl, pH 7.5, 300 mM 
NaCl, 0.03% N-Dodecyl-β-maltoside, 0.2% BSA). 100 µl of cell culture supernatant was ap-
plied to the plate after it was mixed 9:1 with dilution buffer (2 M Tris-Cl, pH 8.0, 10% N-
Dodecyl-β-maltoside). The plate was washed after an hour. Goat anti-mouse alkaline phos-
phatase conjugate antibodies (1:1000 in wash buffer) were incubated with the supernatant for 
60 minutes. The plate was thoroughly washed to remove unbound material. Then, 100 µl of 
the alkaline phosphatase substrate solution (10% diethanolamine pH 9.8, 0.5 mM MgCl2, 1 
mg/ml pNPP) was applied to the plate and incubated for 30 minutes. Next, the results were 
analyzed in a microplate reader at wavelength of 405/450 nm. 
13.2.9  Cell culture sterility 
Mouse hybridoma cell lines were cultivated without use of antibiotics. The plates were in-
spected using a light microscope in regular time intervals. The presence of mycoplasma, was 
excluded using the commercial detection assay MycoAlert ™ (Cambrex).  
13.3  PURIFICATION OF MONOCLONAL ANTIBODIES 
Monoclonal antibodies were purified via one step affinity chromatography using a protein G 
column connected to a low pressure liquid chromatography system (BioLogic ™ BIORAD). 
Protein G is a bacterial cell wall protein from Streptococci group G. To reduce unspecific 
binding, the albumin and cell surface binding sites were eliminated in recombinant protein G, 
which is commonly expressed in E.coli. The Fc region binds most mammalian antibodies, in 
the same manner as Protein A. In this project, protein G immobilized by the CNBr method to 
Sepharose 4 Fast Flow was used (GE Healthcare).  
Isolation of immunoglobulins from cell culture supernatants was carried out as follows. A 
5 ml column was pre-equilibrated with four column volumes of 20 mM sodium phosphate 
buffer, pH 7.0 at a flow rate of 1 ml/min. The cell culture supernatant was applied to the col-MATERIALS AND METHODS  
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umn according to its binding capacity (6 mg IgG/ml drained medium). Loading was usually 
done over night at 4
oC because the flow rate was limited to 0.5 ml/min. Then, the column was 
washed with 15 milliliters 20 mM sodium phosphate buffer, pH 7.0. Antibodies were eluted 
with 6 column volumes of 0.1 M glycine buffer, pH 3.0 directly afterwards. In order to avoid 
possible denaturation of IgGs at low pH, 28 µl of 1 M Tris-Cl, pH 9.0 buffer were placed in 
the collection tubes just before the program was started. The peak fractions were loaded on a 
10% SDS-PAGE to verify the presence and purity of the antibodies. Concentration was per-
formed in VivaSpin™ concentrators (Sartorius) MWCO 100000, along with buffer exchange 
for 0.01 M PBS, pH 7.2. The purified antibodies were shock frozen in aliquots and stored in 
liquid nitrogen. Repeated thawing and freezing was avoided. 
The protein G column was regenerated with 2 column volumes of 0.1 M glycine buffer, pH 
3.0, and re-equilibrated with 4 column volumes of 20 mM sodium-phosphate buffer, pH 7.0. 
Next, it was washed with 15 ml water and stored in 15% ethanol, 10 mM Tris-Cl, pH 7.2 at 
4 
oC. 
13.4  AFFINITY  MEASUREMENTS  OF  MONOCLONAL  ANTI-BODIES 
AND Fab FRAGMENTS USING SURFACE PLASMON RESONANCE (BI-
ACORE) 
The affinities of the monoclonal antibodies 1F5, 31A8 and 44G10 towards complex I were 
measured by surface plasmon resonance and were carried out on a Biacore X100™ System. 
The experiments were performed following two approaches. In the first protocol monoclonal 
antibodies (ligand) were immobilized on CM5 sensor chip via anti-mouse antibodies (Mouse 
antibody capture kit, Biacore), which in turn, were covalently attached to the chip by amine 
coupling. The final concentration of the ligand was 3 µg/ml. The running buffer was 150 mM 
NaCl, 20 mM Tris-Cl, 1mM EDTA, pH 7.4 supplemented with 0.025 % DDM. Complex I 
(analyte) was probed on the antibody coated chips at increasing final concentrations (0.1, 0.2, 
0.5, 1, 2, 5, 10, 20 nM) depending on the antibody. Regeneration of the sensor chip was per-
formed using 0.1 M glycine buffer pH 1.7. In the second approach, complex I (ligand) was 
immobilized on the nickel coated NTA sensor chip via the His-tag. The final concentration of 
complex I was 5 nM, which allowed ultra-low density surface measurements. Monoclonal 
antibodies (analyte) were probed on the complex I-derivatized chip with increasing concentra-
tions (0.5, 1, 2, 5, 10 nM). 350 mM EDTA in the running buffer was used to regenerate the 
chip. The affinity of Fab fragments was assessed only by the second approach.  MATERIALS AND METHODS  
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In order to evaluate the effect of NADPH on antibody binding, complex I was pre-incubated 
with  increasing  concentrations  of  NADPH  (0.1,  1,  5,  10  µM).  A  null  concentration  of 
NADPH (complex I alone) was included in the first cycle of the experiment as a control. The 
incubation took place for at least 30 minutes on ice. The sample was probed on an antibody-
coated chip and the relative response at the end of each binding event was recorded. The rela-
tive  response  was  plotted  against  the  NADPH  concentration  to  assess  the  influence  of 
NADPH on antibody binding to complex I. 
13.5  PRODUCTION OF  PROTEOLYTIC Fab FRAGMENTS  
13.5.1  Digestion of immunoglobulins 
Three different methods for production of proteolytic antibody fragments were employed in 
this project. Immobilized papain digestion was chosen as a standard procedure. 
13.5.1.1  Immobilized ficin (Pierce) 
Monoclonal antibodies were fragmented using immobilized ficin pre-packed columns (Pierce) 
according to the supplier’s procedure.  
13.5.1.2  Crystalline papain (Roche Diagnostics) 
Fragmentation  of  immunoglobulins  with  crystalline  papain  was  based  on  a  protocol  by 
Adamczyk et al., [115]. Purified antibodies (1-2 mg/ml) were dialyzed against sample buffer 
(1 mM EDTA, 50 mM sodium phosphate, pH 7.0). Papain (10 µl, 10 mg/ml suspension) was 
mixed with 90 µl freshly prepared activation buffer (1 mM EDTA, 10 mM cysteine, 50 mM 
sodium phosphate, pH 7.0) and was activated for 10 minutes at 37 
oC.  Digestion was carried 
out at different papain/antibody ratios (0.2, 0.5, 1.0, 2.0, 5.0, 15.0 w/w %) in order to find 
optimal digestion conditions. The mixtures were incubated at 37
oC for 2 hours. The reaction 
was terminated by addition of N-ethylmaleimide (NEM) to a final concentration of 30 mM. 
Results were analyzed on 10 % SDS-PAGE. The reaction time, amount of cysteine and NEM 
were optimized in additional experiments. 
13.5.1.3  Immobilized papain (Pierce) 
Digestion of monoclonal antibodies with immobilized papain was performed according to the 
supplier’s suggestions (Pierce). 0.5 ml of concentrated IgGs (10-20 mg/ml in sample buffer 20 
mM sodium phosphate, 10 mM EDTA, pH 7.0) were diluted with an equal amount of diges-
tion buffer (20 mM sodium phosphate, 20 mM cysteine HCl, 10 mM EDTA, pH 7.0).  Using MATERIALS AND METHODS  
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a cut pipette tip, 0.5 ml of the immobilized papain slurry was transferred to a 15 ml test tube. 
Papain was activated by two fold washing with 4 ml of freshly prepared digestion buffer. 
Both washes were discarded.  The gel was separated from the buffer by centrifugation and 
resuspended in 0.5 ml of digestion buffer. 1 ml of antibody solution was added to 1 ml of ac-
tivated papain suspension and the test tube was placed in a thermo-shaker. The reaction was 
carried out at 37
oC, 750 rpm for 14-16 hours. The reaction was stopped by addition of 1.5 ml 
of 10 mM Tris-Cl, pH 7.5 to the digest. Next, the sample was centrifuged to separate the su-
pernatant containing IgG fragments from immobilized papain.  
13.5.2  Purification of proteolytic Fab fragments 
13.5.2.1  Anion exchange – Mono Q column (GE Health Care) 
The immobilized papain digest was dialyzed into 50 mM NaCl, 25 mM Tris-Cl, pH 8.0, and 
applied to the Mono Q column (1 ml, GE Health Care) pre-equilibrated with the same buffer. 
The separation was achieved by means of a linear gradient (10 column volumes) with 400 
mM NaCl as a target concentration. In order to increase resolution, the final concentration of 
the gradient was decreased to 250 mM NaCl. The column was prepared in 25 mM NaCl, 25 
mM Tris-Cl, pH 8.0 buffer. The column was regenerated with 1 ml 1 M NaCl, 25mM Tris-Cl, 
pH 8.0.  After re-equilibrating with the start buffer, the column was washed with water and 
stored in ethanol at 4 
oC. The peak fractions were analyzed by 10 % SDS-PAGE.  
13.5.2.2  Cation exchange – S Hyper D column (Bio Sepra) 
The column was pre-equilibrated with 50 mM sodium-acetate buffer, pH 5.0. The digestion 
mixture was prepared in the start buffer and loaded on the column. Fractions were eluted us-
ing a salt gradient (10 column volumes) with a final concentration of 400 mM NaCl in 50 mM 
sodium acetate buffer, pH 5.0.  1 ml of 1 M NaCl, 50 mM sodium acetate buffer, pH 5.0 was 
used to regenerate the column. Finally, the column was re-equilibrated with the start buffer, 
washed with water and stored in ethanol at 4 
oC.  Eluted fractions were analyzed by 10% 
SDS-PAGE. 
13.5.2.3  Immobilized protein G magnetic beads (Dynabeads®Protein G) 
Separation of the antibody fragments was done for three volumes of magnetic beads: 14, 30 
and 100 µl. The beads were washed three times with 0.5 ml of sodium acetate buffer, pH 5.0. 
100 µl of 0.5 mg/ml immobilized papain digestion mixture was added to each of the three 
reaction tubes and incubated at room temperature for 60 minutes under gentle shaking. Start-MATERIALS AND METHODS  
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ing at time zero, samples for analysis were taken every 20 minutes (in total 4 samples per 
each reaction tube). After washing, the beads were treated twice with 30 µl 0.1 M citrate buf-
fer, pH 3.0 to elute the bound IgGs and their fragments. For reuse, magnetic beads were 
brought to neutral pH directly after elution and stored in buffer supplemented with 0.05% 
Tween 20®.  
13.5.2.4  Immobilized  protein  G  columns  –  NAb™  Protein  G  Spin  Col-
umns (Pierce) 
The separation of antibody fragments was performed according to the suppliers’ protocols. 
Briefly, a 1 ml column was pre-equilibrated with binding buffer (20 mM sodium-phosphate, 
buffer, pH 7.0). 2 ml of the IgG digest was applied to the column and incubated at room tem-
perature with end-over-end mixing for 10 minutes. The unbound fractions were separated by 
centrifugation at 1,000 x g. The column was washed three times with the binding buffer. 0.1 
M glycin buffer, pH 3.0 was used for elution of the bound sample. Fractions were analyzed by 
10% SDS-PAGE, as well as by Western Blot. The column was regenerated with the low pH 
buffer, re-equilibrated with PBS buffer (0.1 M phosphate, 0.15 M sodium chloride, pH 7.2) 
and stored in 0.02% sodium azide in PBS at 4 
oC. 
13.5.2.5  Size  exclusion  chromatography  –  HiLoad  16/60  Superdex  (GE 
Health Care) 
Purification of Fab fragments was done with a SEC column connected to an HPLC system. 
The column was pre-equilibrated with 150 mM NaCl, 50 mM sodium-phosphate, pH 7.2 buf-
fer. The peak fractions were analyzed by 10% SDS-PAGE and pooled according to purity. 
The column was washed with water and stored in 15% ethanol, 10 mM Tris-Cl, pH 7.2 buffer 
at 4
oC. 
13.5.3  Storage of purified Fab fragments 
The Fab fragments were sterile filtered directly after concentrating them and were stored in 20 
mM sodium phosphate, 10 mM EDTA, pH 7.0 buffer at 4
oC for 2-3 weeks.  
13.6  GENERAL PROTEIN CHEMISTRY METHODS 
13.6.1  Growth of Yarrowia lipolytica 
A Yarrowia lipolytica strain lacking sulfur-transferase [180] was used in this project. Colonies 
were grown on YPD plates. For pre-cultures 30 ml YPD medium were inoculated with a sin-MATERIALS AND METHODS  
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gle colony and grown in 300 ml shaking flasks at 28
oC for 16-18 hours.  The pre-culture was 
used to start a 400 ml culture that was grown in 2 L shaking flasks at 28
oC for 8 hours. This 
culture was used to initiate fermentation in a 10 L fermenter (Biostat). After 16-18 hours fer-
mentation yielded 45-55 g cells/L (wet weight). The cells were shock frozen and stored at -
80
oC. 
 
YPD medium             YPD agar plates 
10% Bacto™ Yeast Extract          1L YPD medium 
20% Bacto™ Peptone          15 g agar 
2,5% D-glucose 
             
13.6.2  Preparation of mitochondrial membranes 
200 g of cells were resuspended in 500 ml buffer (600 mM sucrose, 1 mM EDTA, 20 mM 
MOPS, pH 7.2). The cell walls were broken in a cooled cell disintegrator (Bernd Euler Bio-
technologie, Frankfurt) filled with 0.5 mm glass beads for 2 hours in the presence of 2 mM 
PMSF (protease inhibitor). The cell debris was separated from the supernatant containing the 
mitochondrial membranes by a 30 minute centrifugation at 2000 x g. The supernatant was 
ultracentrifuged for an hour at 100,000 x g. The pellet (mitochondrial membranes) was homo-
genized in a glass-ceramic Dounce homogenisator and resuspended in the same buffer as be-
fore, without EDTA. The ultracentrifugation step was repeated and the mitochondrial mem-
branes were shock frozen and stored at -80
oC. 
The quality of the membranes was characterized using specific NADH:HAR oxidoreductase 
and dNADH:DBQ oxidoreductase activity tests (see 1.5.6 Activity measurements). 
13.6.3  Purification of complex I 
His–tagged complex I was purified form isolated mitochondrial membranes by affinity chro-
matography according to a modified protocol [105]. The membranes were solubilized with 
0.8 g/g N-dodecyl-β-maltoside. The Ni
2+-NTA column was pre-equilibrated with buffer con-
taining 400 mM NaCl, 20 mM sodium phosphate, 55 mM imidazol, pH 7.2 and 0.025 % N-
dodecyl-β-maltoside. The detergent was exchanged for C12E9 during wash step on the Ni
2+-
NTA column (wash buffer: 400 mM NaCl, 20 mM sodium phosphate, 55 mM imidazol, pH 
7.2 with 0.015% C12E9). Elution was performed using 140 mM imidazol in the wash buffer. 
Next, the sample was loaded on a size exclusion column, equilibrated with 100 mM NaCl, 20 MATERIALS AND METHODS  
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mM Tris, 1 mM EDTA, pH 7.3 with 0.02 % C12E9. The purified complex I was concentrated 
in VivaSpin™ concentrators (Sartorius) MWCO 100,000 and sterile filtered. The quality of 
the  isolated  enzyme  was  assayed  using  specific  NADH:HAR  oxidoreductase  and 
dNADH:DBQ oxidoreductase activity tests (13.6.6). The purity and subunit composition was 
checked by Tricine-SDS-PAGE [181] and dSDS-PAGE [170] 
13.6.4  Protein quantification 
Protein concentration was determined according to the modified protocol of Lowry et al., 
[182]. 
13.6.5  Doubled SDS-Polyacrylamide Gel Electrophoresis 
Subunits of isolated complex I were resolved using Tricine dSDS-PAGE [170]. In short, lanes 
cut out from the first dimension gels (10% polyacrylamide, 6 M urea) were incubated in low 
pH buffer (100 mM Tris, 150 mM HCl, pH 2) for 30 minutes and subsequently analyzed by 
second dimension SDS-PAGE (16% polyacrylamide).  
13.6.6   Activity measurements 
13.6.6.1  NADH:HAR oxidoreductase activity 
The  measure  of  detergent-  and  inhibitor-insensitive  NADH:HAR  (hexa-ammine-
ruthenium(III)-chloride) oxidoreductase activity was the NADH oxidation rate (E340-E400) in 
the presence of 200 µM NADH and 2 mM HAR in 20 mM HEPES, 250 mM sucrose, 0.2 mM 
EDTA, 2 mM NaN3, pH 8.0 [183] . In this assay HAR serves as an artificial electron acceptor. 
The reaction was started by addition of either mitochondrial membranes or purified complex I 
and was monitored using a Shimadzu UV 300 spectrophotometer. The NADH:HAR oxidore-
ductase activity is specific for complex I [183] and  depends on the presence of FMN [184] 
13.6.6.2  dNADH:DBQ oxidoreductase activity  
For determination of complex I catalytic activity, dNADH oxidation (E340-E400) was measured 
in the presence of the ubiquinone analogue DBQ (electron acceptor). The assay was per-
formed in 30
oC buffer (20 mM Na-MOPS, 50 mM NaCl, 2 mM KCN, pH 7.2) supplemented 
with 100 µM dNADH and 80 µM DBQ. The reaction was started by addition of decylubiqui-
none and was followed on Shimadzu UV 300 spectrophotometer. Since, NADH serves also as 
a substrate for the alternative NADH-dehydrogenase, dNADH is used to differentiate between 
complex I and alternative NADH-dehydrogenase activities [185]. MATERIALS AND METHODS  
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13.6.7  Western blotting 
Proteins separated by PAGE were blotted onto polyvinylidene fluoride (PVDF) membrane 
(Immobilion P, Millipore) in a semidry mode. Blotting cartoons were soaked in blotting buf-
fers (cathode buffer: 300 mM 6-aminocaproic acid, 30 mM Tris, pH 9.2; anode buffer: 300 
mM Tris, 100 mM Tricine, pH 8.7). The PVDF membrane was rinsed with methanol. Gels 
were blotted overnight at 50 mA and 20 V. Blotted membranes were stained for 5 minutes 
with 0.02% SBG, 25 % methanol and 10 % acetic acid. De-staining was done 3 times for 10 
minutes using 25% methanol and 10 % acetic acid.  
13.6.8  Immunodetection  
13.6.8.1  Chemiluminescent detection 
The blotted membranes were blocked for 45 minutes with 0.5% Tween 20® in PBS. Next, the 
membranes were washed once for 15 minutes and twice for 5 minutes with PBS buffer con-
taining 0.1% Tween 20®. Primary antibodies (anti S. cerevisiae Ugp1p produced in rabbit), 
diluted 1:5,000 were incubated with the membranes for 3 hours at room temperature. The 
blots were washed as before. Secondary antibodies, (goat anti-rabbit IgG horse radish perox-
idase conjugate in case of Ugp1p detection and anti-mouse HRP conjugate for Fab detection) 
were diluted 1:20,000 in PBS buffer and incubated with the membranes for one hour at room 
temperature. The washed membranes were incubated in a 1:1 mixture of ECL-1 solution (2.5 
mM Luminol, 450 µM p-coumaric acid) and ECL-2 (0.03% hydrogen peroxide). Chemilumi-
nescence of the Luminol oxidation by the peroxidase could be detected on X-ray film.  
13.6.8.2  Chromogenic detection 
Except  for  the  last  step,  the  procedure  was  identical  to  the  chemiluminescent  detection 
(13.6.8.1). Anti-mouse IgG (Fc specific) alkaline phosphatase conjugate, as well as Fab spe-
cific immunoglobulins were used as secondary antibodies. The detection was performed using 
SigmaFast™BCIP®/NBT tablets. The BCIP/NBT reaction leads to formation of formazan, 
which is an intensely blue, insoluble dye. The membranes were incubated in BCIP/NBT solu-
tion until the color appeared. The reaction was stopped with water. 
13.6.9  Determination of lipid phosphorus by malachite green assay 
The lipid content in purified complex I and complex I/Fab co-complex was determined indi-
rectly using the malachite green assay as described in [186]. Briefly, an 11 point standard MATERIALS AND METHODS  
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curve was prepared (0-40 nmol potassium phosphate). 200 µl of 70% perchloric acid was 
added to the protein sample (glass reaction tube) and standard solutions. The protein sample 
(as double determination) was incubated at 180
oC for 30-60 minutes. After cooling, 200 µl of 
water was added. Next, 2 ml of malachite green/phosphomolybdenum mixture was added to 
each of the reaction tubes, including standards. Following 30 minutes incubation time at room 
temperature, the absorbance at 660 nm was measured using a UV-160A Shimadzu spectro-
photometer. 
13.7  PREPARATION OF COMPLEX I Fab CO-COMPLEXES 
The initial steps in complex I preparation were as described in 1.5.3. After elution from the 
Ni
2+-NTA column, the sample was concentrated in Centriprep YM-50 concentrators (Milli-
pore). Complex I was mixed with purified Fab fragments in a molar ratio of 1:2-3 respective-
ly. The binding reaction was performed either at analytical (< 1 ml) or preparative scale (≤ 5 
ml). At the preparative scale, Fab solution was added to complex I and the mixture was stirred 
gently in a 10 ml cylinder at 4
oC for at least 30 minutes. After that, the sample was sterile 
filtered and loaded on a size exclusion chromatography column (TSK G4000sw, TOSOH Bi-
oscience) to verify the stability of the co-complex and remove the unbound excess of Fab mo-
lecules. Gel chromatography was performed in 100 mM NaCl, 1 mM EDTA, 20 mM Tris-Cl, 
pH 7.2 with 0.02% C12E9 on a column connected to an Äkta FPLC system (GE Health Care). 
For analytical scale experiments, a TSK G300swxl column was used (TOSOH, Bioscience). 
Peak fractions were analyzed by SDS-PAGE and Western Blot.  
13.8  PURIFICATION OF UGP1P FROM YARROWIA LIPOLYTICA 
UDP  glucose  pyrophosphorylase  displays  affinity  to  Ni
2+-NTA  and  was  co-purified  with 
complex I. Size exclusion chromatography fractions containing Ugp1p were pooled and con-
centrated. After buffer exchange with 50 mM NaCl, 1mM EDTA, 20 mM TrisCl, pH 7.5 the 
sample was applied to a Mono Q column, which was pre-equilibrated with the same buffer. 
The separation was performed using a linear salt gradient with a NaCl target concentration of 
350 mM. The peak fractions were analyzed by 10% SDS PAGE as well as by Western blot-
ting using S. cerevisiae anti-Ugp1p antibodies (courtesy of Prof. Jared Rutter, University of 
Utah School of Medicine). Purified Ugp1p was frozen in liquid nitrogen or used directly for 
crystallization.  MATERIALS AND METHODS  
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13.9  CRYSTALLIZATION TECHNIQUES 
13.9.1  Preparation of the CI/Fab crystallization sample  
The final detergent concentration in the CI/Fab solution was 0.02 % C12E9.  The crystalliza-
tion sample was prepared in a buffer containing the same amount of the primary detergent in 
addition to other detergents and additives. Most commonly phosphocholine/Cymal 4™ or 
DQA (2-decyl-4-quinazolinyl amine) were used in the dilution buffer and crystallization solu-
tion. Whereas, C12E9 was always present in the crystallization buffer, the secondary detergents 
varied.  When  the  amount  of  endogenous  lipids  was  higher  than  ~130  nmol  phosphocho-
line/mg complex I, no additional lipids were used in the dilution and crystallization buffers.  
13.9.2  Vapor diffusion  
Crystallization experiments were carried out at 4, 10 and 18
oC. 
13.9.2.1  Hanging drop 
The hanging drop method was performed using 24-well VDX™ plates (Hampton Research). 
Typically, drops between 1-5 µl were placed on siliconized glass cover slides (Hampton Re-
search) over 1 ml well solution.  
13.9.2.2  Sitting drop 
Sitting  drop  experiments  were  performed  using  polypropylene  Micro-Bridges®  (Hampton 
Research). Drop volumes between 1 and 5 µl were used. The well solution volume was 1 ml. 
13.9.2.3  pH fine tuning of the crystallization conditions 
In order to find optimal conditions for crystal growth a fine tuning of the pH of the crystalliza-
tion buffers was performed as follows: buffer A (for example: 6% PEG 3350, 12% glycerol, 
40 mM calcium acetate, pH 6.0) was mixed with buffer B (for example: 6% PEG 3350, 12% 
glycerol, 40 mM calcium acetate, pH 7.0) in the wells at variable ratios: 100 µl A + 900 µl B, 
200 µl A + 800 µl B, 300 µl A + 700 µl B etc.  The reservoir volume was 1 ml.  
13.9.2.4  pH/PEG fine tuning of the crystallization conditions 
In this experiment, not only the influence of pH of the buffers was tested in minute value in-
tervals, but also the PEG concentration was altered in small steps. The protein was mixed 1:1 
with crystallization buffers of increasing PEG concentrations (4, 5, 6, 7 and finally 8% PEG, MATERIALS AND METHODS  
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10% glycerol 100 mM sodium potassium phosphate, pH 5.2) and placed over reservoir solu-
tion (8% PEG 3350, 10% glycerol 100 mM sodium potassium phosphate, pH 4.5).  
13.9.2.5  pH gradient vapor diffusion 
The pH gradient in vapor diffusion experiments (hanging and sitting drop) was achieved by 
adjusting the reservoir solution one or two pH units below the pH value of the drop solution. 
Example,  reservoir  solution:  8%  PEG  3350,  10%  glycerol  100  mM  sodium-potassium-
phosphate,  pH  4.3  versus  drop  solution:  8%  PEG  3350,  10%  glycerol  100  mM  sodium-
potassium-phosphate, pH 5.2. 
13.9.2.6  Vapor diffusion with oil barrier 
An oil barrier was introduced into vapor diffusion experiments (hanging and sitting drop) to 
slow down the supersaturation process. The oil layer thickness was varied in the screening 
procedure. Silicon, paraffin oil and Al’s oil (50% silicon:50% paraffin oil) as well as their 
mixtures were tested. The experiments were carried out at 18 
oC. 
13.9.3  Dehydration of the co-complex crystals 
The purpose of the dehydration experiments was to improve the diffraction range of the co-
complex  crystals.  The  dehydration  solution  withdraws  water  molecules  from  the  crystals, 
which can lead to tighter packing and at the same time increase the order of the crystal pack-
ing. The dehydration experiments were carried out by transfer of the cover slide with the pro-
tein drop containing crystals over a well with 1 ml dehydration solution (50% PEG 400, 20% 
glycerol, 40 mM calcium acetate, pH 7.3 or 100 mM sodium potassium phosphate, pH 5.2). 
After 1-3 hours the crystals were frozen by plunging in liquid nitrogen without use of addi-
tional cryoprotectant. The experiments were performed at 10 
oC.   
13.9.4  Soaking of the co-complex crystals in Ta6Br12
2+ 
The compound Ta6Br12
2+ (dodecabromohexatantalum cation) was reported in literature as a 
promising  derivatization  agent.  Additionally,  the  cluster,  having  a  roundish  structure  may 
incorporate into the crystal structure providing more ordered packing of the crystals in some 
cases  [187].  Moreover,  the  green  color  of  Ta6Br12
2+  allows  easy  control  of  the  soaking 
process. For the soaking experiments, 10 mM water solution of Ta6Br12
2+ was prepared. The 
compound was kindly provided by Prof. Grzegorz Bujacz (Institute of Technical Biochemi-
stry,Technical University of Lodz, Poland). The crystals were fished from the original drops 
and transferred to fresh drops with reservoir solution of the same volume, where the Ta6Br12
2+ MATERIALS AND METHODS  
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end
 concentration was 0.01, 0.02, 0.05 and 0.1 mM. After 24 hours the crystals displayed 
green color, which was gone from the drops. Alternatively, few crumbs of Ta6Br12
2+ were 
added directly to the drop containing crystal of interest. No damage to the crystals was ob-
served for either of the methods. The crystals were cryoprotected according to standard pro-
cedure (described in 13.9.8.1). 
13.9.5  Microbatch 
Crystallization under oil was performed using 72-well microbatch plates (Hampton Research) 
or in 96 Well IMP@CT™ plates (Greiner Bio-One). Silicon, paraffin oil and Al’s oil as well 
as their mixtures were tested in different volumes. Plates were covered with an oil layer. Pro-
tein drops were laid on the bottom of the wells and precipitant solution was added subsequent-
ly. Drop volumes were usually 1-2 µl. The experiments were carried out at 18 
oC. 
13.9.6  Seeding 
Seed stock was prepared using 4-6 crystals, which were transferred to a stabilizing solution 
(of 4% higher PEG 3350 concentration with respect to the well of the crystal’s origin) and 
crushed using the Seed Bead™ kit (Hampton Research). Serial dilutions were prepared from 
the stock seed by 10-fold dilution in the range from 1 x 10
0 to 1 x 10
-7. Three seeding tech-
niques were applied: 
 1)  Direct  seeding,  where  0.5  µl  of  seed  from  each  dilution  was  added  to  2  µl  non-pre-
equilibrated drop (1:1 diluted with reservoir solution). 
2) Streak seeding, with use of a cat whisker on a non-pre-equilibrated drop.  
3) Streak seeding, with use of a cat whisker on a pre-equilibrated drop.  
 
13.9.7  Screening for optimal conditions 
13.9.7.1  ‘Traditional’ screening 
Screening was performed  in 24 well plates using either specifically designed solutions or 
commercial screens (Hampton Research, Qiagen, Molecular Dimensions, Fluka, Jena Bios-
ciences). The protein drops were usually 1-4 µl and the well solution was 1 ml. This method 
was more time- and material-consuming, but avoided problems associated with up-scaling of 
the crystallization conditions. MATERIALS AND METHODS  
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13.9.7.2  Automated screening and monitoring 
Two types of crystallization robots were used for automated screening in this project: Carte-
sian MicroSys™ (Genomic Solutions, UK) and Mosquito™ (TTP Labtech, UK). Experiments 
were carried out in 96 well plates (see  ‘Materials’ section). Commercial, as well as  self-
prepared solutions were used for testing. The drop volume working range 25 nL – 120 µl al-
lowed extensive screening with sparse material. The crystallization experiments were moni-
tored at 18
oC using Crystal Farm 400 and at 4
oC, using Crystal Farm 150 (Bruker). 
13.9.8  Cryoprotection and freezing 
The cryoprotection method was optimized according to the crystal type and its growth condi-
tions.  
13.9.8.1  Complex I/Fab co-complex crystals 
Co-complex crystals grown from PEG 3350 were cryoprotected using two methods. The crys-
tals were sequentially immersed in a cryosolution with PEG 3350 at a concentration 1-3% 
higher than the mother liquor and with increasing concentrations of glycerol. 5 µl of solution 
A (20% glycerol) was added to increase the volume of the drop and avoid drying of the crys-
tals while fishing. Next crystals were transferred to a 5 µl drop of pure solution A. After 10 
minutes, 2,5 µl of solution A was replaced by 2.5 µl of solution B (25% glycerol) and the step 
was repeated to ensure uniform concentration of glycerol. After another 10 minutes, 2.5 µl of 
solution B was replaced by 2.5 µl of solution C (30% glycerol) and the step was done again. 
According to the second method, crystals were soaked for 1-10 minutes in solution containing 
50% PEG 400 instead of PEG 3350. The crystals were fished using a nylon loop and frozen 
by plunging into liquid nitrogen or cold propane. 
13.9.8.2  Ugp1p crystals 
24% PEG 400 in the growth buffer was used for cryoprotection of the Ugp1p crystals. The 
crystals  were  fished  with  a  nylon  loop  and  frozen  by  plunging  into  liquid  nitrogen.AUSFÜHRLICHE DEUTSCHSPRACHIGE ZUSAMMENFASSUNG  
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14 AUSFÜHRLICHE  DEUTSCHSPRACHIGE  ZUSAMMEN-
FASSUNG 
14.1  NADH:UBICHINON OXIDOREDUKTASE (KOMPLEX I) 
Die  NADH:Ubichinon  Oxidoreduktase  (Komplex  I,  EC  1.6.5.3)  ist  der  größte,  kompli-
zierteste aber am wenigsten bekannte Enzykomplex der Atmungskette [1]. Das Enzym kop-
pelt den Transfer von zwei Elektronen von NADH auf Ubichinon an die Translokation von 
vier Protonen über die innere mitochondriale Membran oder die Plasmamembran von vielen 
Bakterien. Der erzeugte elektrochemische Protonengradient wird von der ATP-Synthase zur 
Produktion von ATP genutzt. Elektronenmikroskopische Aufnahmen zeigen eine L-förmige 
Struktur des Komplex I mit einem membranständigen und einem zur Matrixseite orientierten 
peripheren  Arm  [3-7].  Fehlfunktionen  der  NADH:Ubichinon  Oxidoreduktase  wurden  bei 
zahlreichen neurodegenerativen Erkrankungen identifiziert, darunter dem Leigh-Syndrom und 
der  hereditären  Leberschen  Optikusneuropathie  (LHON) [11].  Neben  dem  Cytochrom  bc1 
Komplex, ist der Komplex I eine wichtige Quelle von toxischen Sauerstoffradikalen, für die 
eine Beteiligung am biologischen Alterungsprozess diskutiert wird [12;14].  
Der eukaryotische Komplex I besteht aus mehr als 40 Untereinheiten und hat eine molekular 
Masse von circa 1 MDa [15-18]. Die 14 zentralen Untereinheiten sind zwischen Prokaryoten 
und Eukaryoten konserviert und bilden die Minimalform von Komplex I [19]. Sieben dieser 
Untereinheiten (75-kDa, 51-kDa, 49-kDa, 30-kDa, 24-kDa, TYKY, PSST) bilden den peri-
pheren Teil, sind kernkodiert und enthalten alle bekannten Redoxgruppen (ein FMN und bis 
zu neun Eisen-Schwefel-Zentren [20;21]). Die übrigen sieben Polypeptide (ND1 bis ND6 und 
ND4L) befinden sich im Membranarm,  sind stark hydrophob und werden bei den meisten 
Eukaryoten von der mitochondrialen DNA kodiert. Zusätzlich zu den 14 zentralen besitzt der 
eukaryotische Komplex I sogenannte akzessorische Untereinheiten deren Funktion bis jetzt 
unklar ist.  
Komplex I ist die letzte Komponente der Atmungskette deren atomare Struktur unbekannt ist. 
Vor kurzem wurde die Röntgentruktur des hydrophilen Arms des Komplex I aus Thermus 
thermophilus  gelöst  [37].  Diese  Teilstruktur  (PDB  2fug)  beinhaltet  acht  Untereinheiten  
Nqo1-6, Nqo9, und Nqo15, sowie neun Eisen-Schwefel-Zentren. Die Struktur des Komplex I 
aus Yarrowia lipolytica wurde bis jetzt mit Elektronmikroskopie untersucht und lieferte das 
derzeit beste Strukturmodell des eukaryotischen Enzyms [6]. Dennoch ist eine Röntgenstruk-AUSFÜHRLICHE DEUTSCHSPRACHIGE ZUSAMMENFASSUNG  
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tur des Holoenzym erforderlich, um den Zusammenhang zwischen der Redoxchemie im peri-
pheren Arm und der Protonentranslokation im Membranarm zu verstehen. 
14.2  KRISTALLISATION VON MEMBRANPROTEINKOMPLEXEN MIT 
HILFE VON ANTIKÖRPERFRAGMENTEN 
Membranproteine sind an vielen zellulären Prozessen wie z.B. dem Stoffwechsel, dem Trans-
port von Ionen und anderen Stoffen, der Atmung, der Umsetzung von Energie und der Sig-
naltransduktion beteiligt. Außerdem sind Membranproteine wichtige Angriffspunkte für Me-
dikamente. Für das  Verständnis der Funktion  eines Enzyms  ist die  Aufklärung seiner 3D 
Struktur mit atomarer Auflösung von großer Bedeutung. Im Gegensatz zu 49000 bekannten 
Strukturen von löslichen Proteinen gibt es nur 171 von Membranproteinen, die bis heute in 
der Protein Daten Bank (PDB) deponiert wurden. Die Schwierigkeit dreidimensionale Kristal-
le von Membranproteinen herzustellen, liegt vor allem in der amphiphilen Natur ihrer Ober-
fläche. Mit Hilfe von Detergenzien werden die Membranproteine möglichst in der nativen 
Konformation aus biologischen Membranen solubilisiert und gereinigt. Die Protein-Detergenz 
Komplexe  dienen  dann  als  Ausgangmaterial  für  die  Kristallisation.  Die  Röntgen-
kristallographie erfordert dreidimensionale Kristalle, bei denen die spezifischen Kristallkon-
takte primär von den polaren Teilen der Proteine vermittelt sind. Leider ist dieser Anteil in 
vielen Fällen nicht groß genug, um ausreichende Kristallkontakte ausbilden zu können. Eine 
Möglichkeit  die  polare  Oberfläche  zu  vergrößern,  ist  die  Verwendung  von  Antikörper-
fragmenten [87]. Zusätzlich können Fragmente von Immunglobulinen bestimmte Proteinkon-
formationen  stabilisieren  und  dadurch  die  Kristallisation  fördern.  Fv  und  Fab  Antikörper-
fragmente wurden mit Erfolg zur Kristallisation von integralen Membranproteinen verwendet. 
Cytochrom c oxidase aus Paracoccus denitrificans wurde als erstes mittels Fv Fragmenten 
kristallisiert [61;68]. Danach wurde die Struktur eines Fv Co-Komplexes des Cytochrom bc1 
Komplexes aus Saccharomyces cerevisiae gelöst [60]. Die erste Fab-vermittelte Kristallisa-
tion wurde für den Kalium Kanal KcsA aus Streptomyces lividans berichtet. Außer zur Ver-
größerung der  hydrophilen Domäne, wurden die Antikörperfragmente auch zur Phasenbe-
stimmung verwendet [85]. Das jüngste Beispiel für die erfolgreiche Kristallisation eines Fab-
Membranprotein Co-Komplexes ist  der humane Adrenorezeptor β2AR [67].  
In  Anlehnung  an  die  beschriebenen  erfolgreichen  Versuche  zur  Kristallisation  von  ver-
schiedenen Membranproteinen mit Antikörperfragmenten, wird in der vorliegenden Arbeit die 
Kristallisation von Komplex I mit Hilfe von proteolytischen Fab Fragmenten beschrieben.  AUSFÜHRLICHE DEUTSCHSPRACHIGE ZUSAMMENFASSUNG  
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14.3  HERSTELLUNG UND REINIGUNG VON Fab FRAGMENTEN 
14.3.1 Reinigung monoklonaler Antikörper 
Die in dem Projekt verwendeten monoklonalen Antikörper (1F5, 31A8 und 44G10) wurden 
nach Standardtechniken  für die  Kultur von Hybridomazellen ohne Zusatz von  Antibiotika 
gezüchtet. Typische Ausbeuten waren: 55 mg/L Zellkultur für 31A8, 35 mg/L Zellkultur für 
1F5 und 30 mg/L Zellkultur für 44G10. Die monoklonalen Antikörper wurden aus dem Zell-
kulturüberstand  mittels  Protein  G  Affinitätschromatographie  gereinigt.  Polyacrylamid-
gelelektrophorese  zeigte  einen  hohen  Reinheitsgrad  der  isolierten  Immunglobuline.  Deren 
Funktionalität wurde sowohl in nativen ELISA Tests als auch in Bindungsexperimenten mit 
dem nativen Komplex I geprüft. Bindungskonstanten im nanomolaren Bereich wurden für die 
Antikörper und die entsprechenden Fab Fragmente gefunden. 
14.3.2 Einfluss der Komplex I Konformation auf die Bindung von mo-
noklonalen Antikörpern 
Die monoklonalen Antikörper 31A8 und 44G10 sind Western Blot negativ und binden nur an 
Komplex I im nativen Zustand. Der Antikörper 1F5 hingegen erkennt ein lineares Epitop des 
Komplexes. Es wurde gezeigt, dass NADPH die Sensitivität von  verschiedenen  Unterein-
heiten bei der limitierten Proteolyse von Komplex I beeinflusst [96;97]. Oberflächenplasmon-
resonanz-Experimente zeigten, dass NADPH keinen Einfluss auf die Bindung der Antikörper 
31A8 und 44G10 an Komplex I aus Y. lipolytica hat. Eine signifikante Abnahme in den Ober-
flächenplasmonresonanzsignalen wurde überraschenderweise für den Antikörper 1F5 beob-
achtet, der im distalen Teil des Membranarms bindet. 
14.3.3 Herstellung von Fab Fragmenten 
Die Herstellung von reinen Fab Fragmenten, die für die für Co-Kristallisations Experimente 
geeignet waren, war eines der wichtigsten Ziele des Projekts. Um ein optimales Protokoll für 
die proteolytische Spaltung zu entwickeln, wurden mehrere Proteasen  (immobilisiertes Pa-
pain, immobilisiertes Ficin, kristallines Papain und Trypsin) und unterschiedliche Reaktions-
bedinungen, wie verschiedene pH und Cysteinkonzentration getestet. Da der Verdau mit Pa-
pain sehr gute Ausbeute zeigte, und die Durchführung einfach und zuverlässig war, wurde 
diese Protease für weitere Experimente benutzt. Fab Fragmente wurden aus dem Proteolyse-
ansatz gereinigt. Die Fc Teile  enthaltenden Fragmente wurden durch Protein G Affinitäts-
chromatographie entfernt. Anschließend wurde die Probe mittels Gelfiltration gereinigt.  Die AUSFÜHRLICHE DEUTSCHSPRACHIGE ZUSAMMENFASSUNG  
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Bindung der Fab Fragmente an den nativen Komplex I wurde mit analytischer Gelfiltration 
und Oberflächenplasmonresonanz geprüft. Die Fab Fragmente 1F5 und 44G10 zeigten hohe 
Affinität zum Komplex I und konnten in Western Blot Experimenten nachgewiesen werden. 
Die Bindungskonstanten lagen im nanomolaren Bereich. Demgegenüber konnte keine Bin-
dung des Fab 31A8 an Komplex I gezeigt werden. Daraus wurde geschlossen, dass der  Ver-
dau mit Papain die Antigenbindungsstelle von 31A8 Antikörper beschädigt.  
14.4  HERSTELLUNG VON Fab-KOMPLEX I CO-KOMPLEXEN 
Reine Fab Fragmente wurden in 1.5 fachem molaren Überschuss zu Komplex I eingesetzt. 
Die ungebundenen Fragmente wurden durch Gelfiltration entfernt. Es wurde gezeigt, dass die 
Bindung der Fab Fragmente die spezifische Aktivität von Komplex I (NADH:HAR Oxidore-
duktase und dNADH:DBQ   Oxidoreduktase) nicht verändern. Der Phospholipidgehalt des 
isolierten Ko-Komplexes war vergleichbar mit Komplex I Präparation ohne Fab Zusatz. We-
gen beeinträchtigter Affinität des Fab 31A8, konnten keine funktionalen Untersuchungen mit 
diesen Antikörperfragment  durchgeführt werden. 
14.5  KRISTALLISATION VON KOMPLEX I-Fab CO-KOMPLEXEN 
Zur Kristallisation von Komplex I-Fab Co-Komplexen wurden bekannte Verfahren nach dem 
Prinzip der Dampfdiffusion (hängende Tropfen und sitzende Tropfen) eingesetzt. Kristallisa-
tionsroboter (Max-Planck-Institut für Biophysik, Frankfurt am Main) wurden für die Asuwahl 
von Initialbedinungen verwendet, wobei auch verschiedene kommerzielle „sparse matrix kits“ 
getestet wurden. Die ersten Kristalle von Komplex I-Fab 44G10  wuchsen in Ansätzen im 
Nanomaßstab, ließen sich aber nicht im größeren Maßstab reproduzieren. Daraus wurde ge-
schlossen, dass Fab-Fragmente von 44G10 eine unvorteilhafte Kristallpackung bewirken und 
die Bildung von Kristallen eher verhindern. 
Die initialen Kristalle des Co-Komplexes mit dem Fab-Fragment von 1F5 wuchsen unter ähn-
lichen Bedinungen wie der native Komplex I. Die Kristallqualität war jedoch limitiert und es 
konnten nur Reflexe bis 18 Å an der ID14 des ESRF in Frankreich beobachtet werden. Um 
die  Qualität  zu  verbessern,  wurden  verschiedene  Methoden  angewendet,  wie  seeding,  pH 
Gradient und unkontrollierte Dehydratation. Zusätzlich wurden konsequent die  Kristallisa-
tionsbedingungen,  wie  Salztyp,  Temperatur,  Proteinkonzentration  und  Zusätze  variiert.  Es 
wurde gezeigt dass der Lipidgehalt eine sehr wichtige Rolle für die Kristallqualität spielte. 
Die verbesserten Kristalle zeigten Röntgenbeugung von bis zu 7 Å an der ID14-2 des ESRF in AUSFÜHRLICHE DEUTSCHSPRACHIGE ZUSAMMENFASSUNG  
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Frankreich. Die vorläufigen Auswertung der Datensätze zeigt eine kubische Einheitzelle mit 
folgenden Dimensionen: a = 471 Å, b = 471 Å, c = 472 Å, α = 90˚, β = 90˚, γ = 90˚.   
Die weitere Verbesserung der Kristallqualität ist die Grundvoraussetzung für die strukturelle 
Charakterisierung der Co-Komplexe. Als erstes müßten die Bedingungen für das Einfrieren 
optimiert werden. Die Anwendung von flüssigem Propan zeigte beim nativen Komplex I Vor-
teile gegenüber der Anwendung von flüssigem Stickstoff. Zweitens könnte eine weitere Ver-
größerung der hydrophilen Domäne z.B. durch Bindung von Protein L an das Fab Fragment 
hilfreich sein [188;189]. Diese Methode birgt allerdings das Risiko größerer struktureller Fle-
xibilität. Drittens scheint die Anwendung einer Humiditätskammer, die die kontrollierte De-
hydratation von Proteinkristallen erlaubt, eine aussichtsreiche Methode für die Optimierung 
der Kristallqualität zu sein [98].  
Die  vorliegende  Arbeit  repräsentiert  die  erste  erfolgreiche  Kristallisation  von  Komplex  I 
(NADH:Ubichinon Oxidoreduktase) aus Y. lipolytica mit gebundenen Fab Fragmenten. Durch 
konsequente Optimierung wurden die Beugungseigenschaften der Kristalle deutlich verbes-
sert. Die initiale Datenanalyse deutet auf eine andere kristallographische Raumgruppe  als die 
der  Kristalle  des  nativen  Enzyms  hin.  Die  Aufklärung  der  Struktur  von  Komplex  I-Fab 
Komplexen wird eine wichtige Informationsquelle für die strukturelle Charakterisierung der 
NADH:Ubichinon Oxidoreduktase (Komplex I) sein. Überdies könnten Antikörperfragmente 
als wichtiges Hilfsmittel für die Kristallisation von  Komplex I Subkomplexen oder auch ein-
zelnen Untereinheiten dienen.  
14.6  UDP-GLUCOSE PYROPHOSPHORYLASE  
UDP-Glucose  Pyrophosphorylase  (UGP1,  Ugp1p,  UTP:α-D-Glukose-1-Phosphat  uridylyl-
transferase, UDPGP, EC 2.7.7.9) katalysiert die Mg
2+-abhängige Bildung von UDP-Glucose 
und Pyrophosphat aus Glucose-1-Phosphat und UTP [126].  UDP-Glucose ist der wichtigste 
Glykosyl-Donor im Stoffwechsel und dient als aktivierte Vorstufe für viele Glykosylierungs-
reaktionen. In S. cerevisiae wird die UDP-Glucose zur Synthese der β-Glukane (1,6-β-Glukan 
and 1,3-β- Glukan) der Zellwand benutzt [133]. Die β-Glukane repräsentieren über 55% der 
Zellwandkohlenhydrate und sind wichtig für die Morphologie und osmotische Integrität der 
Hefezellen. Die Deletion des Gens für UDP-Glucose Pyrophosphorylase (UGP1) in S. cerevi-
siae war letal für die Zellen [134]. In tierischen Zellen werden die UDP-Glucose Einheiten  
für den Aufbau des Speicherpolysaccharids Glykogen verwendet.  
UDP-Glucose Pyrophosphorylase gehört zu den sogenannten UGPasen, für die eine SGC-
Domäne mit dem Signaturmotif LXXGXGTXXXXXXPK im aktiven Zentrum charakteris-AUSFÜHRLICHE DEUTSCHSPRACHIGE ZUSAMMENFASSUNG  
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tisch ist [156]. Für die pflanzliche UGPase wurde eine Regulation der Enzymaktivität über 
den Oligomerisierungszustand  des Enzyms vorgeschlagen, wobei die aktive Form ausschließ-
lich  das  Monomer  ist  [190]. In  Hefezellen  spielen  möglicherweise  die  PAS-Kinasen  eine 
wichtige Rolle bei der Regulation der Enzymaktivität [191]. In der Bäckerhefe wurden aktive 
Enzyme nur als Oktamere gefunden [161]. Bis heute wurden Röntgenstrukturen von UGPasen 
aus folgenden Organismen gelöst: A. thaliana [166], Leishmania major [167], Corynebacte-
rium glutamicum [192], Escherichia coli [168] und S. cerevisiae [161].  
UDP-Glucose Pyrophosphorylase aus Y. lipolytica wurde bis jetzt noch nicht charakterisiert. 
Das Enzym zeigt 70% und 52% Sequenzidentität zu den Enzymen aus S. cerevisiae und A. 
thaliana. UDP-Glucose Pyrophosphorylase aus Y. lipolytica weist Affinität zu Ni
2+-NTA auf, 
weshalb es während der His-tag Affinitätsreinigung von Komplex I zusammen mit diesem 
aufgereinigt wurde. Die mit Ionenaustausch-Chromatographie weiter gereinigte Protein konn-
te mit einem Antikörper gegen das Enzym aus S. cerevisiae in einem Western Blot nachge-
wiesen  werden.  LILBID  (laser-induced  liquid  bead  ion  desorption)  Massenspektrometrie 
wurde zur Bestimmung des Oligomerisierungszustandes verwendet und zeigte dass, das En-
zym aus Y. lipolytica, ähnlich wie aus S. cerevisiae als Oktamer mit einer molekularen Masse 
von ~ 450 kDa vorkommt.  
Die bekannte Struktur des pflanzlichen Enzyms wurde für die Konstruktion eines Struktur-
modells des Enzyms aus Y. lipolytica verwendet. Das Modell zeigt die typische Architektur 
von Pyrophosphorylasen mit einer zentralen SGC Domäne. 
Die erste Kristalle wuchsen als sehr dünne Nadeln aus einem Ansatz mit PEG 400 als Fäl-
lungsmittel und zeigten ein Beugungsmuster mit einer Auflösung von 4 Å (gemessen an der 
PX II, SLS, Schweiz). Anwendung der microbatch Technik ergab größere Kristalle, die bis 
3.2 Å beugten. Die Raumgruppe war I4 und die Einheitszelledimensionen waren wie folgt: a 
= 295 Å, b = 295 Å, c = 110 Å, α = 90˚, β = 90˚, γ = 90˚. Die Struktur soll nun durch moleku-
lar replacement anhand der bekannten Struktur der S. cerevisiae UDP-Glucose Pyrophospho-
rylase gelöst werden (Zusammenarbeit mit Carola Hunte, Universität Leeds).  
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15 ABBREVIATIONS 
µM    micromolar 
ADP    adenosine-5'-diphosphate 
AGPase   ADP- glucose pyrophosphorylase 
ATP    adenosine-5'-triphosphate 
BSA    bovine serum albumin 
C12E9    dodecyl nonaethylene glycol ether  
CI      complex I 
CMC    critical micelle concentration 
COX    cytochrome c oxidase 
DBQ     n-decylubiquinone 
dNADH  deaminodihydronicotinamide adenine dinucleotide 
DQA    2-decyl-4-quinazolinyl amine 
EDTA   ethylenediaminetetraacetic acid 
EPR    electron paramagnetic resonance  
Fab    antigen binding fragment 
Fc    crystallizable fragment  
FMN    flavine mononucleotide  
Fv    variable fragment 
GPCR   G protein coupled receptor 
HAR    hexa-ammine-ruthenium III-chloride 
HEPES  N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid 
IgG    immunoglobulin G 
IPD    immobilized papain digest 
kDa    kilo Dalton 
LILBID  laser-induced liquid bead ion desorption 
Mab    monoclonal antibody 
mM    milimolar 
NAD    nicotinamide adenine dinucleotide 
NADH   nicotinamide adenine dinucleotide, reduced 
NADP   nicotinamide adenine dinucleotide phosphate 
NADPH  nicotinamide adenine dinucleotide phosphate, reduced ABBREVIATIONS  
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PAGE   polyacrylamide gel electrophoresis 
PC    phosphatidyl-choline 
PDI    protein disulphide isomerase 
PEG    polyethylene glycol 
PRM    protein – ribosome – mRNA – complex 
QCR    cytochrome bc1 complex 
scFv    single chain variable fragment 
SDS    sodium dodecylsulphate 
Ta6Br12
2+  dodecabromohexatantalum cation 
Tris    tris(hydroxymethyl)aminomethane 
UDP    uridine-5'-diphosphate 
Ugp1p   uridylyl diphosphate glucose pyrophosphorylase 
UGPase  UDP-glucose pyrophosphorylase 
UTP    uridine-5'-triphosphate INDEX OF FIGURES  
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